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Summary  
In recent decades, the incidence of human papillomavirus (HPV) associated 
oropharyngeal squamous cell carcinoma (OPSCC) has increased world-wide. Overall, 
HPV-positive OPSCC patients respond better to treatment (increased survival rate) 
compared to HPV-negative patients. This might be partially associated with a deficiency 
in repair of double-strand DNA breaks, and/or with residual p53 activity in HPV-positive 
tumours. However new studies, specific to HPV-positive OPSCC, are limited due to the 
low number of relevant OPSCC in-vitro models. 
The general aims of this study were to develop new HPV-positive OPSCC cell lines and 
use them, together with established OPSCC cell lines, to investigate responses to ionising 
radiation (IR). These experiments were intended to test that HPV-positive OPSCC cell 
lines were more sensitive to IR than HPV-negative OPSCC cell lines. Two novel OPSCC 
cell lines, one HPV-positive and one HPV-negative, were derived and characterised. 
The HPV-positive OPSCC cell lines demonstrated greater variation in radio-sensitivity 
compared to HPV-negative OPSCC cell lines. However, radio-sensitivity was not 
associated with p53 accumulation and/or cell cycle arrest. All HPV-positive OPSCC cell 
lines showed G2 arrest after IR, but so did several HPV-negative lines. The mRNA 
sequencing data confirmed expression of HPV oncogenes and integration of HPV DNA 
into the host genome, with an increase of integration sites after IR.  
Comparison of irradiated HPV-positive and HPV-negative cell lines did not show 
consistent differences in gene expression associated with DNA repair. The transcription 
of DNA repair factors did not correlate with radio-sensitivity within the HPV-positive 
cell lines.   
The study was successful in generating and characterising new OPSCC cell lines but did 
not find evidence that the better prognosis of HPV-positive tumours is associated with 
defects in DNA repair. This suggests that additional mechanisms may be responsible for 
the improved prognosis of HPV-positive OPSCC patients following treatment.  
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Chapter 1 : Introduction  
 
1.1. Oropharyngeal Squamous Cell Carcinoma  
 
1.1.1. Anatomy of the oropharynx  
 
Head and Neck cancers are comprised of a wide variety of tumours from different 
anatomic structures including the craniofacial bones, soft tissue, salivary glands, skin and 
mucosal membranes (Pai and Westra, 2009).  This includes cancers of the oral cavity, the 
hypopharynx, the larynx, the sinonasal tract, the nasopharynx and the oropharynx 
(Ramqvist and Dalianis, 2010). The focus of this study was the oropharynx, and 
specifically Oropharyngeal Squamous Cell Carcinoma (OPSCC).   
The pharynx is classified into three sections. The nasopharynx is seen posterior to the 
nasal cavity, the hypopharynx lies behind the larynx, and the oropharynx  is found 
posterior to the oral cavity (Hermans and Lenz, 1996). The oropharynx is hence located 
between the nasopharynx and larynx/hypopharynx. It is composed of four distinct parts: 
base of tongue (back 1/3 of the tongue), soft palate, tonsil and back site of the throat 
(posterior pharyngeal wall) (Figure 1-1) (Harrison et al., 2009).  
The oropharynx includes a circular collection of submucosal lymphoid tissue (lingual and 
palatine tonsils) known as Waldeyer’s ring, that is the first line of defence against airborne 
and ingested pathogens.  The tonsil epithelium comprise part of Waldeyer’s ring and 
consist of blind-ending crypts through the full thickness of the palatine tonsil. These 
patches of crypts are lined by a net-like squamous epithelium, known as reticulated 
epithelium, that is structured to enable transport of foreign antigens from the oropharynx 
to the tonsil lymphoid tissue (Pai and Westra, 2009). 
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Figure 1-1: Anatomy of the oropharynx 
The Oropharynx is located between the nasopharynx and larynx/hypopharynx and consists 
of the soft palate, back wall of the throat (, tonsils and back third of the tongue (Picture obtained 
and adapted from Cancer Research UK: www.cancerresearchuk.org; 07.08.2018).  
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1.1.2. Epidemiology of head and neck/oropharyngeal squamous cell carcinoma 
 
Head and neck cancers are the sixth most common cancer types worldwide. 
Approximately 650,000 new patients are diagnosed with this type of cancer and around 
350,000 deaths are reported per year (Argiris et al., 2008). Around 85% of head and neck 
cancers are head and neck squamous cell carcinomas (HNSCC). The incidence rate of 
HNSCC is known to be different according to the geographical region. A high incidence 
of HNSCC is found in Australia, France (Europe), Brazil (South America), Southern 
Africa and the Indian subcontinent (Argiris et al., 2008, Mehanna et al., 2010). 
Over the decades, the incidence rates of HNSCC has changed in the US and the UK. The 
incidence rate for HNSCC overall has either decreased or remained stable. This might be 
attributed to anti-tobacco campaigns resulting in decreased consumption of tobacco. 
However, the incidence rates for tonsil and base of tongue has increased, particularly in 
young adults in the USA and European Countries (Argiris et al., 2008, Schache et al., 
2016).  
This increase of Human Papillomavirus (HPV)-positive related OPSCC’s has been 
reported in several countries around the world (Stein et al., 2015). For example, in the 
Netherlands the prevalence of HPV in OPSCC rose from 5% to 29% (1990-2010), 
Australia an increase from 19% (1987-1990) to 47% (2001-2005) was observed. The 
United States reported an increase from 16.3% (1984-1989) to 72.7% (200-2004) (Stein 
et al., 2015). 
Within the UK, increased incidence of HPV-positive and HPV-negative OPSCC cases 
has been documented with a 2-fold increase from 2002, with an age-standardised-rate of 
2.1 per 100,000  (95% Confidence Interval (CI), 1.9-2.2) to 4.1 (95% CI, 4.0-4.3) in 2011  
(Schache et al., 2016). The proportion of HPV-positive cases within the OPSCC patients 
has stayed stable at 50% (Schache et al., 2016). In a study cohort for South Wales, 55% 
of cases were HPV-positive in the time period of 2001-2006 (Evans et al., 2013). 
Compared to HPV-negative OPSCC, HPV-positive OPSCC show characteristic 
pathological, clinical and pathological features. Therefore, it can be characterised as a 
distinct disease entity (Gillison and Shah, 2001).  
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1.1.3. Risk Factors for head and neck cancer  
 
Historically, tobacco products and alcohol consumption are the two main risk factors for 
head and neck cancers. The risk of head and neck cancer increases in proportion to the 
consumption of tobacco (Franceschi et al., 1990). This effect can also be indirect; 
increased risk is also associated with long duration of involuntary smoking exposure at 
home or at work. This effect was stronger for pharyngeal and laryngeal cancer than for 
other head and neck cancer types (Lee et al., 2008, Zhang et al., 2000). Polycyclic 
aromatic hydrocarbons (PAH), which are part of cigarette smoke, are known to have a 
genotoxic/carcinogenic effect. After they are metabolised, some of the resulting products 
can bind to DNA, developing mutagenic DNA adducts (Gelboin, 1980). Due to exposure 
of PAHs, several cytochrome P450 enzymes are induced (e.g CYP1A1 and CYP1B1) via 
the aryl hydrocarbon receptor (AhR). AhR then forms a complex with PAH’s (with 
several other proteins, such as Hsp90, p23 and AhR interacting protein), which creates a 
heterodimer with an AhR nuclear translocator (ARNT) and binds to DNA via the 
xenobiotic response element (XRE). XRE is located in the promoter region of CYP1A 
and CYP1B genes, which then plays a significant role in tumorigenesis mediated by 
PAHs (Ewa and Danuta, 2017). One well known obtained PAH during is process is the 
activation of the carcinogen Benzo-(α)-pyrene (B(α)P) (Androutsopoulos et al., 2009, 
Ewa and Danuta, 2017). A study in 2008 has shown that xenobiotic metabolizing enzymes 
CYP1A1 and CYP1B1 were increased in the oral mucosa of smokers. This is of high 
importance as both CYP1A1 and CYP1B1 were found to convert a wide range of 
carcinogens to active metabolites that can form DNA adducts (Gumus et al., 2008). 
A study in Brazil of 784 cases of mouth pharynx and larynx cancer and 1,578 non-cancer 
control cases, investigated the effect of different tobacco types. It was shown that the risk 
for all upper aerodigestive tract cancers and pharynx decreases for ex-smokers, but stays 
relatively higher for larynx. In general,  relative risk remains higher than for non-smokers 
(Schlecht et al., 1999).  
The second main risk factor is chronic alcohol consumption. The carcinogenic effect of 
alcohol results from metabolism of ethanol into acetaldehyde, with direct DNA damage 
induction (Baan et al., 2007). The metabolism of ethanol occurs in two main steps. First 
alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde, then acetaldehyde gets 
further converted to acetate by aldehyde dehydrogenase (ALDH). Although the major 
acetaldehyde production in humans is found in the liver and gut, the highest level after 
Chapter 1  Introduction 
5 
 
alcohol consumption is found in the saliva, which increases the risk for cancer in the oral 
cavity and other sites of head and neck (Tsai et al., 2014). Alcohol seems to 
synergistically enhance the effect of tobacco metabolites on the cell, due to its 
characteristics as a solvent potentially increasing tissue exposure to the metabolites (Pai 
and Westra, 2009). There is one gene in particular, ALDH2, in which mutations or 
polymorphisms are known to increase the risk to develop HNSCC (Hakenewerth et al., 
2011). Furthermore, in a study by Tsai et al. (2014), the interaction between oral hygiene 
and different genetic polymorphisms of ADH1B and ALDH2 was investigated. ADH1B 
is one of the major ADH enzymes for conversion of ethanol to acetaldehyde. Three 
different alleles are known of ADH1B which are formed by variations at codons 48 and 
370. On the other hand, ALDH2 is well known for the conversion of acetaldehyde to 
acetate (well-known SNP rs671: allele *1 = glutamate at codon 504 and allele *2 = lysine 
at codon 504). Persons with *2/*2 genotype are unable to oxidize acetaldehyde to acetate.  
In this study it was stated that faster or slower activity of these enzymes (ADH1B or 
ALDH2) in correlation with oral hygiene has an effect on decrease/increase of head and 
neck cancer. The study concluded that both fast and slow ADH1B genotypes increase the 
risk for head and neck cancer. In persons with slow ADH1B, poor oral hygiene seemed 
to play a major role in risk for head and neck cancer. Furthermore, the risk was increased 
in people with fast ADH1B genotype and slow/non-functional ALDH2 genotypes  (Tsai 
et al., 2014).  
Besides alcohol and tobacco there are several other possible risk factors for HNSCC. 
Other known risk factors associated with development of HNSCC are the above 
mentioned poor oral hygiene, dental plaque formation, signs of chronic irritation of the 
mouth and/or family history can also play a critical role in HNSCC development (Hashim 
et al., 2016, Lissowska et al., 2003). Another main risk factor for HNSCC is caused by 
an oncovirus, known as HPV. The chapters below will give an overview about this virus.  
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1.2. Papillomaviruses 
  
Papillomaviruses are found in a wide variety of animal species including humans. These 
viruses are likely to have evolved over the last 350 million years. Their origins appear to 
be connected to changes in the epithelium of their ancestral host, with viruses evolving 
to be specific to cutaneous and mucosal epithelia (Doorbar et al., 2015, Egawa et al., 
2015) . Currently, over 200 different papillomavirus have been identified and completely 
sequenced, including around  170 types connected to humans (Doorbar et al., 2015, de 
Villiers, 2013).  
 
1.2.1. Discovery of oncogenic viruses 
 
In 1909 Francis Peyton Rous undertook his famous experiment on viral transmission of 
cancer. His experiment on sarcomas caused by a virus in chickens (“Rous sarcoma 
virus”), built the first milestone in virus-cancer research, which was later important for 
the discovery of human oncogenic viruses. In his experiment sarcomas were ground and 
filtered to eliminate intact cancer cells. The filtrate was then injected into a healthy 
chicken and tumour growth observed (Moore and Chang, 2010, Rous, 1910, Rous, 1911). 
Oncogenic viruses discovered over the last 54 years include hepatitis B virus (HBV), 
hepatitis C (HCV), Epstein-Barr virus (EBV), human herpes virus 8 (HHV8), Merkel cell 
polyomavirus (MCPyV), human T-lymphotropic virus type 1 (HTLV-1) and human 
papillomavirus (HPV) (Moore and Chang, 2010, Chang et al., 2017). 
 
1.2.2. HPV and cancer  
 
Before the discovery was made that linked HPV and cervical cancer, an initial link was 
proposed between herpes simplex virus type 2 and cervical cancer. The connection 
between HPV and cervical cancer was first postulated in 1972 (zur Hausen, 1975, zur 
Hausen, 1977, zur Hausen, 2009). In the 1980s the first HPV-16 sequence was published, 
and the HPV-16 DNA was successfully isolated from cervical cancer by southern blot 
hybridization (Durst et al., 1983, Gissmann et al., 1982a, Gissmann et al., 1982b, zur 
Hausen, 2009). In 2008, Harald zur Hausen was awarded a Nobel prize for establishing 
the causal link between HPV infection and cervical cancer.   
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In the early 1980s the first connection between HPV and oral and laryngeal squamous 
cell carcinogenesis was made (Syrjanen et al., 1983, Syrjanen et al., 1982, Syrjanen, 
2010b). An increase of incidence of head and neck cancers (HNSCC) caused by HPV has 
been reported in the last several years, since the connection of HPV and HNSCC was 
made in Europe and world-wide (Attner et al., 2010, Nasman et al., 2015, Nasman et al., 
2009, Gillison et al., 2015). 
  
1.2.2.1. Diseases caused by HPV  
 
HPV are mainly known for causing cervical cancers. HPV is also responsible for several 
other cancers in the anogenital region. These cancers are caused by mucosal HPV types, 
such as the well-known HPV-16 and -18 (Munoz et al., 2003). Cutaneous HPV types, 
such as HPV-2, are responsible for causing warts on the skin (predominantly arms, hands, 
chest and feet), which are known as common or cutaneous warts.  These warts can be 
spread via skin to skin contact or through contact with contaminated objects, through 
minor breaks in the epidermal barrier (Cubie, 2013).  
Mucosal HPVs are separated into two groups: low-risk (LR) and high-risk (HR) HPV. 
This nomenclature is used to describe the oncogenic potential of the different HPV types. 
LR-HPV are mainly associated with external genital warts, with the most common being 
HPV-6 and -11. External genital warts are the most common sexual transmitted disease 
with a transmission rate of around 60% between partners (Cubie, 2013). High-risk HPV 
types, such as HPV-16 and -18 have a strong epidemiologic association with cervical 
cancer (Munoz et al., 2003, Fakhry and Gillison, 2006). The nomenclature of high-risk 
and low-risk HPV is used for oropharyngeal squamous cell carcinoma (OPSCC) as well, 
as high risk types are associated with an oncogenic potential, and cause several different 
types of cancer (Ang et al., 2010, Shaikh et al., 2017). Furthermore, high risk types can 
cause various anogenital carcinomas or pre-cancers, such as vulval, vagina, anal, penile 
cancers (Munoz et al., 2003). Associated pre-cancers are found as intraepithelial 
neoplasia and are named after the site where they are found e.g. cervical intraepithelial 
neoplasia (CIN). The most common cancer type associated with HPV is cervical cancer. 
Cancers at the vaginal, vulval or penile region are less common, which might be because 
of the lack of a cellular transformation zone, where squamous epithelia merge with 
columnar epithelia (Cubie, 2013).  
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HPV is responsible for around 99% of cervical cancers worldwide. HPV-16 is responsible 
for around 50% of invasive cervical cancer, followed by HPV-18 with around 20%. The 
two most common HPV-types alone are responsible for around 70% of cervical cancer. 
The remaining HPV cervical cases are caused by other HR HPV types (Walboomers et 
al., 1999, Munoz et al., 2003). A meta-analysis of HPV prevalence in 2009 investigated 
HPV prevalence in vulval intraepithelial neoplasia (VIN), vaginal intraepithelial 
neoplasia (VAIN) and anal intraepithelial neoplasia (AIN) in 93 studies across four 
continents. The overall HPV prevalence was identified for VIN as 84% and 40.4% for 
vulvar carcinomas, VAIN as 93.6% and 69.9% vaginal carcinomas and AIN as 92.7% 
resulting in 84.3% anal carcinomas (De Vuyst et al., 2009). 
 
1.2.3. Classification/Taxonomy of papillomaviruses  
 
Papillomaviruses (PV) are included in the family of “Papillomaviridae”, a family of 
small, non-enveloped viruses with double-stranded DNA genomes of 5748 to 8607 bp 
(Van Doorslaer et al., 2018). Originally PVs were grouped together with the 
polyomaviruses as “Papovaviridae”, as they have similar non-enveloped capsids structure 
and both have double-stranded DNA. Later discoveries revealed that these viruses differ 
in genome structure and size as well as possessing different structural and non-structural 
proteins (de Villiers et al., 2004). The viruses were hence split into two separate families 
known as “Papillomaviridae” and “Polyomaviridae” (de Villiers, 2013, de Villiers et al., 
2004). The new order of the two viruses was officially recognized by the International 
Committee on the Taxonomy of Viruses (ICTV) (Van Doorslaer et al., 2018).   
Papillomaviruses are classified according to the DNA sequence of the L1 open reading 
frame (ORF). Subfamilies of PV share less than 45% sequence identity. Papillomaviridae 
are separated into two groups First and Second papillmoaviridae and grouped as genera 
and species (Van Doorslaer et al., 2018). Within the family of Papillomaviridae, a total 
number of 16 different genera were identified. Human papillomaviruses are grouped into 
5 distinctive genera, known as Alpha-, Beta-, Gamma-, Mu- and Nu-papillomaviruses 
genera. These genera are further divided into groups and species. The species are then 
divided into “types” by a diversity of over 10%. Types can be further classified into “sub-
types” by a 2-10 % difference at the L1 ORF. Sub-types can be further divided into 
variants with less than 2 % differences at the L1 ORF region. For example, the most 
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famous HPV type 16, belongs to the Alpha-papillomaviruses, species 9 (de Villiers, 2013, 
de Villiers et al., 2004, Chen et al., 2011). 
 
1.2.4. HPV genome structure  
 
The Human Papillomaviruses are double stranded DNA viruses of around 8000 base pairs 
(Doorbar et al., 2015). The HPV genome is divided into a long-control region 
(LCR)/upstream regulatory region (URR), a late and an early viral region, with a total 
number of 8 ORFs (Figure 1-2).  The LCR region is found between the early (E) and late 
(L) region genes and is involved in the control of gene expression, replication and 
transcription of the genome. The L region then encodes for  L1 and L2 major and minor 
capsid proteins (Ramqvist and Dalianis, 2011). One characteristic of L1 is to 
spontaneously assemble into a 72-pentamer icosahedral structure, either together with L2 
or alone.  L2 is not required for capsid formation, but has an essential role in encapsidation 
of the viral genome and plays an important role in the entry pathway of viral infection. 
The ability of L1 to self-assemble into Virus Like Particles (VLP), is used in production 
of vaccines against HPV infections (Buck et al., 2008, Harper et al., 2006, Longworth 
and Laimins, 2004, Villa et al., 2006).  
The early region contains 6 ORFs, known as E1, E2, E4, E5, E6 and E7. The ORFs of 
E5, E6 and E7 are involved in and modulate the transformation process, whereas E1 and 
E2, known as regulatory proteins, control replication and transcription (Carson and Khan, 
2006, de Villiers et al., 2004). The early gene region contains two important promotor 
sequences. In HPV-16 the early promotor is known as p97 (known as p105 for HPV-18) 
and is involved in the transcription of E6 and E7 and other viral genes. The p670 promotor 
(situated in the E7 ORF) which is also involved in differentiation, is the late HPV-16 
promoter, which results in the expression of L1 and L2 genes (Longworth and Laimins, 
2004, Carson and Khan, 2006). 
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Figure 1-2: HPV-16 genome structure 
HPV-16 has 6 early genes (viral replication), consisting of E1, E2, E4, E5, E6, E7 and two late genes L1 
and L2 (capsid formation). The early gene region contains of two promotors, an early promotor (PE) p97 
and a late promotor (PL) p670. The LCR region is responsible for gene regulation.  
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1.2.5. Transmission and rates of infection by HPV 
 
HPV is one of the most common sexually transmitted viruses. The risk of infection 
increases with number of sexual partners and most sexually active people will be infected 
with HPV at some point in their lifetime. Most of these HPV infections are transient. 
Those HPV infections, which are persistent could result in development of neoplasia 
(Moscicki et al., 2010). The risk of HPV infection in men and women is strongly 
connected to the number of vaginal intercourse and oral sex partners during a lifetime. A 
high number of lifetime sex partners (26 or more vaginal-sex partners, 6 or more oral sex 
partners) are associated with an increased risk of oropharyngeal cancers (D'Souza et al., 
2007, D'Souza et al., 2010, Burke et al., 2014). Studies have detected a higher number of 
HPV infections and OPSCC in men compared to women. This may be related to the 
higher number of sexual partners reported by males compared to women (Burke et al., 
2014). Similar findings have been found for the incidence of oral sex reported among 
men and women in several countries (Gillison et al., 2015). 
Some studies suggest a possibility of non-sexual transmission of HPV, through physical 
but non-sexual contact or via vertical transmission from mother to child (e.g. vaginal 
delivery) (Syrjanen, 2010a, Ryndock and Meyers, 2014). Other studies suggest a 
possibility of infection through contaminated medical equipment. However, these routes 
are only likely to be responsible for a very small proportion of infections. 
 
1.2.6. HPV life cycle – Cell entry to assembly  
 
The main target for HPV infection is the epithelium, specifically the stratified epithelium. 
The cells attached to the basal membrane in the stratified epithelium are normally the 
only cells of that epithelium with the potential for proliferation. During proliferation the 
newly formed daughter cell (after division of the basal cell) detaches from the basal 
membrane. The daughter cell then starts its differentiation process, exits the cell cycle, 
proceeds to terminal differentiation and peels off the epithelium. The HPV lifecycle is 
tightly connected to the differentiation process and is regulated by the host cells (Kajitani 
et al., 2012). The stages of the lifecycle including entry into the host cell, maintenance 
stage, proliferation, amplification and final assembly will be described.  
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1.2.6.1. Cell entry  
 
Viral entry mainly occurs through damaged areas of the epithelium, resulting in infection 
of the basal cells of the host. However, the mechanism for the viral entry, in terms of 
receptor of HPV infection has not been fully understood or characterized. The established 
model of viral entry suggests the requirement for interaction of virus particles with the 
basal lamina, and the interaction of capsids (late proteins L1 and L2) with heparin 
sulphate proteoglycans (HSPG) and possibly laminin (laminin-5) (Doorbar et al., 2012). 
Within the HSPG, syndecans (primarily syndecan-1) are predominant in epithelial cells, 
the target cells of HPV binding. Syndecan-1 serves as the primary attachment receptor, 
due to high expression level in the target cells and the involvement in wound healing 
(Horvath et al., 2010). Binding to the HPSG receptors induces a conformational change 
in L1, which leads to the exposure of a highly conserved furin convertase recognition site 
on L2 N-terminus. This exposure leads to a furin mediated cleavage of the L2 N-terminus 
region. (Day et al., 2008, Horvath et al., 2010, Sapp and Bienkowska-Haba, 2009). 
Several other HPSGs are implicated to be required for successful entry of HPV into the 
host cell, such as alpha-6 integrin (Doorbar et al., 2012, Horvath et al., 2010) 
Following the binding on the cell surface, the virus gains entry into the host cell via 
endocytosis (Schelhaas et al., 2012, Allen et al., 2010). After endocytosis, escape of viral 
DNA from the endosomal compartments, appears to be facilitated by an L2 membrane 
motif and gamma-secretase. A L2-HPV genome complex is then transferred through the 
cytoplasm to the nucleus, where transcription of RNA is initiated (Raff et al., 2013), while 
the L1 protein is retained in the endosome and becomes a subject to lysosomal 
degradation (Doorbar et al., 2012).  
 
1.2.6.2. Maintenance phase & Viral replication 
 
After entry into the host cells, HPV maintains its genome at a relatively low copy number 
of approximately 50-100 copies as nuclear plasmids (episomal form) with low expression 
of early genes (Flores et al., 1999). The number of genomes can vary from lesion to lesion 
and between different sites. This state is described as a non-productive infectious state 
(Stubenrauch and Laimins, 1999, Doorbar et al., 2012, Kajitani et al., 2012).  
Within the second maintenance phase, the viral genome replicates at a constant copy 
number in synchrony with the cellular DNA in dividing cells. The continuously dividing 
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basal cells, function as perfect reservoir for virus during the differentiation process of the 
epithelium.  
The transcription of the expressed E genes is controlled by the p97 promoter, which is 
located in the LCR region (Kammer et al., 2000). After activation of p97 in the early stage 
of infection, E1 and E2 are expressed (Wilson et al., 2005). These early gene products are 
important replication factors of HPV. Both proteins direct the host replication factors to 
the viral origin of replication, resulting in an increase of viral genome copies per cell 
(Kadaja et al., 2009). E1 is the primary replication factor that binds to the origin of 
replication, and exhibits helicase activity, initiating the unwinding or separation of the 
viral DNA strands/DNA double helix (Lin et al., 2002, Longworth and Laimins, 2004).  
E2 functions in combination with E1, binding to the recognition site of the LCR next to 
the E1 binding site (Sedman and Stenlund, 1998). Furthermore, E2 is involved in 
productive infection, as during cell division (mitosis), E2 ensures efficient segregation of 
viral genomes into the daughter cells (Van Tine et al., 2004).   
 
Another role of E2 is the positive and negative regulation of the early promoter p97, 
causing a self-regulation of p97.  Low level expression of E2 leads to a positive regulation 
of the early promotor, whereas a high level expression of E2 causes a negative regulation 
of p97. Thus differential regulation of E2 can lead to a stable viral copy number in 
undifferentiated cells and a stable level of the oncogenes of E6 and E7 (Longworth and 
Laimins, 2004, Steger and Corbach, 1997). 
 
1.2.6.3. Proliferation and amplification  
 
In normal epithelia, basal cells undergo a differentiation process after exiting the cell 
cycle and migrating into the suprabasal layer. During this process, the newly formed 
daughter cells leaves the basal membrane after division of the basal cells (Kajitani et al., 
2012, Madison, 2003).  During HPV infection, cell cycle regulation is disrupted by the 
expression of E6 and E7, leading to a delay in terminal differentiation (Doorbar, 2005). 
The E6/E7 proteins are key players in driving cell proliferation in the basal and parabasal 
cell layers. The proliferation promoting functions of E6 and E7 are linked to the expansion 
in lesion size (Doorbar et al., 2012). 
 
The main function of E7 is down-regulation of the Retinoblastoma protein (pRb), 
degrading both the p105 and p107 forms of pRb, which control cell cycle entry in the 
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basal layer, as well as p130 which is involved in cell cycle re-entry in the upper epithelial 
layers. Another key role of E7 is to interact with proteins involved in cell proliferation, 
such as p21 and p27 (Doorbar, 2005). The primary function of E6 is preventing apoptosis 
by degradation or down-regulation of p53. E6 also maintains telomere integrity during 
repeated cell division (Doorbar et al., 2012, zur Hausen, 2002, Klingelhutz et al., 1996).  
 
Amplification of the viral genome occurs in the upper epithelium, and is necessary to 
produce higher number of viral particles in the host cells (Middleton et al., 2003). The 
expression of E6 and E7 in the upper epithelium, allows infected cells to re-enter S-phase 
and for the viral genome copy number to increase. During the late stage of viral 
amplification, the promoter p670 is activated and this leads to up-regulation of E1 and E2 
(viral replication), which results in a higher copy number (Doorbar et al., 2012, Flores et 
al., 1999).  
 
Next to E1 and E2, E4 and E5 indirectly contribute to genome amplification. It is thought 
that E5 is involved in genome amplification, due to its capacity to stabilize epidermal 
growth factor receptor, as well as enhancing epidermal growth factor signalling and 
mitogen-activated protein (MAP) kinase activity and to modulate extracellular-signal-
regulated kinase 1/2 (ERK1/2) (Doorbar et al., 2015).  
 
1.2.6.4. Virion assembly  
 
In the final process of HPV infection the viral genome is encapsidated in a protein coat 
composed of L1 and L2 proteins, then transported to the cell surface. Expression of L1, 
requires a change in splice sites usage. This leads to an increase of transcription that 
initiates at the late promoter e.g. p670 in HPV-16, which terminates at the late 
polyadenylation site. This process is facilitated by high expression of E2 that down-
regulates p97.  The change in splice sites leads to initiation of genome packaging. Prior 
to the expression of L1, final encapsidation requires L2 to be recruited by E2. L2 then 
assembles the virions. E4 is then involved in organisation of virions that disrupts the 
keratin. This allows the release of virions from the cell surface to allow infection of other 
cells (Doorbar et al., 2015).  
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1.2.7. Molecular mechanisms of HPV mediated carcinogenesis in HNSCC 
 
Human papillomaviruses are one of the main causes of development of pre-neoplastic 
and malignant lesions in cervical and head and neck cancer (Narisawa-Saito and Kiyono, 
2007, Rampias et al., 2014). The two oncoproteins E6 and E7 play an important role in 
cellular transformation and formation of cancer, representing significant characteristics 
of the “hallmarks of cancer” (Hanahan and Weinberg, 2000, Hanahan and Weinberg, 
2011). The individual molecular functions of E6 and E7 in carcinogenesis are explained 
in detail below. The joint effect of the two HPV oncogenes E6 and E7 leads to unregulated 
cell cycle progression, which results in genomic instability and accumulation of mutations 
in the host cell. The simultaneous functions of E6/E7 can lead to incorrect chromosome 
numbers and aberrant mitotic figures (Duensing et al., 2001, Duensing et al., 2000). These 
induced genomic instabilities facilitate viral integration into the host genome. This occurs 
mostly at fragile sites in the human genome. Variation can be seen in the location of 
integration sites, and they are not connected to a specific sequence or site (Thorland et 
al., 2003). Viral integration may be a significant event in carcinogenesis as it prevents 
stochastic loss of HPV episomes and deregulates viral gene expression (Pett and 
Coleman, 2007).  
 
1.2.7.1. Functions of E7 in carcinogenesis  
 
E7 is one of the most important early genes in HR-HPVs. It can target many cellular 
proteins and dysregulate the cell cycle. Its association with members of the pRb family is 
well characterized; E7 protein binds and inactivates Rb and associated family members 
including p103 and p107. Rb is a negative regulator of the cell cycle and prevents S-phase 
entry by associating with E2F family members (Doorbar, 2005). Through binding and 
inactivating hypo-phosphorylated Rb, E7 releases E2F, which then has the ability to 
promote cell cycle progression (Figure 1-3 and Figure 1-4) through activation of many 
other cell cycle genes like cyclin A and E (Duensing and Munger, 2004). This results in 
G1/S checkpoint dysregulation. In normal cells phosphorylation of Rb and E2F activity 
leads to upregulation of p16 which allows the control of kinase activity (cyclin D/CDK4-
6) by a negative feedback loop. Since p16 expression is normally repressed, reduction or 
loss of the hypophosphorylated Rb protein can result in p16 overexpression. The 
interaction of E7 with Rb, leads to release of active E2F in the absence of CDK4/6 (Boulet 
et al., 2007, Giarre et al., 2001, Doorbar, 2005, Hanahan and Weinberg, 2000, Hanahan 
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and Weinberg, 2011). The expression of cyclin E is absolutely necessary for S-phase 
entry, and is expressed during natural infection as a result of E7 expression and disruption 
of the E2F/pRb complex. High levels of cyclin dependent kinase inhibitors in 
differentiated cells can lead to formation of inactive complexes that contain E7, cyclin 
E/CDK2 and either p21 or p27. These CDKs and the inhibitors are important for cell 
cycle regulation.  During normal cell cycle regulation p21 and p27 are involved in 
inhibition of G1/S progression. P21 and p27 get inactivated or neutralized by binding of 
E7, leading to high CDK activity and unregulated G1/S progression (Doorbar, 2005).  
 
1.2.7.2. Functions of E6 in carcinogenesis   
 
Another important function of E6 is the maintenance of telomerase activity, which is 
known as another key factor of the hallmarks of cancer (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011). The maintenance of telomerase activity is highly 
dependent on activation of the human telomerase reverse transcriptase (hTERT) 
promoter, which controls levels of the telomerase catalytic subunit. Studies have revealed 
that E6 mediated activation of the hTERT promoter requires the coordination of an 
E6/E6-AP complex for engagement of activation. Additionally, activation is dependent 
on Myc binding sites in the hTERT promoter (Liu et al., 2005, Liu et al., 2008). Secondly 
hTERT can be activated by degradation of p53 by E6 (Oh et al., 2001). This combined 
disruption of pRb (E7) and telomerase activity leads to immortalized keratinocytes and 
cancer formation (Figure 1-3 and Figure 1-4) (Oh et al., 2001). 
Beside stabilising telomerase activity, E6 has several other roles in the development of 
carcinogenesis. Activation of E2F by E7 leads to induction of p14ARF, which stabilizes 
p53 by inhibiting Mdm2. One of the main functions of E6 is to abrogate the anti-
proliferation response, by inducing the degradation of p53 during proliferation (Duensing 
and Munger, 2004). This degradation occurs after binding of E6-associated protein (E6-
AP), which marks p53 for proteosomal degradation. Loss of p53 subsequently facilitates 
the accumulation of mutations and consequent genomic instability (zur Hausen, 2002) 
(Figure 1-3 and Figure 1-4).  
The capacity of E6 to induce malignancy also comes from its interaction with proteins 
containing PDZ domains. These proteins are involved in regulation of cell attachment, 
cell proliferation and cell signalling (Pim et al., 2012, Thomas et al., 2008). The PDZ 
binding motif is absent from the E6 of low-risk HPV types and thereby represents a 
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molecular signature for the oncogenic potential in high risk HPV types (Rampias et al., 
2014). 
Enabling replicative immortality (telomere activity), sustaining proliferative signalling, 
degradation of pRb blunts the oncogene-induced senescence response (triggered by E7), 
degradation of pRb serves to evade growth suppressors and resist cell death (p53 
degradation by E6) are some important “hallmarks of cancer” which can be found in the 
above mentioned effects of HPV (Hanahan and Weinberg, 2000, Hanahan and Weinberg, 
2011) 
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Figure 1-3: Normal epithelium compared to HPV infected epithelium 
The G1/S cell cycle checkpoint is regulated by the Rb tumour suppressor protein. Compared to HPV 
infected epithelium E2F is only released in normal epithelium when Rb is phosphorylated by cyclin 
D/CDK4. A negative feedback loop by E2F is activated, leading to increased expression of p16 which 
inhibits cyclin D/CDK4. This leads to reduced activity of E2F. Additionally p14-ARF inhibits Mdm2-
mediated degradation of p53, which leads to p53 promoted cell cycle arrest. During HPV infection, Rb 
binds to E7, which causes the release of E2F transcription factor. The negative feedback loops are 
ineffective as release of E2F is not coordinated by cyclin D/CDK4.  
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Figure 1-4: Combined effects of E6 and E7 
E7 downregulates Rb, which results in uncontrolled proliferation. This effect would usually result in p53-
mediated cell cycle arrest, but this is prevented by p53 degradation by E6. Another function of E6 is 
increased telomerase activity. Normally telomeres would shorten due to uncontrolled proliferation and 
would induce replicative senescence, but this is prevented by E6 mediated increases in telomerase activity.  
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1.2.8. Prevention of HPV infection 
 
Once the infectious cause of cervical cancer was established, prophylactic vaccination to 
prevent cervical cancers became a possibility. There were two different prophylactic 
vaccines available before 2014, Gardasil® (Merck, USA) and Cervarix® 
(GlaxoSmithKline, UK). Both vaccines are based on virus like particles (VLPs), formed 
by self-assembled L1 protein, together with an adjuvant. Gardasil is a quadrivalent 
vaccine, protecting against four HPV types (6, 11, 16 and 18) and contains an adjuvant 
of amorphous aluminium hydroxyphosphate sulfate. Cervarix is a bivalent vaccine which 
only protects against two HPV types (16 and 18). The adjuvant for the bivalent vaccine 
is AS04 (aluminium hydroxide and 3-deacylated monophosphoryl lipid A) (Harper et al., 
2006, Villa et al., 2006). Both vaccines protect against HPV type 16 and 18, which are 
responsible for around 70% of cervical cancer. Since 2016 Merck has made a new vaccine 
available for the public known as Gardasil-9, which covers 9 HPV types (31, 33, 45, 52 
and 58) instead of the previous 4 types.  
 
1.2.8.1. Vaccine regulation worldwide  
 
By 2014 according to the World Health Organisation (WHO), HPV vaccination programs 
were implemented in around 58 (30%) countries with the focus on vaccinating girls 
(WHO, 2014, WHO, 2015). The number of countries implementing national HPV 
vaccination programs had increased to 86 countries (40%) by the end of October 2016 
(Gallagher et al., 2018).  Inclusion of boys in HPV vaccination programs is limited 
worldwide, which is suggested to be tightly connected to an economic cost factor 
(Bogaards et al., 2015). Several countries including Australia, Austria, USA and Canada 
have switched to gender neutral vaccination programmes (Prue, 2014, Elfstrom et al., 
2016). The government in England will introduce a vaccination programme for HPV for 
boys aged 12 and 13 by autumn 2019 (Kmietowicz, 2018).  
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1.3. Natural history of HPV infection in the oropharynx  
 
The connection between HPV and oropharyngeal cancer was established recently and 
therefore the natural history of HPV infection in the oropharynx is still not well defined. 
The most common area for  OPSCC to develop seems to be the tonsillar crypts (Begum 
et al., 2005). This means that screening protocols to detect cancerous and pre-cancerous 
cells, such as for cervical cancer, are most likely to be impractical, due to the difficulty 
of detection caused by the location of pre-malignant and early stage lesions deep within 
tonsillar crypts (Franceschi et al., 2015).  
HPV infections in the tonsil tissue are unexpected, due to the immunologically exposed 
environment. However, the specialized epithelium lining the tonsillar crypts might enable 
HPV infection. Specifically, the epithelial cells of the reticulated epithelium are not a 
robust barrier as they consist of a mix of infiltrating lymphocytes and epithelial cells. 
These characteristics of the tonsil tissue may enable virus infection of the epithelial stem 
cells (Egawa et al., 2015). In general people with persistent HPV infection in the oral 
cavity, are at higher risk of developing oropharyngeal squamous cell carcinoma. The 
observed latency period for OPSCC development have been predicted with 
approximately 10-30 years (Gillison et al., 2015). 
OPSCC cases are higher in men, with a 4-fold higher occurrence when compared to 
women. This observation is found independently of the HPV status of OPSCC. Within 
the HPV-negative cases this has been tightly connected to the tobacco and alcohol 
consumption (Evans et al., 2013, Schache et al., 2016). The reason this difference is also 
present with the HPV-positive tumours is less clear. However, it might be related to the 
higher prevalence of oral HR-HPV infections within men or the tendency for men to have 
a higher average number of sexual partners compared to women (Gillison et al., 2012b, 
D'Souza et al., 2014) .   
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1.3.1. Differences between HPV-positive and HPV-negative tumours 
 
Epidemiologically, patients with HPV-positive OPSCC tend to be younger, fitter and 
have no or limited history of tobacco and alcohol use, compared to the majority of HPV-
negative patients (Deschler et al., 2014). Clinically, HPV-positive tumours respond better 
to treatment and have better long-term survival (Evans et al., 2013). A recent study aimed 
to classify OPSCC’s based on different histological features classified the histological 
appearance of HPV-positive OPSCC. The new classification was based on three 
histologically categories as non-keratinizing cell carcinomas (NKSCC), keratinizing 
(KSCC) and a hybrid appearance and determined the frequency of HPV in these subsets 
of tumours. Non-keratinizing cell carcinomas were significantly more likely to be HPV 
and p16 positive compared to keratinizing OPSCC’s (p<0.001) with a better disease 
specific-survival (NKSCC: p=0.0002 and KSCC p=0.0142).  
The standard clinical tumour classification is done according to the tumour-node-
metastasis (TNM) staging system (Hermans and Lenz, 1996, Patel and Shah, 2005). It 
describes the tumour size, involvement of lymph nodes and distant metastasis. Tumours 
are then classified accordingly, Tx – T4 (Tumour size), Nx – N3 (Nodal stage) and Mx – 
M1 (Metastasis stage) (Patel and Shah, 2005). The average tumour size at diagnosis tends 
to be smaller in HPV-positive cases but histologically represents a more advanced stage 
of neck disease, compared to HPV-negative cases. A similar difference is seen at the 
nodal stage, with a higher proportion in nodal metastasis at the time of diagnosis 
(Deschler et al., 2014, Gillison et al., 2012b, Goldenberg et al., 2008).  
Differences in mutation pattern have been observed between HPV-positive and HPV-
negative HNSCC (Stransky et al., 2011). In a study cohort of 92 HNSCC patients, 74 
samples were subjected to whole-exome sequencing of tumour-normal pairs. Half the 
amount of mutations was found in HPV-positive samples compared to the HPV-negative 
cohort with a mean of 2.29 mutations/mega base (Mb) to 4.83 mutations/Mb (p=0.004). 
This study confirmed the expected pattern of TP53 mutation between the groups. TP53 
mutations are common within HPV-negative HNSCC and OPSCC tumours (Stransky et 
al., 2011). The Catalogue of Somatic Mutations in Cancer (COSMIC), is a database to 
explore the impact of somatic mutations on different types of human cancer. However, 
this tool did not show any mutations for human papillomavirus connected to an associated 
cancer, only of the associated cancer itself. Cosmic provides the data of common 
mutations of head and neck cancers, including OPSCC, where TP53 (32%) is the most 
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common mutated gene, followed by CDKN2A (11%), NOTCH1 (9%) and PIK3CA (7%). 
All other mutated genes showed a frequency of less than 5% (Data obtained on the 
4.2.2019 from https://cancer.sanger.ac.uk).  
TP53 mutations in HPV-positive HNSCC are uncommon as a result of the interaction 
with the oncoprotein E6 during viral integration and replication. TP53 mutations in 
HNSCC are generally associated with a poor prognosis and lower survival rate 
(Lindenbergh-van der Plas et al., 2011).  
1.3.1.1. Post-transcriptional modifications/regulations in the p53 network  
 
In general, TP53/p53 is of high importance, as it is involved in regulation of the synthesis 
of mRNA encoding proteins, involved in cellular stress response (cell cycle arrest, 
apoptosis and senescence). Some of these mRNAs are concurrently regulated at the post-
transcriptional level by miRNAs and RNA-binding proteins (RBPs), which can modify 
the p53 transcriptional program in a cell type and stimulus specific manner (Freeman and 
Espinosa, 2013).  
E3 ubiquitin ligase MDM2 is one of the main factors in post-transcriptional regulation of 
p53, with the function of targeting p53 for degradation. This interaction with MDM2 
controls the level of p53. Several miRNAs are capable of targeting MDM2, which can 
diminish the amount of MDM2 produced in response to p53 activity, which leads to 
increased p53 activity in cells. High expression of all these miRNAs can cause a positive 
feedback loop, which causes p53 to upregulate both its own repressor and multiple 
negative regulators to enhance its own expression levels and activity (Freeman and 
Espinosa, 2013, Kubbutat et al., 1997, Momand et al., 1992, Oliner et al., 1993). 
In addition to the action of miRNAs, the p53 transcriptional program is also co-regulated, 
both negatively and positively, by RNA-binding proteins (RBPs) that control the stability 
and translation of mRNAs induced by p53. p21 (CDKN1A). Furthermore, some RBPs 
amplify the signal by providing enhanced mRNA transcript (Freeman and Espinosa, 
2013, Scoumanne et al., 2011). Another function of p53 to mention is the interaction with 
14-3-3σ. This leads to repression of CDC25 transcription, which leads to a p53 induced 
converging signal, involving transcriptional and post-transcriptional regulation that 
provokes G2/M arrest (Freeman and Espinosa, 2013, St Clair et al., 2004). 
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1.3.2.  Detection of OPSCC and HPV testing  
 
Early diagnosis of OPSCC is a key factor for improved prognosis and treatment. 
However, it is important to consider the factors associated with late stage diagnosis. In 
OPSCC, common symptoms such as hoarseness, dysphagia, otalgia and odynophagia can 
lead to early detection. Oropharyngeal cancer can also be detected in the mouth through 
routine dental examinations. Lack of routine dental visits can often lead to a late diagnosis 
(Chen et al., 2007). High-quality imaging is used to determine the stage of the disease, by 
revealing submucosal tumour spread and detecting subclinical adenopathies (Hermans 
and Lenz, 1996, Patel and Shah, 2005).  
Within OPSCC disease, it is important to define the HPV status of each tumour, as in 
general, HPV-positive OPSCC patients respond better to treatment and have a better 
prognosis (Evans et al., 2013). A known biomarker for HPV-positivity is p16 because it 
is generally upregulated in HPV-positive tumours, due to cell cycle dysregulation by E7 
and E6. Immunohistochemistry (IHC) for p16 is routinely performed for OPSCC patients. 
Besides p16 expression HPV can be identified in tumour tissue through DNA and RNA 
testing. One of the main goals of HPV detection is to identify if HPV is the driving force 
behind a certain disease. A standard method to identify HPV within OPSCC and other 
HPV-driven cancers, is to confirm the presence of the two main oncoproteins E6 and E7, 
which are the two main factors for carcinogenic transformation within the host (Schache 
et al., 2011a, Schache et al., 2011b, Wiest et al., 2002).  
Common molecular HPV detection methods are: Nucleic acid hybridization assays (e.g. 
Southern blot or In-situ hybridisation), Signal amplification systems (Hybrid Capture 
systems) or a target amplification systems known as nucleic acid amplification assays 
(e.g. PCR, Real-time-PCR, reverse transcriptase-PCR) (Molijn et al., 2005). 
For subsequent molecular biological test and diagnostic purposes, tissue samples from 
extracted biopsies are fixed in formalin and embedded in paraffin (FFPE). This method 
of storage has been used for decades and can be used for RNA, DNA or protein testing. 
A disadvantage of FFPE, is the potential negative long-term storage effect on the quality 
of RNA. RNA isolation from FFPE was shown to have a negative effect on PCR, RT-
PCR and cDNA testing. After a year the RNA integrity number (RIN) quality tested for 
RNA was between 5-6, which would make it unsuitable for genotyping purposes (von 
Ahlfen et al., 2007). High quality RNA should have a RIN of 8 or above. 
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As described above, p16 is the most well-known biomarker for HPV-positivity. However, 
p16 as a surrogate biomarker lacks specificity, as p16 can be upregulated or present in a 
small percentage (14-17%) of HPV-negative tumours as well (Lewis et al., 2010, 
Rietbergen et al., 2014). Nevertheless, p16 IHC testing of FFPE slides is still the most 
common technique to indicate the HPV status of tumours.  
One procedure to capture all HPV types and variants present in a biological specimen is 
DNA sequencing of the viral genome, either after cloning into a plasmid or via 
polymerase chain reaction (PCR) fragment, for single HPV detection or detection of 
multiple HPV types (Villa and Denny, 2006).  
HPV DNA can be detected by PCR or in situ hybridisation (ISH). Different available 
methods can either detect the presence of a group of HPV types compared to other 
methods detecting HPV-16 alone. Most of the techniques used are either PCR and 
Enzyme Linked Immunosorbent Assay (ELISA) based (Robinson et al., 2012). However, 
tests for p16 or DNA based tests as a standalone test, do not reach the specificity and 
sensitivity of testing via mRNA detection (RNA qPCR).  A combination of these or 
several other tests would provide a more reliable result (Schache et al., 2011a, Smeets et 
al., 2007). A study on clinical tests has presented the combinations of p16/HPV DNA by 
ISH with 88% sensitivity and 90% specificity or p16/HPV DNA qPCR with a 97% 
sensitivity and 94% specificity as tests with high prognostic values (Schache et al., 
2011a).  
 
1.4. Treatment of OPSCC 
 
History has shown that patients with OPSCC (HPV-positive and HPV-negative) were 
often treated when the tumours were large, as smaller tumours did not trigger any 
symptoms and were rarely detected. Traditional treatment of OPSCC included open 
surgery which involves large facial and neck incision (Nichols et al., 2013b). Next to 
surgery, radiotherapy was the standard option for OPSCC treatment in the past. Often a 
combination of surgery and radiotherapy was used (Parsons et al., 2002, Ramqvist and 
Dalianis, 2011). Open surgery and radiotherapy (RT) were seen to be equally effective in 
terms of survival (Nichols et al., 2013b). New approaches in robotic surgery, e.g. trans-
oral robotic surgery (TORS), allow the surgeons to overcome visualization and access 
challenges and avoid incisions in the face and neck. Recent studies have shown that 
combined treatments of chemo-radiotherapy (CRT), usually with cisplatin, have a better 
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survival outcome for patients. However, the survival improvements come with increased 
acute and late toxicities, which can include dysphagia, mucositis, fibrosis, 
osteoradionecrosis, or neurotoxicity. The combined radio- and chemotherapy also 
prolongs risk of long-term gastrostomy tube dependency (Nichols et al., 2013b). 
 
1.4.1. Ionising radiation  
 
The radiation therapy of cancer typically uses ionising photon beams, X-rays or gamma-
ray for local or regional treatment. The cellular damage, measured in Gray (Gy), increases 
with the amount of absorbed radiation dose. It is defined as the amount of energy absorbed 
relative to a volume of a tissue (Trikalinos et al., 2009). The radiation used is called 
Ionising Radiation (IR), as it is capable of forming ions and deposits energy in the cells 
of the tissue it moves through. The stored energy in the cells is able to kill the cancer cells 
by damaging DNA, which results in cell death (Baskar et al., 2012).  
Caesium-137 (Cs-137) is a common radioactive source used for a wide range of 
radiotherapy. Cs-137 damages tissue and cells via free radicals. Gamma radiation is used 
in cancer therapy for its DNA damaging abilities. In general Cs-137 decays indirectly via 
beta radiation with a 93.5% likelihood to metastable Barium 137 (137mBa) and further 
decays via gamma radiation into the stable nuclide Barium 137 (137Ba). (Lahtz et al., 
2012).  
 
1.4.2. Radiotherapy for HNSCC/OPSCC in the UK  
 
For head and neck squamous cell carcinoma, including OPSCC, Intensity-Modulated 
Radiotherapy (IMRT) is the standard therapy for patients undergoing primary or adjuvant 
radiotherapy (Ho et al., 2009). Due to improvements in dosimetry and imaging 
techniques, IMRT enables precise delivery of a high radiation dose to the tumour, but a 
minimal dose to the surrounding tissue. This technique allows more normal tissue to be 
spared, which reduces the risk of late toxicity (Taylor and Powell, 2004). Internationally, 
and in some centres in the UK, the definitive treatment dose remains 70Gy in daily 
fractions of 2Gy over seven weeks. Other centres within the UK use altered fractionation 
regimens of 65-66Gy in 30 fractions (2 -2.2Gy) over six weeks for HNSCC (Ho et al., 
2009). 
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Combined treatment with cisplatin and radiotherapy is the current standard therapy for 
stage III and IV patients <70 years of age. As a combined treatment the RT dose is defined 
as 70Gy in 35 fractions of 2Gy international. However, within the UK a more moderate 
hypo-fractionated schedule of 65-66Gy in 30 fractions has been incorporated into UK 
trials and centres (Pignon et al., 2009, Nutting et al., 2011). Current treatment for HPV-
positive and HPV-negative OPSCC patients is the same in the UK. The aim of a current 
clinical trial, PATHOS (Owadally et al., 2015), is to reduce the intensive adjuvant 
treatment after minimally invasive trans-oral surgery, due to the fact that HPV-positive 
OPSCC have a more favourable prognosis. HPV-positive patients are included in the 
PATHOS study, if showing a cancer stage of T1-T3 N0-N2b with a resectable primary 
tumour via a trans-oral approach. HPV-positivity is tested on biopsy specimens by p16 
immunohistochemistry and high risk HPV in-situ hybridisation. These patients are then 
classified into three pathological risk groups: Patients in the low-risk pathology group 
receive no adjuvant treatment, as in standard practice. Patients in the intermediate-risk 
pathology group are randomised to receive either standard dose post-operative 
radiotherapy (control) or reduced dose radiotherapy. Patients in the high-risk pathology 
group will either receive either post-operative chemo-radiotherapy (control) or 
radiotherapy alone. The goal of the study is to standardize the transoral surgery and post-
operative intensity-modulated radiotherapy protocols in the UK. Additionally, long-term 
dysphagia could be decreased by reducing adjuvant therapy without causing a negative 
clinical outcome.  (Owadally et al., 2015).  
 
1.4.3. Induction of DNA damage by IR  
 
DNA damage constantly occurs in the human body. These DNA lesions can influence the 
processes of genome replication and transcription. Incorrect repair or no repair at all, can 
lead to mutations or causes a wide range of genome aberrations that threatens cell 
viability. DNA lesions within a cell can occur via endogenous (spontaneous) factors, such 
as DNA mismatches during DNA replication, hydrolysis, oxidation or alkylation. 
Secondly, DNA damage can be caused be exogenous (environmental) factors, such as 
ultraviolet radiation (UV), ionising radiation and various chemical agents (Friedberg et 
al., 2004, Jackson and Bartek, 2009). To deal with DNA damage, cells have evolved a 
wide variety of DNA repair mechanisms including: Base excision repair (BER), 
Mismatch repair (MMR), Nucleotide excision repair (NER), Non-homologous end-
joining (NHEJ) and Homologous recombination (HR). These mechanisms are involved 
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in repair of single strand breaks (SSB) or double strand breaks (DSB) (Jackson and 
Bartek, 2009).  
Ionising radiation, as used in radiotherapy, is the main cause of DSB. The mechanisms of 
DNA damage caused by IR, will be explained in this section. IR causes different forms 
of DNA damage, the most toxic are double-strand breaks (DSB) of the DNA (Figure 1-
5). This damage can be caused directly or indirectly to DNA molecules. The direct action 
hits the DNA molecule. For indirect action, radiation hits the water molecules present in 
cells, which leads to the production of free radicals. These free radicals (unpaired 
electrons) react with the DNA molecules, causing molecular structural damage. The 
number of free radicals produced depends on the dose of IR (Desouky et al., 2015).  
The DSB induced by IR carry 3’ blocking ends (e.g. 3’-phosphate or 3’-phosphoglycolate 
moieties), and have single-stranded overhangs of variable length. Furthermore, complex 
induced DSB consist of a high number of oxidised base modifications and abasic (AP) 
sites directly adjacent of the DSB breaks. In transcriptionally active DNA the damage 
increases in yield and becomes more complex with IR dose (Lomax et al., 2013).  
In response to IR induced DNA damage, several cellular responses are initiated (Figure 
1-5). First the MRN (MRE11/RAD50/NBS1) complex binds to DSBs and activates ATM, 
a key PI3K related kinase in the DNA damage response (DDR). This leads to ATM auto-
phosphorylation, inducing activation and phosphorylation of a wide range of substrates 
in the surrounding chromatin. One of the ATM substrates is a H2A histone variant called 
ɣH2AX, which when phosphorylated is one of the first responders in DSB signalling. 
Phosphorylation is amplified through recruitment of MDC1. Through recruitment of 
MDC1, several other proteins such as BRCA1 or 53BP1 are engaged as well, triggered 
by ɣH2AX. The overall signalling pathway causes downstream phosphorylation of 
substrates including CHK2 and p53, triggering cell cycle arrest in G1/S and or G2/M, 
allowing sufficient time for DNA repair (Vignard et al., 2013, Lomax et al., 2013). 
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Figure 1-5: DNA damage response pathway after IR 
One of the most toxic forms of DNA damage by IR are DSBs. The MRN-complex (MRE1-NSB1-RAD50) 
actives ATM. This causes auto-phosphorylation of ATM, including other surrounding key factors, such as 
p53, and H2AX. Binding of Mdm2 to p53, induces apoptosis.  Through phosphorylation of p53, other 
substrates are activated in response to DNA damage, such as p21 and Rb, which are involved in cell cycle 
regulation. This overexpression of Rb, leads to cell cycle arrest. During cell cycle arrest the decision will 
be made for DNA repair or Apoptosis of the damaged cells. The main DNA repair pathways involved after 
IR induced DNA damage are HR and NHEJ.  
  
Chapter 1  Introduction 
30 
 
1.4.4. DNA repair following IR  
 
DNA double strand breaks are the most common damage caused by IR, which is usually 
repaired through DSB repair mechanisms, including homologous recombination (HR) 
and non-homologous end-joining (NHEJ). Other forms of DNA damage are repaired by 
BER, NER or MMR and are recognized as repair mechanism for single stranded DNA 
damage (Jackson and Bartek, 2009). The MMR functions mainly on base-base 
mismatches and is relevant mainly to mis-pairs occurring during DNA replication and 
recombination (Li, 2008, Jackson and Bartek, 2009). NER recognizes helix-distorting 
base lesions, and operates via two sub-pathways known as global genomic NER (GG-
NER) and transcription coupled NER (TC-NER). TC-NER focuses on the template strand 
of actively transcribed genes which are connected to actions of RNA molecules down the 
template strand during transcription. GG-NER addresses the non-template strand of 
transcribed genes and non-transcribed regions of the genome. After recognition of 
damage it cleaves the damaged strand upstream and downstream of the damage, yielding 
a single-strand fragment of 20-30 base nucleotides in length, which is then removed. The 
gaps are filled by DNA polymerase and associated factor before ligation (Jackson and 
Bartek, 2009, Weinberg, 2007).   
In BER, the damaged or chemically altered base is removed after recognition by a DNA 
glycosylase enzyme, which cleaves the glycosyl bond linking the altered base and the 
deoxyribose. The base-free deoxyribosylphosphate is then excised by the enzyme 
apurinic/apyrimidinic endonuclease (APE). Polymerase is induced to fill the gaps and the 
repair is completed by ligase proteins (Jackson and Bartek, 2009, Weinberg, 2007). 
After induction of DSB by IR, the two main pathways for repair are homologous 
recombination (HR) and non-homologous end-joining (NHEJ). How it is determined 
within a cell after DSB, whether HR or NHEJ will be used is still under debate. It is more 
likely that NHEJ is used outside of S/G2 cell cycle phase, if a homologue is not present 
near a DSB during cell cycle S/G2 transition. However, if cells are in S-phase and a sister 
chromatid is close (homology donor), HR will be used (Lieber, 2010). During the NHEJ 
mechanisms, DSB are recognized by the Ku protein, that binds and activates the protein 
kinase DNA-PKcs, leading to recruitment and activation of several end-processing 
enzymes (e.g. X-ray complementing protein 4, XRCC4-like factor, Aprataxin-and-PNK-
like factor and DNA ligase IV) to DSBs (Davis and Chen, 2013, Jackson and Bartek, 
2009).   
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HR requires a wide number of proteins in its multistep process, which operates at the S 
and G2 cell cycle phase. Several sub-pathways exist for HR. However, HR is always 
induced by ssDNA generation, promoted by a group of proteins including the MRE11-
RAD50-NBS1 (MRN) complex. Through RAD51, BRCA1 and BRCA2 the ssDNA 
invades the undamaged template, which is followed by actions of polymerases, nucleases, 
helicases and other components. The final step involves DNA ligation and substrate 
resolution (Jackson and Bartek, 2009).   
 
1.5. HPV-positive and HPV-negative OPSCC prognosis  
 
The incidence of OPSCC cases is increasing and HPV is one of the main causes. Several 
studies have shown that HPV-positive OPSCC patients respond better to treatment 
compared to HPV-negative OPSCC patients. This better response to treatment is observed 
with several modalities including surgery followed by RT, CRT or as a stand-alone 
treatment. In a study in South-Wales, the data indicated a significantly better overall 
survival for HPV-positive patients with 82.6% survival after 3 years, and 75.4% after 5 
years with compared to HPV-negative patients with 32.2% and 25.3%. This corresponds 
to a reduction of death rate of 78% in HPV-positive cases (HR 0.220, 95% CI; 0.132-
0.366, p<0.001) (Evans et al., 2013). In a meta-analysis in Canada, a similar range of 
overall survival was observed with a three year survival rate in HPV-positive patients of 
85% versus 49% in HPV-negative patients (Nichols et al., 2013a). 
Similar data was obtained from a study in the United States with a 3-year survival rate of 
82.4% in HPV-positive patients and 57.1% in HPV-negative patients (p<0.001 by the log-
rank test). This study further estimated a 9% difference in the overall survival within the 
HPV-positive OPSCC cases. Death in both HPV-positive and HPV-negative groups 
increased with each additional pack-year of tobacco smoking (Ang et al., 2010). The 
adverse influence of smoking on the overall survival of OPSCC patients beside HPV 
status has been reported in several other studies (Gillison et al., 2012b).  
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1.5.1. Possible reasons for improved prognosis of HPV-positive OPSCC/HNSCC 
 
HPV-positive OPSCC patients respond to treatment better than HPV-negative OPSCC 
patients. The better responses might be associated with a reduced capacity to repair DNA 
damage in HPV-positive tumours. During the HPV lifecycle, ATM, ATR, BRCA1, 
RAD51 or RPA are recruited to viral DNA during genome amplification (Gillespie et al., 
2012). Due to the recruitment of DNA repair factors during the viral lifecycle, HPV-
positive cells might be deficient in DNA repair.  
Deficiency of DNA repair and increased IR sensitivity were suggested by two previous 
studies using small panels of HNSCC cell lines. These two studies have suggested that 
HPV-positive cell lines are in general, less able to repair DSB induced by IR. The 
persistence of DSB after induction of DNA damage correlated with greater radio-
sensitivity in HPV-positive cell lines (Kimple et al., 2013, Rieckmann et al., 2013).  Both 
studies agreed that due to the accumulation of DSB after IR, cells fail to progress through 
the G2/M cell cycle checkpoint, which resulted in a higher number of cells accumulating 
in G2 after IR (Kimple et al., 2013, Rieckmann et al., 2013). However, the events 
following G2 arrest are less well understood. One study suggested that accumulation of 
cells at G2, would give cells sufficient time for DNA repair, before progression through 
the cell cycle (Rieckmann et al., 2013). However, an extended time course, to investigate 
a possible decrease of cells in G2, was not performed.  
The improved treatment response could be closely connected to the tumour suppressor 
protein p53. Incomplete loss in HPV-positive tumours might play a role. Even if E6 
causes ubiquitination and proteosomal degradation of p53, re-accumulation of p53 may 
be possible. One of the studies observed that HPV-positive cell lines showed increased 
levels of p53 and p-p53 following IR, which was associated with apoptosis (Kimple et 
al., 2013).  
Some studies have also suggested the influence of an immune target in better treatment 
response of HPV-positive OPSCC patients.  It has been shown that HPV-positive OPSCC 
tumours have a higher number of tumour infiltrating lymphocytes (TILs) relative to HPV-
negative OPSCC, and furthermore showed an increase in CD8+ cells within HPV-positive 
tumours (Nasman et al., 2017, Ward et al., 2014).  
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In summary, several factors could influence the better treatment response of HPV-
positive OPSCC patients, and these include deficiency in DNA repair, incomplete 
degradation and re-accumulation of p53 or an immune response against HPV. 
  
1.5.2. Importance of in-vitro models  
 
Advances in genomic research have opened new possibilities for translational research 
and direct evaluation of clinical samples. However, there is still a need for reliable 
preclinical models to test and improve therapeutic strategies. Currently, human cancer 
cells lines are the most widely used models to study the biology of cancer and to improve 
efficacy of treatment. The importance of cell line models is, that according to current 
knowledge they mimic some of the typical characteristics of tumours, e.g. they have 
similar genetics and molecular biology to the original tumour. They also have many 
advantages relating to convenience of use, being a potentially inexhaustible resource that 
allow investigations to be conducted in controlled conditions and with appropriate 
repetition. This makes cell lines ideal to test novel or current treatments, as they may 
retain their sensitivity to relevant target agents, and can be important to identify and 
characterize target molecules. They also allow study of certain sensitivity and resistance 
responses (Gillet et al., 2013). Therefore, cell line models are a potentially useful tool to 
investigate HNSCC and OPSCCs.  
The study of OPSCC is limited due to the small number of HPV-positive OPSCC cell 
lines. A higher number of cell lines is needed, and these should mimic the typical 
characteristics of HPV-positive OPSCC patients. HPV-positive patients tend to be 
younger, fitter and are less likely to smoke than HPV-negative patients (Evans et al., 
2013, Schache et al., 2016). One study reported that HPV-positive patients had a mean 
age of 57.4 years compared to HPV-negative patients with a mean age 61.4 years 
(Schache et al., 2016).  
In 2014, only eight published HPV-positive OPSCC cell lines were available, including 
UMSCC-47, UPCI-SCC-90, UMSCC-104, 93-VU-147T, UD-SCC-2, UT-SCC-45, 
UPCI-SCC-152 andUPCI-SCC-154. The majority of these cell lines were derived from 
smokers or former smokers. The vast majority of HNSCC cell lines are HPV-negative 
cell lines. Some of the HPV-negative HNSCC cell lines were also derived from tumour 
receiving chemotherapy or radiotherapy, such as UMSCC-4 (derived from tumour 
receiving post-treatment of 2 chemotherapies) or UMSCC-74a (originated from a 
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recurrent tumour – after receiving chemotherapy) (Arenz et al., 2014, Bradford et al., 
2003, Brennan et al., 1995, Brenner et al., 2010, Descamps et al., 2014, Ferris et al., 2005, 
Kimple et al., 2013, Lin et al., 2007, Rieckmann et al., 2013, Steenbergen et al., 1995, 
Tang et al., 2012). The influence of chemotherapy on resistance to treatment was 
investigated in a study by Di Nicolantonio et al. (2005), which showed a slightly increase 
in resistance in biopsies of various cancer types post-chemotherapy (Di Nicolantonio et 
al., 2005). Therefore, chemo-resistance could be observed in in-vitro experiments.  
The number of available OPSCC HPV-positive has since increased to 10 cell lines, 
because two novel HPV-positive OPSCC cell lines (CU-OP-2 and CU-OP-3) were 
successfully derived in a previous study in Cardiff (Pirotte, 2017). It is important to 
develop further new HPV-positive to support research in the field of head and neck 
cancer, and to study the treatment responses of “typical” head and neck patients (HPV-
positive, non-smokers and young)  
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1.6. Aims and hypotheses 
 
According to the literature, there is a shortage of available in-vitro models of HPV-
positive OPSCC cell lines. This reduces the potential for a complete biological 
understanding of this disease. It also limits the attempts to understand the molecular 
mechanisms that might explain the better treatment response of HPV-positive patients. 
Therefore, a major aim of this thesis was to derive new HPV-positive and HPV-negative 
OPSCC cell lines and fully characterize them. The new derived cell lines could be then 
incorporated into a larger panel of cell lines and used to investigate the biology of HPV-
positive OPSCC relative to HPV-negative OPSCC.  
The investigation of the biology of HPV-positive or HPV-negative cell lines was based 
on the expected different response to ionising radiation. Therefore, this study focused on 
identifying differences in survival after IR treatment between the HPV-positive and HPV-
negative OPSCC cell lines. This was then followed by investigating p53 
accumulation/activation, cell cycle abnormalities and gene expression changes. The 
current study did not specifically measure DNA damage/repair after each individual 
experiment. The idea was to identify the individual effect of cell lines in survival, p53 
accumulation, cell cycle abnormalities and gene expression changes after IR. Possible 
changes in gene expression in DNA repair was started to be investigated during basic 
mRNA sequencing analysis. Future studies on DNA damage and DNA repair will specify 
the direct involvement in the collected data of the current study.  
The study aimed to test the following main hypotheses: 
1. Sensitivity will be correlated to the HPV status. Therefore, cell lines derived from 
HPV-positive OPSCC will be more sensitive to ionising radiation than HPV-
negative OPSCC cell lines. 
2. HPV-positive cell lines will show accumulation of p53 following ionising 
radiation, in correlation with accumulation of p21 and p-p53. 
3. HPV-positive OPSCC cell lines will show greater variations in cell cycle arrest 
(e.g. G2 arrest) compared to the HPV-negative OPSCC cell lines  
4. Difference in gene expression between HPV-positive and HPV-negative cell lines 
after IR will be observed.  
a. Differences in gene expression between untreated and treated samples 
after IR will be observed. 
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Chapter 2 : Materials and methods  
 
2.1.  Cell culture 
 
This section contains information about the cell lines, reagents and culture conditions 
used in the current study.   
 
2.1.1. Established cell lines  
 
2.1.1.1. 3T3 mouse fibroblast  
 
In 1963 the mouse embryo fibroblast cell line J2 3T3 was established by George Todaro 
and Howard Green at the New York University (Todaro and Green, 1963). This became 
the standard fibroblast cell line for use in many experimental studies. 
Stocks of 3T3 mouse fibroblast (J2 3T3 feeder cells) were received as kind gift from Dr. 
Sally Roberts (University of Birmingham, UK). They were used in this project to support 
the growth of Primary Culture Oropharyngeal Cells (PCOC) (known officially as Cardiff 
University Oropharyngeal (CU-OP) cells) and to supplement growing cells at low cell 
density during the clonogenic assays (radio-sensitivity assay).  
 
2.1.1.2. HeLa cell line  
 
The HeLa cell line was derived from a cervical cancer in a 31 year-old African-American 
woman. It is a HPV-18 positive cell line (Scherer et al., 1953). The cell line was received 
from the American Type Culture Collection, short ATCC (cat. Number: CCL-2).  
 
2.1.1.3. SiHa cell line  
 
SiHa was derived from a cervical squamous cell carcinoma in a 55-year-old Asian woman 
(Friedl et al., 1970). This cell line is HPV-16 positive and was received from the ATCC 
(cat. Number HTB-35).  
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2.1.1.4. CaSki cell line  
 
The CaSki cell line was derived from an epidermoid carcinoma metastasised to the small 
bowel in a 40 year-old Caucasian woman (Pattillo et al., 1977). CaSki cells contain an 
integrated HPV-16 genome (about 600 copies per cell). Cells were obtained from the 
European Collection of Authenticated Cell Cultures, short ECACC (cat. Number: 
87020501).  
 
2.1.1.5. UPCI-SCC-90 cell line  
 
The UPCI-SCC-90 cell line is derived from an oral squamous cell carcinoma, from a 44 
year-old Caucasian male smoker (Ferris et al., 2005) and carries 100-150 copies of 
integrated HPV-16 genome. It was received from the Leibnitz-Institute DSMZ Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (cat. Number: ACC 670).  
 
2.1.1.6. UMSCC-47, -4, -6, -19 and -74a 
 
UMSCC-47 (HPV-positive cell lines) and UMSCC-4, UMSCC-6, UMSCC-19 and 
UMSCC-74a (HPV-negative cell lines) were derived at the University of Michigan 
(USA) and obtained from Professor Thomas Carey.  
 
UMSCC-47 is a HPV-positive cell line, derived from the oral cavity (tongue squamous 
cell carcinoma) in a 53-year-old man and carried integrated HPV-16 genome (Lin et al., 
2007, Brenner et al., 2010).  
 
UMSCC-4 is a HPV-negative cell line, derived from a tongue squamous cell carcinoma 
in a 47-year-old woman (Baker, 1985). 
 
UMSCC-6 is a HPV-negative cell line, derived form a tongue squamous cell carcinoma 
in a 32-year-old male (Baker, 1985). 
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UMSCC-19 is a HPV-negative cell line, derived from a tongue squamous cell carcinoma 
in a 66-year-old male (Baker, 1985).  
 
UMSCC-74a is a HPV negative cell line, derived from a tongue squamous cell carcinoma 
in a 50-year-old male (Takebayashi et al., 2004, Brenner et al., 2010).  
 
2.1.2. Human epidermal keratinocytes 
 
Primary human epidermal keratinocytes (HEKn), isolated from neonatal foreskin, were 
purchased from Thermo Fisher Scientific (Paisley, UK) (cat. Number: C0015C). This 
keratinocyte cell line was derived from normal (healthy) tissue and is HPV-negative. This 
cell line was used as a control in various assays including radio-sensitivity experiments, 
flow cytometry for cell cycle analysis and as a positive control in Western blotting. With 
the appropriate culture conditions, the cells can sustain around 30 population doublings 
(PD).   
 
2.1.3. CU-OP-2, CU-OP-3, CU-OP-17 and CU-OP-20 
 
CU-OP-2, -3, -17 and -20 were derived at the HPV Group at Cardiff University.  CU-OP-
17 and -20 were derived during this project. CU-OP-2 and CU-OP-3 were derived during 
an earlier project by Dr. Evelyne Pirotte. All were of oropharyngeal squamous cell 
carcinoma origin. CU-OP-2, -3 and -20 are HPV-16 positive cell lines, whereas CU-OP-
17 is HPV-negative. All cell lines were derived from male patients. The development and 
characterisation of these lines is described in detail in section 2.1.6. 
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2.1.4. Cell culture material  
 
2.1.4.1. Culture vessels  
 
Cell lines were grown in tissue culture flasks in a size range from T-25, T-75 to T-175 
(Fisher Scientific, Loughborough, UK), or tissue culture plates in a size range from 
60x15mm or 100x15 mm (VWR, Lutterworth, UK).  
 
2.1.4.2. Cell culture media  
 
Supplements were added to the compositions of the different cell culture media. For the 
established cell lines (keratinocytes), Dulbecco’s Modified Eagle Medium (DMEM) was 
used; for novel cell lines (CU-OP cell lines), Glasgow Minimum Essential Medium 
(GMEM) was used, and for normal human keratinocytes, EpiLife Media with 1% Human 
Keratinocyte Growth Supplement (HKGS). Supplements added to the media are listed in 
Table 2-1.  
All components were prepared according to supplier’s instructions. All components were 
aliquoted and stored at -20°C or 4°C and thawed at 37°C in a water bath before use.  
 
 
Table 2-1: Reagents used for cell culture media  
Reagents   Supplier 
Penicillin / Streptomycin (Pen/Strep) 
Sigma-Aldrich, Gillingham, UK 
Hydrocortisone  
Epidermal Growth Factor (EGF) 
Fetal Bovine Serum (FBS) 
Newborn Calf Serum (NCS) 
L-Glutamine 
Cholera Toxin  
Non-essential amino acids (NEAA) 
HKGS Thermo Fisher Scientific 
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2.1.4.3. Dulbecco's modified eagle medium for developed keratinocytes and J2 
3T3 Feeder cells   
 
The standard Dulbecco’s modified eagle medium (DMEM) media (Sigma-Aldrich 
D6429) was used for following cell lines: UMSCC-47, UPCI-SCC-090, UMSCC-4, 
UMSCC-6, UMSCC-19 and UMSCC-74a and J2 3T3 feeder cells (different composition 
listed in Table 2-2 and Table 2-3).  
 
Table 2-2: DMEM 500ml media for developed cell lines (keratinocytes)  
Reagents Concentration 
NEAA 0.2% 
FBS 10% 
Penicillin 100 U/ml 
Streptomycin 100 ng/ml 
L-Glutamine 2mM 
 
Table 2-3: DMEM 500ml media for J2 3T3 Feeder cells 
Reagents Concentration 
NCS 10% 
Penicillin 100 U/ml 
Streptomycin 100 ng/ml 
 
 
2.1.4.4. Glasgow minimum essential medium  
 
The standard Glasgow minimum essential medium (GMEM) media (without Glutamine) 
(Sigma-Aldrich G5154) was used for culture of the keratinocytes cell lines of CU-OP-2, 
CU-OP-3, CU-OP-17 and CU-OP-20. Supplements added to the GMEM media are listed 
in Table 2-4. All GMEM media were set-up without EGF. EGF was added 24 hours after 
passaging a CU-OP cell line to support cell growth (Table 2-4).  
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Table 2-4: GMEM 500ml media composition 
Reagents Concentration 
Cholera Toxin (CT) 0.1nM 
Hydrocortisone (HC) 1.5nM 
Penicillin 100U/ml 
Streptomycin 100ng/ml 
L-Glutamine 2mM 
FBS 10% 
EGF 10ng/ml 
 
2.1.4.4.1. GMEM supplements  
 
2.1.4.4.1.1. Cholera toxin 100nM (1000x)  
 
0.5 mg of Cholera Toxin was dissolved in 0.6mL distilled water. The dissolved solution 
was made up to 60 mL with GMEM media. 5mL aliquots were stored at 4C.  
2.1.4.4.1.2. Epidermal growth factor (EGF) 1µg/ml (100 x) 
 
0.1 mg of EGF was dissolved in 100 mL GMEM media. Aliquots of 5mL were stored at 
-20C.  
2.1.4.4.1.3. Hydrocortisone 1mg/mL (2000x)  
 
10 mg of Hydrocortisone was dissolved in 5 mL of 100 % absolute Ethanol (does not 
dissolve in media or distilled water properly).  The dissolved solution was made up to a 
final volume of 5 mL with distilled water. Aliquots of 250µl were stored at -20C.  
2.1.4.4.1.4. L-Glutamine 200mM (100x)  
 
10 mL media to vial of Glutamine with a final stock concentration of 200 mM and was 
stored at 4C. 
2.1.4.5. Cell culture solutions 
 
A ready-made 1xPhosphate Buffer Saline (PBS) (Gibco, UK) was used to wash cell 
layers, to dilute solutions and for washing cells after fixation before staining for cell cycle 
analysis.  
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To detach cells from the culture flask 1x Trypsin 0.05 % ethylenediaminetetraacetic acid 
(EDTA) 0.02 % (TE) was used. This was obtained by diluting a 10x TE stock solution 
(Sigma Aldrich) with 900mL of 1xPBS. TE was aliquoted and stored at -20°C.   
 
2.1.5. General cell culture  
 
2.1.5.1. General cell culture conditions  
 
All cell lines were cultured, according to standard cell culture procedure, in a humidified 
incubator at 5 % carbon dioxide (CO2) and 37°C. Cell culture was performed in a class II 
safety cabinet using aseptic techniques. Surfaces were cleaned using 70% industrial 
methylated spirit 74 O.P. (IMS). Cell culture reagents were warmed up for 20-30min in 
a 37°C water bath prior to use. Liquid waste was inactivated in a sodium 
dichloroisocyanurate (NaDCC) solution (Presept, Johnson Johnson, USA) (diluted 
according to manufacturer’s instructions). Plastic waste was discarded into yellow waste 
bags (infectious waste) and stipites and pipette tips collected in Bio-bins designed for 
infectious waste. 
2.1.5.2. Cell counting and viable cell count  
 
Cell numbers were determined by using a Beckman Coulter Vi-cell®. For each count a 
1:10 dilution was prepared (50 µl of sample + 450µl of PBS) in a sample cup and placed 
into the Vi-cell carousel. Sample name and dilution factor was entered into the Vi-cell 
software and the count started. The live camera option, gave the opportunity to double 
check, if the appropriate cells (size) were being counted. For each count Vi-cell 
automatically added Trypan blue for live/dead cell determination, which resulted in a 
final output of viable cells per millilitre.  
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2.1.5.3. Freezing and storage  
 
Cell lines were collected and counted using standard cell culture procedure. 2x106 cells 
were frozen down per cell line in a prepared freezing media, suitable for storage at -80°C 
or LN2 storage.  
Cells were spun down and re-suspended in Freezing media and transferred to cryovials 
and placed in a Nalgene Mr Frosty freezing device. Tubes were stored at -80°C for 3-7 
days and then transferred to liquid nitrogen (LN2) for long-term storage. 
 
2.1.5.3.1. Freezing medium for established cell lines (keratinocytes)  
 
Freezing medium for established immortal cell lines was 80% DMEM media, 10% FBS 
and 10% DMSO. For the following cell lines UMSCC-47, UPCI-SCC-90, UMSCC-19, 
UMSCC-4, UMSCC-6 and UMSCC74a, 2x106 cells/ml were frozen. Information of 
freezing media composition for the established cell lines was provided by the University 
of Michigan.  
 
2.1.5.3.2. Freezing medium for CU-OP cell lines  
 
Freezing medium for primary cell lines (derived from biopsy tissue at Cardiff University) 
consisted of 90 % FBS and 10 % DMSO. 2x106 cells/ml were frozen.   
2.1.5.4. Thawing of cell lines  
 
Rapid thawing of frozen cell lines was done by briefly placing frozen tubes in the water 
bath (37°C) until the contents were thawed. These were transferred to a sterile conical 
tube containing 9 mL of pre-warmed media (to dilute DMSO) then centrifuged for 5min 
at 180g. The cell pellet was re-suspended in 5mL of fresh media and added to the culture 
flask containing the appropriate volume of culture media for the flask size. 
Established keratinocytes were seeded into a T25 flask containing 5mL DMEM media. 
HEKn cells were seeded at the defined cell density of 2x103 cells/cm2 into a T175 culture 
flask. The CU-OP cell lines were seeded into a 10cm tissue culture plate together with 
2x106 irradiated J2 3T3 feeder cells in 10 mL EGF-negative GMEM media. The media 
for the CU-OP cell lines was changed to GMEM EGF-positive after 24 h.  
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2.1.5.5. Subculture  
 
Cells were split once 80% confluence was reached in the tissue culture flask and re-seeded 
at a defined ratio (Table 2-5). The media was removed from the culture flask and the cell 
layer washed with a 1xPBS solution. Cell were then incubated with TE solution until 80-
90% of the cells detached from the culture flask (time indicated in Table 2-5). The 
remaining cells were detached by carefully tapping the culture flask. With an equal 
amount of media, the TE was inactivated and transferred to a sterile universal container 
or 15mL/50mL Falcon tube. Cells were centrifuged for 5min at 180g and resuspended in 
the designated media for established cell lines (DMEM), CU-OP culture (GMEM) or 
HEKn (EpiLife media).  
Established cell lines were split according to a defined ratio (Table 2-5). The appropriate 
amount of media was added to T25, T80 or T175 culture flasks. Due to their high cell-
cell adhesion UPCI-SCC-90 were first incubated for 15-20min with 2mM PBS/EDTA 
then 5min with TE.  
CU-OP subculture was performed in the presence of irradiated J2 3T3 feeder cells to 
support cell growth. Tissue culture plates were rinsed with PBS, followed with a 2min 
TE incubation to remove the remaining J2 3T3 feeder cells. Cells were washed again with 
PBS and incubated with TE (time listed in Table 2-5). CU-OP cells were counted and a 
cell density of 0.8 to 1x106 plated per 10cm together with 2x106 irradiated J2 3T3 feeder 
cells in a total of 10ml GMEM EGF-negative media. Media was then replaced every two 
days with GMEM EGF-positive media and irradiated J2 3T3 feeder cells replaced if cover 
was sparse (1-2 times per week).  
HEKn cells were counted and 2x103 cells/cm2 seeded per T175 flask and 25mL EpiLife 
media was added. Every two days’ media was changed until the flask was 50% confluent 
then every day until 80% confluent.  
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Table 2-5: TE incubation time and split ratio of cell lines.  
Cell line TE incubation time (min) Split ratio 
UMSCC-47 10 1/3 
UPCI-SCC-90 5 ½  
CU-OP-2 15  
-A CU-OP-3 15 
CU-OP-20 15 
CU-OP-17 10 
UMSCC-4 10 1/3 
UMSCC-6 10 ½  
UMSCC-74a 7 ½  
UMSCC-19 10 ½  
HEKn 5 2x105 cells/cm2 
J2 3T3 feeder cells 5 -A 
A CU-OP cell lines and J2 3T3 feeder cells were re-seeded after defining the cell density by cell counting  
 
 
2.1.6. Primary Culture of Oropharyngeal Cells  
 
2.1.6.1. Sample collection and processing  
 
Ethics and NHS R&D approval (reference 13/WA/0002) were obtained for the PCOC-
study and it was adopted into the National Institute for Social Care and Health Research 
(NISCHR) portfolio. Subsequently any newly developed primary cell lines were changed 
to the official nomenclature of CU-OP – Cardiff University Oropharyngeal Cancer). 
Biopsy samples from PCOC-1 to PCOC-12 for the PCOC-study were handled by Dr 
Evelyne Pirotte, biopsy samples PCOC-13 to PCOC-23 were managed by Stefan 
Holzhauser.  
Patients for this study were recruited and consented by the clinical team (Dr. Evans, Mr. 
Al-Husseini and Mr Owens), during the head and neck cancer clinics at Velindre Hospital 
and Heath Hospital in Cardiff. Patients were recruited at different stages of their disease, 
either at the beginning of the treatment or at the beginning of diagnosis. During surgery 
an extra biopsy was collected for the PCOC-study during panendoscopy and placed in the 
provided transport media (for more details of the PCOC study see the designated protocol 
attached in Appendix 1). The process of handling the biopsy is shown in Figure 2-1.  
After receiving the biopsy sample, the transport media was discarded and the biopsy 
sample placed in the tissue culture plate. The sample was cut in half, one half was used 
for cell culture and the other half prepared for nucleic acid extraction. The tissue was 
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washed 3 times with a mix of PBS/Pen-strep and 1x/amphotericin B 5.6mg/l (Sigma 
Aldrich). The sample was then incubated for 15min in the last wash.  
The tissue sample was covered in a thin layer of FBS. The biopsy was placed on a new 
tissue culture plate and cut into small pieces (≤ 2 mm), using scalpels or curved scissors. 
Additional FBS was added during this process to prevent the tissues drying out. The small 
fragments of the biopsy sample were evenly distributed over several 10cm tissue culture 
plates (number of plates depended on the size of the biopsy) and incubated for 2 hours at 
37°C with 5% carbon dioxide in an inverted position. After incubation 10mL of GMEM 
EGF-negative media containing 2x106 irradiated J2 3T3 cells was added slowly to the 
plate to avoid detaching the fragments. The plate was then returned to the incubator.   
  
 
Figure 2-1: CU-OP (PCOC) biopsy processing 
After surgery, biopsies were collected and placed in transport media until processed. Biopsy was cut into 
two pieces. One half was lysed and prepared for DNA/RNA extraction. The other half was used for cell 
culture, washed with PBS/Pen-strep Amphotericin, then cut into small pieces and placed into a FBS coated 
tissue culture plate. This plate was inverted and incubated for 2h. After 2h incubation GMEM EGF-negative 
media containing J2 3T3 feeder cells were added. 
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2.1.6.2. Early cell culture  
 
After two days GMEM EGF-negative media was taken off and switched to GMEM EGF-
positive, this was subsequently changed every two days. Irradiated J2 3T3 feeder cells 
were replaced twice a week, when coverage in the tissue culture plate became sparse. 
Photographs were taken at the early stage of cell culture using a Zeiss Axiovert 35M 
inverted bright field microscope and camera to record the development of cell outgrowth 
(Zeiss, Cambridge, UK). Once some colonies were visible (outgrowth of biopsy) with a 
diameter of around 3-4mm, cells were passaged the first time. TE incubation times were 
slowly defined by increasing the incubation time every 5min (Incubation time for early 
passage of different biopsies were 5-10min). It was important to detach all cells during 
the first passage.  The TE cell suspension was placed in a tube and inactivated with media. 
Fresh TE was added to the remaining cells in the tissue culture plate. This process was 
repeated until all cells were detached. The total cell suspension was then centrifuged and 
the cell pellet re-suspended in fresh GMEM EGF-negative media. The cells were placed 
into a new tissue culture plate (2x106 J2 3T3 feeder cells were added) and labelled with 
passage 1.  New GMEM EGF-negative media with 2x106 irradiated 3T3 feeder cells was 
added to the plates containing biopsy pieces still attached. This process was repeated until 
biopsy outgrowth stopped.  
Early stage primary cultures were passaged once colonies were 50-70% confluent. Cells 
were frozen down at every passage if enough cells were available, otherwise cells were 
placed back into a new tissue culture plate and culture continued until a consistent growth 
was obtained.  
2.1.7. Culture of J2 3T3 feeder cells (support growth for primary culture)  
 
2.1.7.1. Thawing and seeding of J2 3T3 
 
J2 3T3 feeder cells were thawed and plated as previously described into a T25 flask 
containing 5ml of DMEM media. After the cells reached 80% confluence they were 
transferred into a T80 flask (15ml media), then into several T175 flask until 80% 
confluent.  
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2.1.7.2. Subculture of 3T3 feeder cells  
 
J2 3T3 feeder cells were passaged until they reached 80% confluence in a T175 flask. 
Cells were harvested (5-8min TE), counted and a density of 0.5-1x106 cells re-seeded in 
T175 flasks containing 25mL DMEM media. The collected J2 3T3 feeder cells were 
placed into a sterile universal tube and stored at 4°C until irradiation with 60Gy.  
2.1.7.3. Irradiation 
 
The J2 3T3 cells were irradiated using a Gammacell® 1000 with a caesium-137 source 
until a dose of 60Gy was achieved (Best Theratronics, Ottawa, Canada). Irradiation keeps 
3T3 cells in a post mitotic stage, which means that they are unable to divide, but remain 
capable of secretion of extra cellular matrix proteins. Irradiated J2 3T3 feeder cells were 
used immediately or stored for a maximum of 1 week at 4°C.  
 
2.1.8. Mycoplasma detection  
 
2.1.8.1. Reagents preparation and storage  
 
A standardized PCR assay was used to periodically test all cell lines in culture for 
mycoplasma contamination.  This assay was performed by using the Venor®GeM 
detection kit (Minerva Biolabs, Berlin, Germany), which is specific to the highly 
conserved 16s rRNA coding region which allows for the detection of a wide range of 
mycoplasma species.  
The reagents were rehydrated using PCR grade water according to manufactures 
instructions and stored below -18°C. As recommended by the manufacturer, Internal 
Control DNA and Positive Control DNA were stored in aliquots to avoid repeated 
freezing and thawing.  
2.1.8.2. Sample collection, preparation and storage  
 
Supernatants (500μl) of all the test cultures were collected and transferred to a 1.5mL 
microfuge tube. 100μl of the cell culture supernatant was transferred to a new microfuge 
tube and incubated at 95°C for 10 minutes. The remaining supernatant was stored at            -
20°C. After 10min samples were briefly centrifuged (~5 s at approximately 8000g) to 
pellet cellular debris and 2μl of supernatant was added to the PCR reaction mix (prepared 
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in a designated PCR hood under sterile conditions). Ingredients of the PCR reaction mix 
are shown in Table 2-6.  
23μl of this mix was transferred to each tube and 2μl of sample, negative control or 
positive control were added to each designated tube.  DNA polymerase (5 U/μl) was 
ordered separately as it was not included in the provided kit (Minerva Biolabs, Berlin, 
Germany). The amplification of the reaction is described in Table 2-7 using a Nexus 
GSX1 thermal cycler (Eppendorf, Stevenage, UK).   
 
Table 2-6: Mycoplasma reaction mix 
Reagents Volume n=1 (μl) 
PCR grade water 15.3 
10x reaction buffer 2.5 
Primer/nucleotide mix 2.5 
Internal control  2.5 
DNA polymerase 0.2 
Total Volume 23 
 
 
Table 2-7: Mycoplasma PCR conditions  
Step Temperature  (°C) Time Cycles 
Initial denaturation 94 2min 1 
Denaturation  94 30sec  
39 Primer annealing  55 30sec 
Extension  72 30sec 
Final extension 72 30sec 1 
 
2.1.8.3. Gel electrophoresis and gel interpretation  
 
A 1.5% standard agarose gel was made including ethidium bromide (2μl/100mL gel). A 
detailed description of Agarose gel preparation is shown in section 2.2.7.1.  
The electrophoresis was run for 20min at 100V (2cm run distance) and the gel observed 
under UV light.  The success of the reaction was measured according to the size of internal 
control 191bp, negative control 191bp and positive control 267bp.  
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2.2.  Nucleic acid extraction  
 
This section describes DNA and RNA extractions from biopsy samples and cell lines. 
The working area and equipment was cleaned with RNaseZap (Sigma Aldrich) to 
eliminate RNase which could degrade the RNA sample, before any RNA extraction 
process.  
 
2.2.1. DNA extraction from cultured cell lines  
 
For all DNA extractions the QIAamp DNA Mini Kit was used (Qiagen, Manchester, UK). 
This kit contains ready-to-use proteinase K solution (storage 2-8°C), lysis buffer AL, two 
washing buffers AW1 and AW2, and elution buffer AE. Buffers AW1 and AW2 were 
prepared according to company’s instructions. 2x106 to 5x106 cells were used to perform 
the DNA extractions. All extractions were carried out at room temperature (15–25°C). 
Cells were collected as previously described. For DNA extractions the cell pellet was re-
suspended in a final volume of 200μl and stored at -20°C.  
Blanks were prepared in between each sample. Therefore, 200µl of sterile water were 
added to each tube to match the volume of the sample. The blanks were treated the same 
way as the samples. 20μl Qiagen proteinase K were added to each tube and mixed 
properly. Lysis buffer was added to each tube (200μl Buffer AL) and mixed by pulse-
vortexing for 15 seconds. This allowed thorough mixing to ensure efficient lysis.  The 
samples were incubated at 56°C on a preheated heating block for a minimum of 10 
minutes. Tubes were briefly centrifuged to remove drops from the inside of the lid. 200μl 
ethanol (96–100%) were added to each sample, and mixed again by pulse-vortexing for 
15 seconds. After mixing, the 1.5 ml micro centrifuge tube were briefly centrifuged to 
remove drops from the inside of the lid. 
For the next step 600µl the mixture was carefully added to the QIAamp Mini spin column, 
which was provided with the kit (in a 2ml collection tube) without wetting the rim and 
centrifuged at 8000g for 1min. The QIAamp Mini spin column was placed in a clean 2 
mL collection tube (provided). The contained filtrate was discarded.  
The QIAamp Mini spin column was carefully opened and 500μl Buffer AW1 were added 
without wetting the rim. The cap was closed and centrifuged at 8000g for 1min. The 
QIAamp Mini spin column was placed in a clean 2 mL collection tube, and the filtrate 
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was discarded. Next 500μl Buffer AW2 were added to the QIAamp Mini spin column 
without wetting the rim. The cap was closed and centrifuged at 20,000g for 1min. 
To help to eliminate the chance of possible Buffer AW2 carry-over the QIAamp Mini 
spin column was placed in a new 2ml collection tube and centrifuged at 10,000g speed 
for 3min. 
The QIAamp Mini spin column was placed in a clean 1.5ml micro centrifuge tube, and 
the filtrate was discarded. 200μl Buffer AE was carefully added directly on the filter of 
the QIAamp Mini spin column. It was incubated at room temperature (15–25°C) for 5min, 
and then centrifuged at 6000g for 1min. The eluate (final DNA) was stored at -20°C.  
2.2.2. RNA extraction from cell lines  
 
RNA was extracted from untreated and irradiated (2Gy) cell line samples. Irradiated 
samples were harvested after 24h and RNA extraction performed as described below.  
For all RNA extractions the QIAamp RNA Mini Kit was used (Qiagen). This kit contains 
ready-to-use RLT buffer, DNase I (550µl RNase-free water added) and RDD buffer, RW1 
and RPE buffer (96-100% ethanol added).  
Cells were harvested from all cell lines in culture (2x106 cells) and the defined volume of 
RLT lysis buffer was added (350µl), according to manufacturer’s instructions. 350µl of 
70% ethanol was added to the lysate and mixed well by pipetting. 700µl of sample, 
including any precipitate was transferred to an RNeasy Mini spin column (placed in a 2ml 
collection tube) and centrifuged for 15 seconds at 8000g and the flow-through discarded.  
Steps for DNA digestion:  
350µl of RW1 buffer was added to each tube and centrifuged for 15 seconds at 8000g and 
the flow-through discarded. 10µl DNase I was mixed with 70µl buffer RDD and the 80µl 
added to each tube and incubated at room temperature for 15min. After 15minutes, 350µl 
of RW1 was added to each tube and centrifuged at ≥8000g and the flow-through 
discarded.  
700µl RW1 buffer was added to the spin column and centrifuge at 8000g for 15sec and 
the flow-through discarded. Then 500µl of RPE buffer was added, centrifuge at 8000g 
for 15sec. This step was repeated with 500µl RPE buffer and centrifuged at 8000g for 2 
minutes. The RNeasy spin column was placed into a new 1.5 collection tube and 50µl 
RNase-free water added directly to the spin column membrane and centrifuged for 1min 
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at 8000g to elute RNA. This step was repeated by adding the eluted 50µl again to the 
membrane to increase the yield of RNA.   
RNA concentration was measured using spectrophotometry and RNA was stored at -80°C 
until needed. 
 
2.2.3. Genomic DNA and total RNA extraction from oropharyngeal cancer 
biopsies.  
 
DNA and RNA were extracted simultaneously by a method used combining QIAamp 
DNA Mini kit and RNeasy fibrous tissue kit (Qiagen). 
One half of the collected biopsy was stored for nucleic acid extraction. This half was 
homogenised using a TissueRuptor (Qiagen) for 10-20sec in 600µl RLT buffer containing 
6µl of 14.3 M β-mercaptoethanol (Sigma-Aldrich) and reagent DX (final concentration 
of 0.5% v/v) (Qiagen) was added to prevent foam formation. 
The 600µl sample was divided into two tubes containing 300µl, which were processed in 
parallel and combined in the final elution steps. The samples were mixed with 708µl of 
RNase free water and 20µl of Proteinase K (provided with the kit) and incubated for 
10min at 56°C, followed by centrifugation for 3min at 8000g and 650µl of supernatant 
was removed for RNA extraction. The pellet was resuspended in the remaining solution 
and placed on the heating block at 55°C for later DNA extraction.  
 
2.2.4. RNA extraction from tissue sample  
 
 RNeasy fibrous tissue kit was used to extract RNA from the biopsy samples. This kit 
contained the same reagents and columns as the described RNeasy mini kit. However, 
there were differences in some of the steps and in the volumes of reagents used.  
The lysed & homogenized sample (650µl), described in a previous step, was mixed with 
1 volume of 70% ethanol and 700µl centrifuged through the RNeasy mini column 
(provided with the kit) at 8000g for 15sec to bind the RNA to the silica membrane. The 
centrifugation step was repeated until the entire volume has passed through the mini 
column. The column was then washed with 350µl of RW1 buffer, centrifuged for 15sec 
at 8000 g. The flow through was discarded after each step.  
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DNase I was then added to each sample to eliminate DNA contamination before the final 
wash and elution of total RNA. The DNase I working solution was prepared by dissolving 
the DNase powder with 550µl of RNase-free water (provided with the kit), according to 
manufacturer’s instructions. The DNase I solution (10µl) was mixed with 70µl RDD 
buffer. The mixed solution of 80µl was directly added to the column membrane of the 
RNeasy mini column and incubated at room temperature for 15 minutes. The next step 
was to add 350 µl RW1 buffer, followed by two washes of 500 µl with buffer RPE. A 
longer centrifugation step of 2 minutes at maximum speed was used to dry the membrane 
before the last wash. The RNeasy mini column was placed on a new collection tube and 
centrifuged for 1-2 minute to remove any RPE cross over. The RNA was eluted twice 
with 50µl RNase free water, by centrifugation for 1 minute at 8000g and stored at -80°C. 
 
2.2.5. DNA purification from biopsy samples  
 
Following the RNA extraction, the tube containing the homogenized biopsy at 55°C was 
used for DNA purification. The sample was mixed with 350µl of buffer AL and incubated 
for 10min at 70°C before mixing with 350 µl of 96-100% ethanol. The sample was then 
loaded onto the membrane of the DNA spin column with 600µl at a time and centrifuged 
for 1min at 8000g. The flow through was discarded. The steps were repeated until the 
remaining sample has passed through the column.  
Washing and elution steps were the same as described in the DNA extraction protocol for 
cell lines using the QIAamp DNA Mini kit in section 2.2.1.  
 
2.2.6. Nucleic acid quantification  
 
The purity and concentration of the nucleic acids were measured using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. A blank measurement was done with 2µl of the corresponding elution 
solution. The absorbance at 260nm and 280nm wavelength was measured for each sample 
(2µl). The concentration was presented in ng/µl.  If the ratio between 260/280nm was 
between 1.8 and 2, it indicated a high purity of nucleic acids. 
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2.2.7. DNA integrity 
 
DNA integrity of the extracted DNA and suitability for further PCR set-ups was measured 
by PCR amplification of the housekeeping gene β-globin (fragment size: 209bp). Primers 
were purchased from Sigma-Aldrich (de Roda Husman et al., 1995, Saiki et al., 1988) 
and are shown in Table 2-8. The overall PCR technique and electrophoresis is described 
in this section, which is used for all other PCR based techniques (section 2.4 HPV typing 
HPV-16 E6 and HPV-18).  
 
Table 2-8: β-globin primer sequence and amplicon size  
Primers Forward Primer 5’-3’ Reverse Primer 5’-3’ Amplicon 
(bp) 
PCO3(F)/
PCO5(R) 
ACACAACTGTGTTCACTA
GC 
GAAACCCAAGAGTCTTCT
CCT 
209 
 
 
2.2.7.1. General master mix set-up  
 
All PCR reactions were set up in a designated PCR hood. The hood was sterilized for 30 
min with UV light before preparation start.  The master mix was made of PCR grade 
water, primers, buffers and Taq polymerase (Sigma Aldrich and QIAGEN). From this 
master mix 20µl were transferred in the designated PCR tubes. Five microliters of DNA, 
water for negative control or 5µl of HPV-positive sample for positive control were added 
to the designated tubes. The concentration and volume of the reagents used is shown in 
Table 2-9 and used for the remaining PCR reactions (including HPV typing for HPV-16 
and HPV-18).  
The sealed tubes were placed in a Nexus GSX1 thermocycler (Eppendorf). The reaction 
(amplification) was performed according to the conditions in Table 2-11. The samples 
were stored at -20°C for long-term storage or at 4°C for short-term storage.  
Table 2-9: Composition of general PCR-reaction  master mix 
Reagents  Concentration  Volume n=1 (µl) 
Primers (each F + R) 5 µM 2.5 
Deoxynucleotide 2 mM 2.5 
10X reaction buffer 1x 2.5 
Hotstar Taq polymerase 5U/µl 0.1 
PCR grade water - 9.9 
DNA 1/10 5 
Total volume  - 25 
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2.2.7.2. Agarose gel electrophoresis  
 
A 2% w/v agarose gel was prepared using a 1x Tris/Borate/EDTA (TBE) buffer. The 
TBE buffer was diluted from a ready-to-use 10x solution to a 1x TBE buffer. Agarose 
and 1μl 10mg/ml ethidium bromide per 100mL gel were added (Sigma-Aldrich).  To each 
sample 5μl of Orange G loading dye (Sigma-Aldrich) was added and properly mixed. The 
first well and last well before and after samples was loaded with 10μl of PCR Ranger 
ladder for amplicons up to 1000bp (Norgen Biotek, Thorold, Canada). The well between 
the ladders were loaded with 15μl of the combined Sample-Orange G mix. The gel was 
run for 1h at 100 V (3-4 cm run distance) in an electrophoresis tank containing 1xTBE 
buffer.  The bands were visualised under UV-light in a Gel doc (Imager station). Product 
sizes of 161bp for HPV-16 E6, 209bp for Beta-globin (indicating presence of DNA 
fragments/suitable for further PCR analysis) and 90bp for HPV-18 E7 were observed.  
  
2.2.8. RNA integrity  
 
Total RNA quality and quantity was analysed using an Agilent 2100 Bioanalyser and a 
RNA Nano 6000 kit, a chip electrophoresis assay, (Agilent Technologies, Santa Clara, 
USA).  
During these assays RNA molecules are separated by size in the chip’s micro-fluidic 
channel and detection is done by using a fluorescence nucleic acid stain. The exact 
molecular weight (RNA) was determined by comparison with a ladder of known fragment 
sizes (provided with the RNA Nano 6000 kit). The amount of RNA is equivalent to the 
amount of fluorescence measured. Results were provided as electropherograms. RNA 
integrity number (RIN) was automatically calculated by an algorithm developed by the 
manufacturer.  The software automatically assigns an integrity number to a eukaryote 
total RNA sample (Agilent).  RIN values between 8 and 10 were accepted as good quality 
RNA. A value of 10 indicates un-degraded RNA. Values below 8 indicates degradation 
of RNA, where 0 represents totally degraded RNA.  
The gel dye-mix was brought to room temperature for 30 min and protected from light. 
The RNA Nano chip was taken out of a sealed bag and placed on the chip priming station. 
Of the gel-dye mix 9μl were pipetted at the bottom of the indicated wells. The plunger 
was positioned at 1ml and released after 30 seconds to distribute the dye mix. The chip 
priming station was opened and 9μl of the gel-dye mix was transferred in each marked 
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well.  Wells labelled with ladder and sample were loaded with 1μl of ladder or 1μl sample 
(on arrival the ladder was denatured for 2 min at 70°C, the vial immediately cooled down 
on ice an aliquoted in RNase-free vials with the required volume and stored at -70°, before 
use thawed and kept on ice). To each well with ladder and samples 5μl of RNA 6000 
Nano marker was added. The chip was placed on the mixer and vortexed for 60 s between 
2000-2400 rpm. The chip was then inserted in the Agilent 2100 bioanalyzer and the run 
started within 5min. The chip was then analysed according to manufacturer’s instructions.  
 
2.3. Short Tandem Repeats – cell line authentication  
 
Short tandem repeats (STR) consist of short repeat units that are 2-6 base pairs (bp) in 
length. Tandem repeated DNA is widespread throughout the human genome. These 
repeats can be detected through polymerase chain reaction (PCR), and are effective 
polymorphic markers (Ruitberg et al., 2001). This assay was used to confirm the identity 
of the developed primary cell lines with the collected biopsy sample. Furthermore, the 
identity of all the cell lines in this study was confirmed through the Cellosaurus website 
(https://web.expasy.org/cellosaurus/) and DSMZ database. 
This assay was performed in assistance from Public Health England (PHE) and their cell 
authentication service in collaboration with NorthGene Ltd., using the Promega 
Powerplex 16 HS kit (Promega, Southampton, UK). This kit was used to analyse 
differences at 16 different hypervariable genetic loci (15 STR loci and Amelogenin), 
which are listed in Table 2-9. Those STR loci are amplified in a single multiplex PCR 
reaction simultaneously (fluorescence labels for primers are listed in Table 2-10), which 
results in different product sizes, depended on the number of repeats at different STR loci 
sites.  
DNA samples were sent on FTA cards (GE Healthcare, Amersham, UK) with the 
recommended 50µl of DNA with a minimum concentration of 10 ng/µl. A minimum yield 
of 0.5ng of DNA in a 25µl reaction volume was needed for the Promega Powerplex 16 
HS system. The components of the PCR amplification mix are listed in Table 2-11. The 
PCR amplification mix was added in the appropriate wells of the reaction plate and a 
plunger was used to punch a piece out of the FTA card (size of 1.2mm) into the 
appropriate well containing the PCR master mix (Table 2-10). Direct amplification of 
DNA occurred from the FTA card punch in the well with the PCR amplification mix.  
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The amplification was done using a GeneAmp®PCR System 9700 thermal cycler and 
cycle conditions shown in Table 2-12.  
 
Table 2-10: STR loci with chromosomal location in the human genomes  
STR Locus Chromosomal Location 
Fluorescence label of 
primer 
D3S1358 3p21,31  
 
Fluorescein (FL) 
 
THO1 11p15.5 
D21S11 21q21.1 
D18S51 18q21.33 
PENTA E 15q26.2 
D5S818 5q23.2  
 
6-carboxy-4’ ,5’ –dichloro-2’ 
,7’ –dimethoxy-fluorescein 
(JOE) 
 
D13S317 13q31.1 
D7S820 7q21.11 
D16S539 16q24.1 
CSF1PO 5q33.1 
PENTA D 21q22.3 
Amelogenin X: p22.1-22.3    Y: p11.2  
Carboxy-
tetramethylrhodamine 
(TMR) 
vWA 12p13.31 
D8S1179 8q24.13 
TPOX 2p25.3 
FGA 4q31.3 
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Table 2-11: PCR amplification mix for amplification of STR loci.  
PCR amplification mix - Reagents Volume per reaction 
Water, Amplification Grade 12.5µl 
PowerPlex® HS 5X Master Mix 5.0µl 
PowerPlex® HS 10X Primer Pair MixA 2.5µl 
5X AmpSolutionTM Reagent 5.0µl 
 A Primer pair mix contains fluorescence labelled primers  
 
Table 2-12: STR typing thermal cycler conditions  
Phase Temperature (°C) Time (seconds) Cycles 
Initial denaturation 96 120 1 
Denaturation 94 30  
10 Primer annealing 60 30 
Extension 70 45 
Denaturation  90 30  
27 Primer annealing 60 30 
Extension 70 45 
Final extension 60 30 1 
 
The PCR products were separated using capillary electrophoresis and detected on an API 
Prism 310 Genetic Analyser (Applied Biosystems, Warrington, UK). The dyes were 
distinguished using virtual CCD imaging and the light was collected with the ABI Prism 
310 data collection software. Electropherograms and a final report with the total counts 
at each loci sites for each cell line were generated by PHE.  
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2.4.  Amplification of HPV-16 E6 gene and HPV-18 E7 gene  
 
Table 2-13: HPV-16 E6 primer sequence and HPV-18 E7 primer sequence  
Primers Forward Primer 5’-3’ Reverse Primer 5’-3’ Amplicon (bp) 
HPV-16 E6 GAACAGCAATACAA
CAAACC 
GATCTGCAACAAGAC
ATACA 
161 
HPV-18 E7 GAACCACAACGTCA
CACAATG 
CAGAAACAGCTGCTG
GAATG 
90 
 
 
The amplification of a 161bp fragment of HPV-16 E6 gene and 90bp fragment of the 
HPV-18 gene was used to confirm the presence of HPV-16 or HPV-18. Details of the 
primers are illustrated in Table 2-13.  
The general PCR reactions mix is identical for HPV-16 E6, HPV-18 E7 β-globin shown 
in Table 2-9. Thermal cycler conditions for HPV-16 E6, HPV-18 E7 and are identical and 
shown in Table 2-14.  
 
Table 2-14: Thermal cycler program for HPV-16, HPV-18 and β-globin PCRs 
Assay Steps Temperature Time Cycles 
HPV-16 E6 Initial denaturation 94 15min 1 
Denaturation 94 30sec  
40 HPV-18 E7 Primer annealing 55 30sec 
Extension 72 60sec 
β-globin Final Extension 72 4 min 1 
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2.5.  Clonogenic assays for measurement of radio-sensitivity  
 
2.5.1. Crystal violet staining  
 
Both the plating density assay (section 2.5.2) and radio-sensitivity assay (section 2.5.3) 
required staining the cells with a crystal violet solution (Thermo Fisher Scientific), 
pictures were taken of the plate and the number of colonies were determined using image 
analysis (section 2.5.4).  
Media was removed from the 60x15mm culture dishes using a pipette. Before the media 
was discarded it was used to remove 3T3 feeder cells from the 60x15 mm culture dishes. 
5mL 1xPBS was added to the culture dishes and was slowly pipetted up and down to 
remove the remaining 3T3 feeder cells and media. The PBS suspension was removed.  
In the next step 5mL of 50 % v/v 1xPBS/methanol was added to the plates for 2 min to 
prepare the cells for the final fixing step with methanol. The mix of 1xPBS/Methanol was 
removed and absolute methanol added to the plates for 10min and incubated at room 
temperature. The methanol (Thermo Fisher Scientific) was discarded and the plates left 
to dry (evaporation of methanol) for 10-20min.  
5mL of Crystal violet solution was added per plate. The cells were stained for 10 min at 
room temperature. The Crystal violet solution was removed, filtered, collected and reused 
for other experiments. The plates were gently washed with tap water twice and left to dry 
at RT. 
 
2.5.2. Plating density assay 
 
This assay was used to define the cell density to be used in the radio-sensitivity assay.  
Cells were collected according to standard cell culture procedure. The cells were counted 
as described in section 2.5.4  
The collected cells were diluted to a range of cell densities. The range was defined from 
20,000 to 1000 cells per 60x15mm cell culture plate. The density test was set-up with and 
without 3T3 feeder cells to support cell growth. The optimal cell density for each cell line 
was then defined according to state of confluence within the set-up range of 20,000; 
15,000; 10,000; 5,000 and 1,000.  and were defined for CU-OP-17 within 5,000 and 10,00 
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cells and for CU-OP-20 within 5.000 and 1,000 cells. 2500 cells more than the 5.000 cells 
of the density plate.  
Cells were seeded with 5mL media per plate and incubated at 37°C at 5% CO2 for 7 days. 
After 7 days the media was changed and the plates incubated for another 7 days under the 
same conditions. After 10-15 days (when colonies with >50 cells were observed) the 
plates were stained with Crystal violet (section 2.1).  Using this assay, defined optimal 
cell densities were for UMSCC-6 (4000), CU-OP-17 (7000 per plate) and CU-OP-20 
(4500).  
All other optimal cell densities were defined by Dr. Evelyne Pirotte (Table 2-15).  
 
Table 2-15: Defined cell densities for clonogenic assays 
Cell lines Defined cell densities per plate 
UMSCC-47 2500 
UPCI-SCC-90 12.500 
CU-OP-2 4400 
CU-OP-3 4400 
UMSCC-4 7500 
UMSCC-19 7500 
UMSCC-74a 3000 
HEKn 3000 
 
2.5.3. Radio-sensitivity testing of OPSCC cell lines  
 
All cell lines were plated at low cell density on 60x15 mm culture dishes. 3T3 feeder cells 
were plated with each cell line to support cell growth. A stock suspension was prepared 
for each cell lines in three 50ml media Falcon tubes, containing 8x106 J2 3T3 feeder cells 
(1x106 cells/mL per plate). 5mL out of this stock suspension was added to each 60x15 
mm culture dish and incubated at 37°C with 5 % CO2 for 24 hours. After 24 hours, the 
cells were firmly attached to the culture plate. The plates were protected by wrapping in 
Para-film, before transportation to the -irradiator, a caesium/137 source (Gammacell-
1000 MDS Nordion, Ottawa, CA).  
The plates were treated with 0, 0.5, 1, 2, 4 or 6 Gy to assess survival of cells across a 
range of radiation doses. After irradiation the media was changed and plates incubated at 
37°C with 5% CO2 for 7 days.  For the CU-OP cell lines media was changed from 
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GMEM/EGF-negative to GMEM/EGF-positive media. After 7 days the media was 
changed and plates again incubated at 37°C with 5 % CO2.  Depending on the growth 
characteristics of the cell lines the assay was stopped after 10-15 days as determined 
during cell density tests. Photographs were taken at different magnifications and cells 
were stained with crystal violet and colonies counted. All experiments were performed 
three times in triplicate (3 plates per 3 runs). 
 
2.5.4. Colony counting  
 
Pictures of the stained colonies were taken and colonies >50 cells were counted using a 
Colony counter (ColonyDoc-It Imaging Station, UVP, Cambridge, UK). The plates were 
labelled on the side with A, B, and C (to confirm exact position at a later point), as three 
pictures were taken at three different positions, plates being moved at 90° degrees. These 
pictures were taken with a Canon EOS Rebel T3 camera connected to the counter. White 
light (base lighting) was used with light coming from below the plates.  
The counting area was defined for a 60x15 mm cell culture plate and a template made for 
each cell line. The template was defined by different colour pixels. The numbers of pixels 
varied for each cell line. The aim was that almost all colonies were counted automatically 
after defining the template. A small percentage of colonies had to be added manually or 
split (as colonies had merged). These were checked using a microscope. The average 
number of colonies was calculated per run (3 pictures per plate). The plating efficiency 
and the surviving fraction of each cell line per dose was calculated.  
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Plating efficiency  
Plating efficiency was determined using the equation shown below: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑙𝑎𝑡𝑒𝑑
∗ 100 
 
Surviving fraction  
The surviving fraction was determined using the equation shown below: 
 
𝑃𝑙𝑎𝑡𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑝𝑒𝑟 𝑑𝑜𝑠𝑒
𝑛𝑜𝑛 − 𝑖𝑟𝑟𝑎𝑑𝑖𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
∗ 100 
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2.6.  Western blotting 
 
2.6.1. Materials and preparation of lysis buffer 
 
All materials used for protein extraction, western blotting and imaging are listed in Table 
2-16. Components for lysis buffer are listed in Table 2-17.   
 
Table 2-16: Materials for Western blot 
Materials Manufacturer 
Mini gel tank  
 
 
 
Thermo Fisher Scientific 
Novex Bolt transfer buffer 20x 
Bolt 4-12% Bis-Tris plus gels 15 wells 
Novex Bolt Mops SDS running buffer 20x 
Novex Bolt LDS sample buffer 4x 
Novex Bolt sample reducing agent 10x 
Novex Bolt Antioxidant  
SeaBlue®Plus-2 Prestained standard  
PVDF membrane 0.45µm GE Healthcare 
Electrophoresis Power Supply EPS 1001 Amersham Pharmacia biotech 
p53 antibody (rabbit) cat:9282  
 
Cell Signalling, Danvers, USA 
Phospho-p53 (Ser15) antibody (rabbit) cat:9284 
P21 Waf1/Cip1 (12D1) antibody (rabbit) cat:2947 
Β-actin (13E5) antibody (rabbit) cat:4970 
JUNB (C37F9) antibody (rabbit) cat:3753 
NDRG1 (D8G9) XP® anribody (rabbit) cat:9485 
Goat Anti-Rabbit IgG (H+L) AP conjugate cat:1706518 BioRad 
CL X-posure Film  Thermo Fisher Scientific 
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Table 2-17: Reagents for phopho-protein lysis buffer 
ReagentsB For 10ml For 1ml Manufacturer 
2x Lysis bufferA 5mL 0.5mL - 
10% NP40 1mL 0.1mL Fluka Biochemika 
Protease inhibitor 
cocktail 
100µl 10µl  
 
 
Sigma Aldrich 
 
Phosphatase inhibitor 
cocktail 2 
100µl 10µl 
Phosphatase Inhibitor 
cocktail 3 
100µl 10µl 
PMSF 100mM 100µl 10µl 
Na3VO4 100mM 100µl 10µl 
ddH2O 3.5mL 0.35 L - 
A 2x Lysis buffer consists: of 100mM Hepes (Sigma Aldrich), 10mM NaF (Sigma Aldrich), 10mM 
Iodoacetamide (Sigma Aldrich), 150mM NaCl (Fisher Scientific) filled up to a total of 100mL.  
B The 2x Lysis buffer was prepared separately and stored at 4°C. All other reagents were added immediately 
before use, because some components in the buffer are not stable for more than 30min in aqueous solution. 
The protease inhibitor cocktail was added to inhibit enzymes that degrade proteins. Phosphatase inhibitor 
cocktail 2 inhibits tyrosine protein phosphatases. Phosphatase Inhibitor cocktail 3 inhibits alkaline and 
serine threonine protein phosphatases.  
 
 
2.6.2. Sample preparation for Western blotting  
 
Cells were plated as described in Table 2-18 and treated with 2 or 6Gy ionising radiation. 
After a 24h incubation, 2x106-2.5x106 cells were collected per cell line and treatment 
dose (2 and 6Gy 24h) and transferred to 1.5 mL tubes for cell lysis. Per 1x106 cells/ml 50 
µl of lysis buffer were added. Lysis buffer was added to the cell pellet and cells lysed for 
20-30min on ice and vortexed 1-2 times during the 20-30min lysis. The lysate was 
clarified by centrifugation (10,000g, 20mins, 4’C). The volume of lysis buffer was noted 
before and after centrifugation to allow determination of exact protein concentration. 
Samples were stored at -80°C, until determination of protein concentration by performing 
a Bradford assay.  
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Table 2-18: Number of cells seeded for cell cycle analysis, Western blotting and mRNA sequencing 
set-up 
Cell lines Number of cells seeded 
UMSCC-47 4x105 
UPCI-SCC-90 3.5x105 
CU-OP-2 1x106 
CU-OP-3 1.2x106 
CU-OP-20 1.2x106 
CU-OP-17 1x106 
UMSCC-4 4x105 
UMSCC-6 4.5x105 
UMSCC-19 4.5x105 
UMSCC-74a 8x105 
HEKn 7x105 
 
2.6.3. Bradford assay 
 
All samples were slowly thawed on ice. A 1/20 dilution in water of each sample was 
performed in a 96 well plate. Duplicates of this dilution (10µl) were pipetted in new 
wells.190µl of Bradford solution (1:1 dilution with double distilled water) was added to 
each sample. The plate was incubated for 25 min at RT protected from light. The 
absorbance was measured at a wavelength of 595nm. A standard curve of different protein 
concentrations of 10µg/ml, 7µg/ml, 4µg/ml, 1µg/ml and 0µg/ml was used to estimate the 
protein concentration of each sample. The different protein concentration for the standard 
curve were diluted with distilled water from a stock concentration of 2mg protein/ml 
(Sigma Aldrich).  
2.6.4. Protein sample preparation  
 
A final loading concentration of 1000μg/ml was prepared for each sample. Sample 
volume was calculated, depending on the number of gels operated per experimental run. 
Reducing agent and LDS loading buffer were added to each sample. All samples were 
well mixed and briefly centrifuged to remove any liquid from the caps. The samples were 
then incubated for 5min at 100°C. A brief centrifugation was done to remove all 
remaining condensation from the caps. All tubes were stored on ice until electrophoresis. 
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2.6.5. Electrophoresis 
 
The gel tank was assembled according to the manufacturer’s instructions (Thermo Fisher 
Scientific) and rinsed with deionized water to remove any residues. The tank was filled 
with 1xRunning buffer (50mL from 20xMOPS stock solution with 950mL double 
deionized water). The pre-cast gel cassette (15 wells, Life technologies) was removed 
from its packaging and rinsed with deionized water. The tape at the bottom of the cassette 
(back of the gel) was peeled off and the comb gently removed to avoid damage to the 
wells. The cassette and the wells were rinsed three times with 1x MOPS running buffer. 
The cassette was placed into the tank and fixed by clamps. The wells were left out of the 
buffer for loading the samples. Twenty microliters of sample were loaded per well and 
5µl of ladder was loaded in the first and last wells. The gel was lowered into the buffer 
and filled with 1x running buffer until the indicated line of the tank. The electrophoresis 
was run for 35-40 min at 170 V (constant) and 100mA.  
2.6.6. Transfer from gel to membrane 
 
Assembly of the Western Blotting Sandwich for protein transfer is illustrated in Figure 2-
2. The PVDF membrane and Transfer Buffer were prepared during the electrophoresis 
run. The PVDF membrane was placed in methanol for 30 seconds and rinsed once with 
deionized water. The membrane and transfer pads were soaked in 1x transfer buffer 
(Table 2-19) for several minutes. The filter paper was also soaked in transfer buffer briefly 
before use. The cathode and anode were rinsed with deionized water and transfer buffer. 
5ml of transfer buffer was placed into the cathode chamber. After the electrophoresis the 
cassette was laid down flat and separated using a gel knife by inserting it into the narrow 
gap between the two plastic plates. The top plate was gently removed and the wells were 
cut off with the gel knife. A briefly soaked filter paper was placed on top of the gel and 
any trapped air bubbles were removed. The plate was turned (gel and filter paper facing 
downwards) and the gel pushed off the remaining plate and the foot of the gel was cut 
off. One transfer pad was placed into the cathode and the gel with filter paper (facing 
downwards) was placed on top of it. The pre-soaked membrane was placed on top of the 
gel followed by a filter paper and transfer pad. The module was closed with the anode 
and placed into the electrophoresis tank. The centre of the module was filled with 1x 
transfer buffer, the outer champers with deionized water just below the electrodes. A 30V 
constant voltage and 170mA were applied for 1:30 hours.  
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Table 2-19: 1xTransfer buffer composition for 1000mL  
Reagents Volume (ml) 
Bolt transfer buffer (20x) 50 
Bolt antioxidant 1 
Methanol 100 
Water 849 
 
 
 
Figure 2-2: Assembly of the Western blotting transfer sandwich 
 
2.6.7. Blocking and immuno-probing  
 
The membrane was taken out of the blot module and rinsed with PBS-Tween (PBS-T). 
The membrane was incubated with iBT-buffer (Table 2-20) for a minimum of 1 hour 
(RT) for blocking. After 1 hour the membrane was removed from the blocking agent and 
probed with the primary specific antibody (e.g p53 – 1:1000 in iBT) overnight at 4°C.  
The membrane was removed from the primary antibody and washed three times (10 min) 
with PBS-T, followed by probing with the secondary antibody (goat anti-rabbit) for 1 
hour. The membrane was removed from the secondary antibody and washed three times 
(10 min) with PBS-T.  
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Table 2-20: Blocking solution  
ReagentA Concentration Manufacturer 
Tropix I-Block 0.2% (1g in 500mL) Applied Biosystems 
Tween-20 0.1% (0.5mL in 500mL) Sigma-Aldrich 
Sodium Azide 0.4% (2g in 500mL) Sigma Aldrich 
A Solution was prepared in 500mL PBS (Fisher Scientific) and heated up to 80°C to be able to dissolve 1g 
I-Block powder. As soon as the powder was dissolved and the solution cooled down sodium azide was 
added to prolong the usage of the buffer for a 2-4 weeks. (I-Block is a highly purified casein-based 
blocking reagent & provides the highest signal to noise performance in combination with CDP Star 
substrate for alkaline phosphatase experiments for Western Blotting). 
 
2.6.8. Chemiluminescence  
 
The PBS-T was discarded after the last wash and membrane washed for 4min with 1x 
Alkaline phosphatase (AP) buffer (10x Assay Buffer, Applied Biosystems). This allows 
enzyme attachment to the goat anti-rabbit–AP conjugate secondary antibody. The 
membrane was put on tissue to remove the excess buffer and transferred on a plastic sheet. 
The membrane was incubated for 5min in Tropix CDP-star, a chemiluminescent substrate 
for alkaline phosphatase stained membranes (Applied Biosystems). The excess detection 
reagent was removed from the plastic sheet using paper tissues. The plastic sheet was cut 
to size and placed in a film cassette-using tape to secure. The membrane was exposed to 
a photographic film (10min initially to define longer exposure time, if necessary), by 
using a film developer (Xograph Imaging Systems Compact X4). Exposure time points 
were set, according to the initial results obtained. Images were analysed and quantified 
using Image Studio Lite (LI-COR Biotechnology, Cambridge, UK). 
  
2.6.9. Re-probing of membrane 
 
The membrane was rinsed with PBS-T and washed twice in PBS-T for 5min on a shaker. 
The membrane was then placed into a plastic bag containing 25mL of 1xMESNA buffer 
(Table 2-21) for 1 hour at 55°C in a water bath with shaking the plastic bags every 10 
min. After stripping off, the membrane was washed for 30min with PBS-T, changing the 
buffer every 10min.  The membrane was then blocked with iBT for 1 hour and re-probed 
with primary antibody as described in section 2.6.7.  
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Table 2-21: Reagents for a  5x MESNA stripping stock solution 
Reagents 5x stripping buffer in 
100mlA 
Manufacturer 
Tris-HCI pH 6.8 31.25 mL  
Sigma Aldrich SDS 10 g 
2-mercaptoethansulfonate 
(MESNA) 
4.1 g 
A For stripping off the membrane the solution was diluted to a 1x working solution. 
 
2.7.  Determination of cell cycle distribution using flow cytometry  
 
2.7.1. Sample preparation  
 
Cells were harvested and counted, according to standard cell culture procedure, once 70-
80% confluent. The number of cells plated varied with each cell line as previously 
described (Table 2-18). Cells were seeded in sixteen plates (6cm tissue culture plates) and 
treated with 2Gy and 6Gy the next day (when ~50-60% confluent). No J2 3T3 feeder cells 
were used in the set-up of the experiments to avoid misleading cell cycle results. Cells 
were collected according to the defined time point of 8h, 24h and 48h. 4 plates of 
untreated cells were collected immediately after treatment (time zero). Reagents used in 
this assay are described in Table 2-22.  
Cells were harvested and plated at a defined cell density in cell culture dishes (60x15 
mm). Cells were treated with ionising radiation (IR) when 60-70% confluent and 
collected at defined time points. 4 plates were set-up for untreated cells, 2 plates per dose 
(2 and 6Gy) and incubation time point (8h, 24h and 48h). Cells were collected after 
defined time points and 500,000 cells transferred to labelled Fluorescence-activated cell 
sorting (FACS) tubes and fixed in 1mL of 70 % ethanol and stored at -20°C for a 
minimum of 1 hour before propidium iodide staining.  
Table 2-22: Reagents for cell cycle analysis  
Reagents Working concentration  Manufacturer 
Propidium Iodide 50µg/ml 1ug/ml Sigma Aldrich 
Ribonucelase A (RNase A)  10 µg/ml  
Ethanol  70% Fisher Scientific 
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2.7.2. Propidium iodide staining  
 
Tubes were centrifuged for 10min at 360g after ethanol fixation. Then cells were washed 
with PBS and centrifuged for 5min 270g. PBS was removed and 100µl of RNase A was 
added to all tubes to eliminate any RNA contamination (propidium iodide (PI) binds to 
RNA). The tubes were incubated at 37°C for 45 minutes. Cells were then re-suspended 
in 250µl of PI (1ug/ml) and incubated for 15min at 37°C.   
 
2.7.3. Initial cell cycle distribution measurement 
 
Cell cycle distribution was then measured using the BD Accuri (BD Biosciences, 
Wokingham, UK) low pressure flow cytometer. The initial gating was defined on the 
Accuri C6 software, during data collection with PI staining (PI is excited at 488nm). Each 
run was stopped after 30,000 events under standard voltage settings on the BD Accuri 
flow cytometer. 
 
2.7.4. Flow cytometry analysis  
 
Data was extracted as FCS files and later analysed using FlowJo analysis (version 10) 
software with the gating strategy seen in Figure 2-3. The cell cycle pattern was analysed 
using the Watson pragmatic algorithm (Watson et al., 1987).  
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Figure 2-3: Gating strategy FlowJo (Version 10) for Cell Cycle Analysis 
(A) Axes were defined as SSC-A/FSC-A to separate dead and live cells (Gate defined as Lymphocytes by 
FlowJo); (B) SSC-H/SSC-A was set to separated doublets and single cells; (C) Cell cycle peaks – axes 
defined as Y-axe (count) to X-axe (FL2-A) for to determine the number of cells stained with PI; (D) 
represents the cell cycle phases of G1/S/G2 defined by the Cell Cycle Analysis Tool within FlowJo. 
 
Excel 2016 was used to generate 100% stacked bar charts. Statistical analysis was 
performed in GraphPad Prism 7 using a two-way ANOVA with a Sidak post-test to the 
panel of cell lines (treatment dose and time points) with each other to identify any 
significance.   
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2.8.  mRNA sequencing 
 
Experiments for mRNA sequencing were set-up as described in section 2.2.2 RNA 
extraction from cell lines. Number of cells plated is shown in Table 2-18. RNA was then 
extracted, quantified and RNA integrity tested as described. Sequencing libraries were 
prepared using the Illumina® TruSeq® Stranded Total RNA with Ribo-Zero Gold™ kit 
(Illumina Inc.). The libraries were sequenced using a 75-base paired-end (2x75bp PE) 
dual index read format on the Illumina® HiSeq2500 in high-output mode according to 
the manufacturer’s instructions. 
Library preparation and mRNA sequencing were carried out through commercial 
service/collaboration with Wales Gene Park. Sequencing data was then analyzed with the 
support of the bioinformatics service provided by Wales Gene Park (Dr. Kevin Ashelford 
and Dr. Peter Giles) described in section 2.8.4. Data analysis included quality control of 
sequencing, analysis of viral genes and integration, differential gene expression, 
comparison/grouping of non-irradiated and irradiated samples (including different levels 
of gene expression between non-irradiated and irradiated samples), and Gene Ontology 
(GO) analysis.  
 
2.8.1. Library preparation  
 
Library preparation was performed using the Illumina® TruSeq® Stranded Total RNA 
with Ribo-Zero Gold™ kit (Illumina Inc.). This kit offers strand information of RNA 
transcript and capture of both coding, as well as multiple forms of non-coding RNA. 
Library preparation was done by Wales Gene Park in accordance with manufacturer’s 
instructions. 
100-900ng of total RNA with a RIN value of 8 or >8 was depleted of ribosomal RNA. 
Manufacturer’s instructions were followed for the whole library preparation, except for 
the clean-up after the ribozero depletion step, where Ampure®XP beads (Beckman 
Coulter) and 80 % Ethanol were used.  
This process was then followed by RNA purification, fragmentation and priming for 
cDNA synthesis (1st strand cDNA synthesis and 2nd strand cDNA synthesis). The 
process of synthesis of the 1st strand of cDNA, reverse transcribes the cleaved RNA 
fragments that were primed with random hexamers into first strand cDNA using reverse 
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transcriptase and random primers. This process removes the RNA template and 
synthesizes a replacement strand, incorporating dUTP in place of dTTP to generate ds 
cDNA. AMPure XP beads are used to separate the ds cDNA from the second strand 
reaction mix to generate a final blunt-ended cDNA. This step is followed by adenylation 
of 3’ ends where a single ‘A’ nucleotide is added to the 3’ ends of the blunt fragments to 
prevent them from ligating to one another during the adapter ligation reaction and a ‘T’ 
nucleotide provides a complementary overhang for ligating the adapter to the fragment. 
Ligating adapters to the ends of the cDNA prepares for hybridization onto a flow cell.  
This step is followed by enrichment of DNA fragments through PCR amplification (12-
cycles) which have adapter molecules on both ends. The last step includes library 
validation before mRNA sequencing.  
 
2.8.2. Library validation  
 
The libraries were validated using the Agilent 2100 Bioanalyser and a high-sensitivity kit 
(Agilent Technologies) to ascertain the insert size, and the Qubit® (Life Technologies) 
was used to perform the fluorometric quantitation. After validation, the libraries were 
normalized to 4nM, pooled together and clustered on the cBot™2 (system to amplify 
hundreds of millions of single-molecule DNA templates simultaneously) following the 
manufacturer’s recommendations. 
 
2.8.3. Sequencing  
 
Sequencing was performed using a 75-base paired end (2x75bp PE) dual index read 
format on the Illumina® HiSeq2500 in high-output mode according to the manufacturer’s 
instructions. It facilitates sequencing of both ends of each fragment generating sequences 
of high output quality. Primers bound to each end of the template and each single dNTP 
corresponding to the sequence (labelled with a fluorescence dye) were added, and then 
cleaved to allow incorporation of the next base. 4 reversible dNTPs are present during 
each sequencing cycle. After each binding of a nucleotide the clusters were excited by a 
light source and a characteristic fluorescence signal is emitted and the signal recorded.  
Each fragment was sequenced both ways and data recorded in pairs. FastQC files were 
generated as the start of the subsequent bioinformatics analysis.  
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2.8.4. Sequencing data analysis 
 
2.8.4.1. Quality control  
 
For each sample, a standard performance of quality was initiated of the reads using a 
combination of FastQC and assessing a number of metrics, as number of reads 
(duplicates), Quality Values (QV) – a per-base estimate of base caller accuracy and insert 
size. Assessing the metrics was done after mapping 10% of the data using a Burrows – 
Wheeler Aligner software package. It is a software tool to map low-divergent sequence 
against a large reference genome. For this QC, BWA-MEM is used as it is recommended 
for high quality performances as fast and accurate software tool.  Having determined that 
all samples passed quality control checks, the original FastQC files were taken forward 
for subsequent analysis on the full dataset. 
 
2.8.4.2. Trimming  
 
To remove adapter sequencer and poor quality ends of reads, trimming was performed 
using Trim Galore, a wrapper tool which uses cutadapt and FastQC to trim and perform 
QC on the trimmed. Trimming was performed in paired-end mode. 
  
2.8.4.3. Sequence mapping  
 
Reads (trimmed) were mapped against a combined human sequence genome hg19 and 
HPV16 genome referne sequence NC_001526 using STAR (Alex Dobin, Git Hub). In 
contrast to many other RNA-sequencing aligners which are extensions to existing short 
read mappers (and work by aligning short reads to a database of splice junctions and/or 
or align split-reads before alignment), STAR is designed to align the non-contiguous 
sequences directly to the reference genome. In order to take a conservative approach to 
issues around secondary mapping issues within the genome, STAR was run with the 
MultimapNMax=1 flag, meaning reads mapping to more than 1 location were considered 
unmapped.  
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2.8.4.4. Gene expression  
 
Expression counts for both exons and transcripts were calculated, using Subread 
featureCounts Version 1.5.1 (Liao et al., 2014), a program for assigning sequence reads 
to genomic features. 
Read summarization (counting) was generated for paired end read fragments. It was 
summarized at exon level and then grouped at transcript level. To provide stringent and 
robust data, reads overlapping more than one feature were excluded from the count 
summary (according to authors recommendations (Liao et al., 2014)).  
To define the exon and transcript locations (raw reads calculation), the RefSeq gene 
model was used. This was provided by the UCSC gene model for the human reference 
hg19 and combined with equivalent information from the NC_001526 HPV16 gene 
model (NCBI).  
   
2.8.4.5.  Principal component analysis 
 
Principal component analysis (PCA) is a statistical procedure, that converts a set of 
observations of possibly correlated variables into a set of values linearly uncorrelated 
variables called principal components. PCA was invented by Karl Pearson as an analogue 
of the principal axis theorem in mechanics (Pearson, 1901). 
Top 5000 most variable transcripts were selected according to Median Absolute 
Deviation (MAD) and PCA applied to the resultant dataset using R environment for 
statistical computing. Output graphs generated included the percentage (%) of variability 
capture within each component and graphs coloured by meta-information (HPV source, 
IR treatment), visualized on plots as component 1 versus component 2 and component 2 
versus component 3.  
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2.8.4.6. ConsensusclusterPlus 
 
To determine the nature of any clustering between samples and the membership and 
stability evidence of these clusters in an unsupervised analysis, the ConsensusclusterPlus 
class discovery tool was applied to the dataset.   The top 5000 most variable transcripts 
(identified according to their median absolute deviation) were filtered. This resultant data 
was used to generate clusters within the dataset (generating consensus cumulative 
distribution function, delta area and tracking plots), displaying a combination of 
hierarchical clustering and Pearson’s correlation co-efficient as the distance metric.  
 
2.8.4.7. Differential gene expression  
 
Differentially expressed genes were identified using an DEseq2 analysis (statistical 
analysis of count matrices for systematic changes between conditions), by using the R 
statistical software/Bioconductor package (Love et al., 2014), on normalised count data. 
For multiple testing and false discovery issues, the generated p-values were corrected 
using the FDR method (Benjamini and Hochberg, 1995). It is a method of hypothesising 
the level of type I errors in null hypothesis testing when conducting multiple comparisons. 
Designed FDR controlling procedures, control the proportions of „findings “that are false.  
Results were presented using heatmaps (a tool to visualise the large and complex matrix 
of values). To group similar data together while revealing any patterns within the dataset, 
the generated data was log2 transformed and median centred before hierarchical 
clustering (using average linkage and Pearson's correlation as the similarity metric). The 
final values were then converted into 3 colour patterns (green, red and black), where green 
represented under expressed (compared to median), black represented values around the 
median expression and red were over expressed values. 
 
2.8.4.8. Gene ontology over-representation analysis 
 
The Gene ontology over-representation analysis (GO ORA) analysis was undertaken 
using the GOstats bioconductor library. The resultant data was corrected for multiple 
testing and false discovery using the FDR method. 
Genes were classified in three categories, its biological processes (BP), molecular 
functions (MF) and cellular components (CC).  
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One of the issues with ORA analysis of very short gene lists was that terms appeared 
significant because combination of a few observations in a gene set with a limited number 
of terms (i.e. an issue of rarity). To overcame this limitation common practise was to 
undertake analysis using a total list of around 200-500 genes in length (even though not 
all of the genes will have passed any significance threshold) to help this shortcoming of 
the maths. 
 
2.8.4.9. Human viral fusion transcript plots (Circos plots) 
 
Circos plots were used to vizualize and identify human (hg19) and viral (HPV-16) mRNA 
fusion transcripts. The software Circos is using a circular layout to display relationships 
within the genomic data (Krzywinski et al., 2009). Each read mapping to a different 
chromosome were extracted and only those reads mapping to hg19 and NC_001526 
(HPV-16) were filtered, using samtools “bad pairs”. These were then converted into 
circos links format before bundling and plotting the links using Circos against a combined 
HPV16 and hg19 karyotype. 
 
2.8.4.10. Integrative genomics viewer 
 
The Integrative Genomics Viewer (IGV) enables real-time visualization of aligned 
sequence reads, different levels of viral gene expression, mutations and mismatches 
compared to the reference sequence, splicing patterns and gene expression. This software 
was downloaded from the Broad Institute (Robinson et al., 2011).  
 
2.8.4.11. Geneview 
 
The Genview software was written by Dr. Peter Giles of the Wales Gene Park. It helps to 
combine expression data alongside annotation data and enabled the rapid visualisation of 
different patterns of gene expression through histograms or generating heatmaps. 
Furthermore, it provides Annotation information of every gene, as cellular components, 
biological processes and molecular functions (incorporated into the software – link to 
NCBI and other databases).
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Chapter 3 : Derivation and characterization of novel OPSCC cell lines 
 
3.1. Introduction  
 
Historically, most OPSCC cases have been associated with tobacco use and alcohol 
consumption, with patients typically being older with an average age of 59.3 years old 
(Schache et al., 2016). This picture has widely changed in conjunction with HPV 
infection, with patients being much younger (mean age for HPV-positive patients 57.4 
years compared to 61.4 years for HPV-negative patients) and non-smokers/infrequent 
smokers with a high number of lifetime sexual partners (Chu et al., 2013, Schache et al., 
2016). HPV positive and negative OPSCC are clinically distinct entities, as HPV-positive 
patients (with a high-risk type of HPV), respond better to radiotherapy compared to HPV-
negative patients (Evans et al., 2013). Furthermore, HPV-positive patients showed a 
better survival rate compared to HPV-negative patients over a period of 5 years (Evans et 
al., 2013, Lill et al., 2017).   
There are no animal models that mimic HPV-associated OPSCC, therefore to study the 
biology and treatment of this disease, HPV-positive in-vitro models are needed. However, 
the study of head and neck cancer biology is hampered by the limited availability of 
suitable cell lines. In 2014, there were 8 known published HPV-positive cell lines – 
consisting of UMSCC-47, UPCI-SCC-90, UMSCC-104, 93-VU-147T, UD-SCC-2, UT-
SCC-45,UPCI-SCC-152 and UPCI-SCC-154 (Arenz et al., 2014, Bradford et al., 2003, 
Brennan et al., 1995, Brenner et al., 2010, Descamps et al., 2014, Ferris et al., 2005, 
Kimple et al., 2013, Lin et al., 2007, Rieckmann et al., 2013, Steenbergen et al., 1995, 
Tang et al., 2012). UPCI-SCC-90 and UPCI-SCC-152 were derived from different 
specimens from the same patient in Pittsburgh (USA). The majority of available head and 
neck cancer cell lines are HPV-negative. Those cell lines used in publications share all 
the same characteristics of a HPV-positive cell line, expressing wild-type 53 and p16 (a 
known surrogate marker for HPV infection). An exception to these published HPV-
positive cell lines is 93-VU-147T which was described with genetic alterations and 
mutated p53 (Steenbergen et al., 1995).   
The majority of the known HPV-positive HNSCC cell lines were derived from former 
smokers. It was established that the smoking characteristics of patients (smoker, non-
smoker) have an impact on patient prognosis in terms of survival and recurrence of a 
tumour. In a study on head and neck cancer it was established that HPV-positive patients 
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who were also tobacco users were at significantly higher risk of disease recurrence than 
non-smokers with HPV-positive tumours, with an effect on general survival (Maxwell et 
al., 2010). All HPV-negative patients in this study were tobacco users and had a 
significantly reduced disease specific survival compared to HPV-positive patients 
(Maxwell et al., 2010).   
In summary, new cell line models are needed to study the impact of treatment response 
in new “typical” head and neck patients (HPV-positive, young and non-smoker). Two 
novel HPV-positive OPSCC cell lines (CU-OP-2 and CU-OP-3) were previously 
successfully derived in Cardiff by Dr. Evelyne Pirotte. CU-OP-2 was derived from an ex-
smoker, whereas CU-OP-3 was derived from a non-smoker. Cell line models, such as 
CU-OP-2 and CU-OP-3, representing the “typical” characteristics of an HPV-positive 
patients need to get increased for better comparison to HPV-positive patients and for 
better comparison to the higher number of HPV-negative head and neck cancer cell lines. 
Development of new cell line models for HPV-positive head and neck cancer should be 
continued to a higher number to mimic better the wider variety of treatment response of 
HPV-positive OPSCC patients.   
The aim of this study was to continue deriving novel cell lines from oropharyngeal cancer 
biopsies, using an explant method (cell outgrowth of <1mm tissue pieces) and to 
characterize the successfully grown lines as potential models for HPV-positive or HPV-
negative OPSCC. The results are described from receiving the biopsy to phenotypical 
characterisation (including morphology). The cell lines were characterised in terms of 
HPV status and their identity validated by comparing similarities via STR typing of the 
original biopsy and the established cell lines.  
 
3.1.1. Terminology  
 
The explant method was used to process the biopsies during cell line development. 
“Explant” describes new cell growth out of the small biopsy pieces. Within this chapter 
the term primary culture is used to indicate the first passage from the outgrowth 
(explants). Early passages are classified as short-term culture. A cell line was classified 
as immortal or established, when it surpassed a certain number of population doublings 
(PD), compared to characteristics of “normal” epithelium cells e.g. HEKn cells (with an 
expected proliferative capacity of around 30 PD). Immortal cell lines are likely to have 
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overcome telomere mediated senescence and programmed cell death, which supports the 
suggestion that these cell lines are derived from cancer cells present in the biopsy.  
The study was named Primary Culture of Oropharyngeal Cells (PCOC), and during 
collection and growth, biopsies were allocated a “PCOC” number. Once lines were 
established, they were referred to as “CU-OP#” lines – indicating Cardiff University 
Oropharyngeal Cancer, with # corresponding to the chronological order of the biopsy 
collection. The passage number of each culture was recorded and is indicated with the 
prefix “p”, e.g. CU-OP-17 p14 indicates the fourteenth passage of CU-OP-17. 
 
3.2. Sample collection & Study samples  
 
Ethical approval for this study was obtained from and NHS Research Ethics Committee 
and the study was adopted into the National Institute for Social Care and Health Research 
(NISCHR) portfolio. Approval was also obtained from the Cardiff and Vale University 
Health Board Research and Development (R&D) Office. Patients were considered for 
inclusion in the PCOC study, if they were likely to be diagnosed with an oropharyngeal 
tumour. These inclusion criteria were: presentation at the Head and Neck Oncology clinic 
at Cardiff and Vale NHS Trust, fine needle aspirate and/or biopsy of a mass in the H&N 
showing presence of squamous cell carcinoma, and ability to give written informed 
consent. (full participant entry seen in full PCOC study protocol – Appendix 1). Patients 
undergoing treatment at the Cardiff and Vale NHS Trust were identified by head and neck 
surgical consultants or consultant oncologists in the course of their clinical practice. 
Biopsies were collected during panendoscopy and placed in transport media to prevent or 
minimize tissue degradation.  
Eleven patients were consented between March 2015 and August 2016 and a 
corresponding biopsy sample collected. All patients were male, except for one patient 
(PCOC-14) and their mean age was 65.45 years. Compared to a major cohort study of 
Schachte et al., (2016), the average age was higher for OPSCC patients in the current 
study. This could be due to the smaller number of patients participating in the current 
study compared to previous study cohorts. Biopsies were taken from two different sites 
of the oropharynx: 6 biopsies were collected from the tonsils and 5 biopsies from base of 
tongue. All biopsies were taken prior to treatment. Characteristics of each biopsy 
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regarding age of the patient, sex (gender), smoking status, site of the tumour, TNM stage, 
p16 status, treatment history and outcome are shown in Table 3-1.  
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Table 3-1: Details of patients recruited to the PCOC study from March 2015 to August 2016   
Study 
number 
Sex 
(M/F) 
Age 
(years) 
Smoking 
statusA Site 
TNM 
StageB 
p16 
IHC TreatmentC Recurrence 
PCOC13 M 78 Ex-smoker Tonsil T4N2cM0 Y Radical RT Y, loco-regional 
PCOC14 F 81 NK 
Tongue 
base T4N2bM1 NK Best supportive care (palliative) NK 
PCOC15 M 68 Y (>20pack/yr) Tonsil T3N2bM0 Y induction chemo then CRT Y, loco-regional 2016 (died) 
PCOC16 M 64 Non-smoker Tonsil T4aN2bM0 Y 
induction chemo, then CRT, then 
neck dissection N 
PCOC17 M 68 Y (100 pack/yr ) Tonsil T4aN1M0 Y 
induction chemo, then CRT, then 
neck dissection N 
PCOC18 M 68 
Ex-smoker 
(10pack/yr) Tonsil T3N2bM0 Y induction chemo, then CRT 
Y, metasases in lungs and mediastinum 
confirmed on biopsy 2018 
PCOC19 M 70 Ex (<10pack/yr) 
Tongue 
base T4aN2cM0 Y induction chemo, then CRT N 
PCOC20 M 55 Never Tonsil T2N2aM0 Y 
Neck dissection followed by CRT 
to primary N 
PCOC21 M 52 Ex (<10pack/yr) 
Tongue 
base T2N2bM0 Y 
Neck dissection followed by CRT 
to primary N 
PCOC22 M 51 Never 
Tongue 
base T4aN2cM0 Y induction chemo, then CRT N 
PCOC23 M 65 Ex (10pack/yr) 
Tongue 
base T3N1M0 Y CRT N 
APack-years(pack/yr): Number of cigarette packs smoked per day multiplied by the number of years smoked; not known (NK) 
B (T: size and extent of tumour; N: number of nearby lymph nodes that have cancer; M: cancer metastasized) 
CRadiotherapy (RT), Chemo-radiotherapy (CRT) 
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The biopsy pieces varied in size, depending on the size of the tumour within the patient, 
and were composed of tumour and surrounding tissue. This was seen in growth of 
different types of cells, during observation within the first 48 hours until the media was 
replaced. Some of the unidentified non-adherent cells, and red-blood cells (blood clots) 
were discarded after the first media changes of the culture. Explants were visible in the 
collected biopsies after 2-7 days of tissue culture. In general, biopsies were considered 
unsuccessful if they did not produce explants (outgrowths) after 7 days (although media 
changes were continued until the last biopsy pieces detached). Some tissue fragments did 
not attach to the plastic tissue culture plate and a few explants were lost due to low 
adhesion during the first media change after 48 h of explant production. No explants were 
lost after the second media change. All biopsies received, produced explants (visible new 
growth) (Table 3-2). Two of these biopsies were successfully grown over multiple 
passages (PCOC-17 and PCOC-20).  
Extended cell growth from explants or after the first 5-6 passages (p) were unsuccessful 
for several reasons. Explants for PCOC-13 (p3), PCOC-14 (p4), PCOC-15 (p8), PCOC-
16 (p9), PCOC-18 (p4), PCOC-19 (p4) and PCOC-22 (p3), were successfully grown for 
a limited number of passages. However, cell growth slowed down and after the final 
passage this was followed by senescence (before senescence, cells appeared bigger and 
heterogeneous). For PCOC-15, PCOC-16 and PCOC-21 cell growth slowed down after 
around p4-p5, but limited colony growth appeared, which resulted in transfer from a 10cm 
tissue culture plate into a 6cm tissue culture plate. After p8 for PCOC-15 and p9 for 
PCOC-16 the last cells appeared senescent.  
PCOC-23 showed a yeast contamination in the plates with the tissue fragments. A 
treatment with amphotericin B appeared to be successful and the explants were passaged 
the first time. Immediately after the first passage, yeast reappeared. Further treatment with 
amphotericin B was unsuccessful; it is possible that yeast cells had developed resistance 
to amphotericin B after the first treatment of the biopsy pieces (Table 3-2).  
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Table 3-2: Growth status of PCOC biopsies  
Biopsy study number  
Explants 
produced 
Max. 
Passage  Final outcome 
PCOC-13 Yes p3 slow growth  (senescence) 
PCOC-14 Yes p4 slow growth  (senescence) 
PCOC-15 Yes p8 slow growth  (senescence) 
PCOC-16 Yes p9 slow growth  (senescence) 
PCOC-17 Yes p25 established cell line 
PCOC-18 Yes p4 slow growth  (senescence)  
PCOC-19 Yes p4 slow growth  (senescence) 
PCOC-20 Yes p20 established cell line 
PCOC-21 Yes p8 slow growth  (senescence) 
PCOC-22 Yes p3 slow growth  (senescence)  
PCOC-23 Yes p1 yeast contamination  
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3.3. Growth of PCOC-17 and PCOC-20 
 
During the early stages of culture of PCOC-17 and PCOC-20, growth characteristics, 
colony and cell morphology were assessed. These observations provided useful 
information about the explants and cell culture (e.g. health and cell types present). Cells 
were checked for any signs of apoptosis or senescence during early culture from tissue 
fragments.  
CU-OP-17 and CU-OP-20 were successfully grown into established cell lines. These two 
cell lines were grown to around 20 passages (p25 and p20). Cell outgrowth was visible 
for PCOC-17 (CU-OP-17) after 4 days and for PCOC-20 (CU-OP-20) after 3 days in 
culture on GMEM-EGF positive media (Figure 3-1). To support cell growth of the 
primary culture a layer of post-mitotic 3T3 feeder layer was plated. These 3T3 feeder 
cells were displaced as the colonies of PCOC-17 or PCOC-20 were growing, as a result 
of division of peripheral cells (Figure 3-2).  
The outgrowth for PCOC-17 (CU-OP-17) reached sufficient size to be passaged after 4 
days and PCOC-20 (CU-OP-20) after 7 days in culture. During the first passage the 
appropriate trypsinisation time was established for both cell lines. This was tested with 
an initial 5 min incubation with TE and inactivation of media, this process was continued 
until all attached cells (explants) were collected. Cells were then plated the first time as 
single cells. Both cell lines produced polygonal cells similar to the shape of keratinocytes. 
PCOC-17 (CU-OP-17) cells were slightly bigger than the PCOC-20 (CU-OP-20) 
counterpart (Figure 3-2).   
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Figure 3-1: Morphology of PCOC-17 and PCOC-20 explants 
A: PCOC-17 explant growth: Explants, indicated with blue arrows, grew in roughly circular pattern from 
the biopsy tissue fragment (red circle) – 50X Magnification 
B: PCOC-17 outgrowth was of polygonal shape growing tightly – 100X Magnification 
C: PCOC-20 explant growth from biopsy tissue fragment in some tight polygonal shape colonies – 50X 
Magnification 
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Figure 3-2: Morphology of CU-OP-17 and CU-OP-20 cells in culture and culture with 3T3 feeder 
cells 
A: PCOC-17 polygonal cells grew tightly together in a rough circular shape without any gaps between the 
single cells – 200X Magnification  
B: PCOC-20 smaller polygonal cells compared to PCOC-17 (similar circular shape) – 200X Magnification  
C: 3T3 feeder cells covering the pates while growing cells out of the biopsy pieces (PCOC) and after support 
growth for established cell lines (CU-OPs). 3T3 feeder cells are compacted between the grown colonies 
(e.g. PCOC-17) – indicated with blue arrows.  
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3.4. Differences in colony morphology within cell lines 
 
During tissue culture of PCOC-17 (CU-OP-17) and PCOC-20 (CU-OP-20) two different 
types of colonies were observed in early passages of these two cell lines. These colonies 
were classified into two types. Type 1 colonies were characterized by growth as flat 
monolayers, whereas type 2 colonies comprised more differentiated cells (with colonies 
growing upwards in multiple cell layers). Type 1 colonies had the tendency to grow faster 
compared to the type 2 colonies. Type 2 colonies had the appearance of a stratified 
epithelium, where cells were growing on top of each other. Cells that reached the top of 
the multilayer detached. Mainly type 1 colonies were observed from early passages in 
PCOC-17 (CU-OP-17) from p1 onwards with around 80% flat growing colonies. Type 2 
colonies were observed for longer in the PCOC-20 (CU-OP-20) cell line until p5 (Figure 
3-3). Over time the proportion of flat growing colonies (flat monolayer) increased, and a 
single pattern of colony growth become dominant; for CU-OP-17 after p5 and for CU-
OP-20 for p6 (Figure 3-3).  
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Figure 3-3: Variation in PCOC-17 (CU-OP-17) and PCOC-20 (CU-OP-20) morphology 
A: PCOC-17 p1: two types of colonies present: 80% of flat colonies, seen with a red circle and 20% 
differentiated growing (top growing) seen with a green circle. 50X Magnification  
B: PCOC17 p5: The amount of multilayer colonies decreased quite quickly and after p5 only flat colonies 
were present – 50X Magnification  
C: PCOC-20 p3: example of multilayer colony after p4 – 50X Magnification  
D: PCOC-20 p5: 70% of cells are flat growing – 30% in multilayers – 50X Magnification  
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3.5. Establishing replicative potential of cell lines  
 
It was important to know whether CU-OP-17 (PCOC-17 biopsy) and CU-OP-20 (PCOC-
20 biopsy) were immortal cell lines (i.e. with the potential to proliferate indefinitely). 
Therefore, population doublings (PD) were estimated and compared with the number of 
PD expected from non-immortal cells. Human Epidermal Keratinocytes (neonatal) 
(HEKn) from Life Technologies were included in some experiments to allow comparison 
with non-malignant cells. The manufacturers suggest that these cells can be grown to 
approximately 30 PD (ThermoFisherScientific, 2009).  
Cells were cultured at a range of seeding densities to determine the optimal plating 
density. The results of these experiments were used to estimate the plating efficiency for 
CU-OP-17 and CU-OP-20. This indicated a plating efficiency of approximately 10% for 
both cell lines (i.e. approximately 10% of plated cells divided and produced new 
colonies). Population doublings of 30 PD for CU-OP-17 and CU-OP-20 were achieved 
after 6 and 5 passages, respectively. The highest passage achieved for CU-OP17 was p25, 
which would indicate a PD level of 125. CU-OP-20 was passaged to a maximum of p20, 
equating to approximately 120 PD.  
Stocks of CU-OP-17 and CU-OP-20 were expanded using the earliest available frozen 
aliquot to obtain a large number of frozen samples with the same passage. At least forty 
aliquots of CU-OP-17 p11 were frozen. Thirty aliquots of CU-OP-20 p11 were prepared 
and frozen.  As they were expanded from early passages, CU-OP-17 and CU-OP-20 are 
likely to comprise genetically heterogeneous populations of cells. Long term culture, 
could result in outgrowth of sub-populations. Experiments were performed using 
heterogeneous populations as they were judged to be more representative of the original 
tumour than cultures derived by single cell cloning. Both cell lines showed a similar 
growth rate as the established cell lines used in this study. This was indicated by the 
established seeding density for the radio-sensitivity assays, which were in the range of 
the other known cell lines. The growth rate for the CU-OP cell lines might also be 
influenced by the support of the 3T3 feeder layer.  
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3.6. Cell line validation 
 
It was important to confirm that the cell lines were derived from the original biopsies. 
This was achieved using DNA fingerprinting based on PCR amplification Short Tandem 
Repeat (STR) sequences, which was performed on DNA extracted from the cell lines and 
from the original biopsies. Mycoplasma testing was undertaken on the established cell 
lines. 
 
3.6.1. STR typing of biopsies & cell lines 
 
STR consist of intronic polymorphisms, which occur frequently in the human genome. 
They consist of tandemly arranged nucleotide repeat units. The most common approach 
to identify STR polymorphisms is the amplification of STR loci (microsatellites) by PCR 
(Tilanus, 2006).  
STR typing was performed by Public Health England (PHE) as a paid for service. DNA 
samples were sent to PHE on Whatman FTA cards with passage number p14 for CU-OP-
17 and p12 for CU-OP-20. The data were returned in graphical and tabulated form, with 
an accompanying report. 
To enable future identification of the newly derived CU-OP cell lines (17 and 20), and to 
confirm that they were derived from the original biopsy, the STR profiles of biopsies and 
cell lines were compared with each other (Figure 3-4 and Table 3-3; Figure 3-5 and Table 
3-3). The STR profiles confirmed that the CU-OP-17 and CU-OP-20 cell lines were 
derived from the original biopsies. It demonstrated as well that CU-OP-17 and CU-OP-
20 differ from each other. The biopsy and cell line of CU-OP-17 share 28 out of 34 alleles, 
while the CU-OP-20 biopsy and derived cell line share 30 out of 33 alleles.  These 
variations are consistent with loss of heterozygosity (LOH) in cell lines, a variation that 
is quite common in immortal cell line development (Dracopoli and Fogh, 1983). This 
genetic instability is common in other head and neck cell lines (Brenner et al., 2010). The 
LOH took place between the initial outgrowth of explants until the identity of the cell 
lines was confirmed at a higher passage number through STR typing. The interpretation 
of the data provided by PHE suggested that this confirmed that both cell lines were 
generated from the original source material.  
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Figure 3-4: STR profiles of the CU-OP-17 biopsy and derived cell line 
Short tandem repeats were amplified at 16 loci. Alleles are listed in the grey bars above the traces and 
number of repeats by vertical lines. The biopsy profile is shown in the upper panel of each image pair and 
outlined in black. The cell line profile is shown on the lower panel of each image pair and outlined in red. 
The STR profile was separated into three profile lanes The green circles indicate the LOH between the 
biopsy and the cell lines.  
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Table 3-3: STR profiles of the CU-OP-17 biopsy and derived cell line 
  
STR locus 
Number of repeats at each lociA 
Biopsy  Cell line  
D3S1358 14, 15 14, 15 
THO1 9.3, 9.3 9.3, 9.3 
D21S11 29, 30, 33.2 30, 33.2 
D18S51 10, 13 10, 13 
PENTA E 7, 16 7, 16 
D5S818 9, 11 11, 11 
D13S317 9, 11 11, 11 
D7S820 12, 12 12, 12 
D16S539 12, 13 12, 13 
CSF1PO 10, 12 10, 10 
PENTA D 11, 14 11, 14 
AMEL X, Y X, Y 
vWA 16, 16 16, 16 
D8S1179 11, 12, 13 11, 13 
TPOX 8, 8 8, 8 
FGA 19, 24 19, 19  
A Biopsy and cell line share 28 out of 34 alleles; alleles that were present in the biopsy but were not identified 
in the cell lines are shown in red.  
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Figure 3-5: STR profiles of the CU-OP-20 biopsy and derived cell line 
Short tandem repeats were amplified at 16 loci. Alleles are listed in the grey bars above the traces and 
number of repeats by vertical lines. The biopsy profile is shown in the upper panel of each image pair and 
outlined in black. The cell line profile is shown on the lower panel of each image pair and outlined in red. 
The STR profile was separated into three profile lanes The green circles indicate the LOH between the 
biopsy and the cell lines. The black circle indicates the stutter peak (experimental error), which was not 
considered as STR peak after receiving the final report.  
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Table 3-4: STR profiles of the CU-OP-20 biopsy and derived cell line   
  
STR locus 
Number of repeats at each lociA 
Biopsy  Cell line  
D3S1358 14, 15 14, 15 
THO1 9, 9 9, 9 
D21S11 28, 31.2 28, 31.2 
D18S51 17, 17 17, 17 
PENTA E 10, 12 12, 12 
D5S818 12, 13 12, 13 
D13S317 12, 12 12, 12 
D7S820 9, 12 9, 11, 12 
D16S539 10, 13 10, 13 
CSF1PO 12, 12 12, 12 
PENTA D 9, 13 9, 13 
AMEL X, Y X, Y 
vWA 17, 17 17, 17 
D8S1179 13, 15 13, 13 
TPOX 8, 9  8, 9  
FGA 23, 23 23, 23 
A Biopsy and cell line share 30 out of 33 allele; alleles that were present in the biopsy but were not 
identified in the cell lines are shown in red. The extra allele shown in D7S820 is likely to be a stutter peak 
(Small extra peak immediately before the actual allele. A similar peak is seen in the electropherogram in 
the biopsy sample, which was not detected).  
 
 
3.6.2. Mycoplasma detection  
 
Mycoplasmas are considered to be the smallest self-replicating organism, with a known 
size of 0.3 – 0.8 µm in diameter. They are slow growing even under optimal conditions 
(Drexler and Uphoff, 2002). Mycoplasma are common contaminants in eukaryotic cell 
cultures, and can cause changes of function, and biochemical and metabolic changes in 
infected cultures (Drexler and Uphoff, 2002, Miller et al., 2003). CU-OP-17 and CU-OP-
20 cultures were tested for mycoplasma contamination by PCR using the Venor GEM kit 
(Minerva Biosciences). Both lines were confirmed to be free of mycoplasma after 
amplification and storage.  
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3.7. Assessment of HPV status 
 
HPV status was confirmed via PCR. DNA was extracted from the original biopsy samples 
and used as template in a PCR targeting a 161 bp region of the HPV-16 E6 gene and a 90 
bp of the HPV-18 E7 gene. HPV-16 and HPV-18 are the two most common HPV types 
for HNSCC worldwide. HPV-16 was chosen as it is the most prevalent, and HPV-18 was 
chosen because it is the 2nd most prevalent worldwide (Ndiaye et al., 2014). The adequacy 
of the extracted DNA for PCR based analysis was confirmed through amplification of a 
209 bp fragment of the human ß-globin gene. The three PCR reactions were set-up on the 
same day.  
The results of these assays are shown in Figure 3-6. DNA from biopsies PCOC-13 to 23 
was tested. Successful amplification of the ß-globin gene showed that all DNA samples 
were adequate for analysis. All the biopsies tested positive for HPV16 except for PCOC-
17 which was negative for both HPV16 and HPV18 DNA. 
P16 IHC is now routinely performed on biopsies from patients with suspected OPSCC. 
Data on p16 IHC for the PCOC patients was obtained from the pathology department at 
the University Hospital of Wales. p16 is commonly upregulated in following HPV E7 
mediated degradation of Rb, and p16 can be used as a surrogate marker for HPV status 
(although the correlation between HPV status and p16 positivity is not perfect). All 
biopsies were p16 positive, which is consistent with HPV-16 positive status. However, 
PCOC-17, tested p16 positive, but was HPV-16 and HPV-18 negative (Figure 3-6).  
The HPV status for the established cell lines, of the newly derived cell lines CU-OP-17 
(PCOC-17) and CU-OP-20 (PCOC-20) was later confirmed via mRNA sequencing 
(Chapter 5).  
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Figure 3-6: PCR amplification of HPV16 E6, HPV18 E7, and ß-globin fragments in PCOC biopsy 
DNA 
PCR was performed for each sample for HPV-16 E6 (161 bp), HPV-18 E7 (90 bp) and ß-globin (BG, 209 
bp). UMSCC-4 was included as known HPV-negative cell line. A negative control of the corresponding 
PCR master mix (MM) was added on each gel. HPV-positive controls were Hela (HPV18), Caski and SiHa 
(both HPV16).  
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3.8. Discussion 
 
One major aims in this study was to develop novel OPSCC cell lines, which was 
successful with two cell lines (CU-OP-17 and CU-OP-20). The new derived cell lines 
were helpful to increase the low number of available models. However, there is still a 
high need to further increase the number of HPV-positive cell lines, as there are still more 
HPV-negative head and neck cancer cell lines available  (Zhao et al., 2011). First of all, 
generating new HPV-positive head and neck cancer cell lines models should be continued 
to get closer to the available number of HPV-negative HNSCC cell lines for a better direct 
comparison of treatment response. Second of all this would give a better reflection and 
comparison to the general diversity of HPV-positive HNSCC patient in treatment 
response. Finally, more HPV-positive HNSCC cell lines are needed to mimic the 
“typical” characteristics of an HPV-positive HNSCC patient (young, fitter, non-smoker). 
The novel OPSCC cell lines derived in the current and previous study at Cardiff 
University reflect these characteristics.    
For the development of new OPSCC cell lines from biopsies the explant method was 
used. This method was based on protocols originally developed for culture of HPV 
positive cervical cancer cells (Stanley, 2002). The success rate for development of new 
cell lines in the current study was 2 out of 11 received biopsies but this was a labour 
intensive method. Regular 3T3 feeder change and media change is required to improve 
successful explant production. The explant method might be improved, by growing tissue 
pieces using a variety of different media, then choosing the media that provides the best 
biopsy growth. 
The CU-OP-17 (125 PD) and CU-OP-20 cell lines both (120 PD) exceeded the growth 
span expected of normal human keratinocytes. The cell lines displayed ongoing vigorous 
growth at 125 and 120 PD respectively, relative to the 30 PD expected lifespan of non-
transformed keratinocytes (ThermoFisherScientific, 2009).  
The origin of the established cell lines was confirmed via STR typing. Some loss of 
heterozygosity was observed between the biopsy and cell line profiles, but this is a known 
phenomenon and the genetic profile of the cell lines can be expected to stabilise over time 
(Dracopoli and Fogh, 1983). The presence of LOH is usually down to chromosomal loss 
through non-disjunction or chromosomal rearrangements through double strand breaks 
(DSB) and Homologous recombination (HR) (Andersen et al., 2008). LOH could be 
caused by the presence of a tumour suppressor gene in a specific chromosomal region. 
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However, a gene can only be called a tumour suppressor in many tumour genomes and if 
the resulting homozygous alleles bear clear and obvious inactivating mutations 
(Weinberg, 2007). This genetic instability (LOH) was observed in other head and neck 
cell lines in a study cohort in Michigan (Brenner et al., 2010). Dysregulation of DNA 
repair factors can cause genomic instability, which is implicated in aging, immune 
deficiencies or cancer (Broustas and Lieberman, 2014). Genomic instability is a key part 
of tumour progression (Weinberg, 2007). Another possible cause for the LOH between 
the cell line and the original biopsy at specific STR loci sites, could be the extended 
passage of the cell lines. LOH might represent the outgrowth of certain clones present in 
the heterozygous tumours. In-vivo the cancer genome can change during progression, 
leading to a heterogeneous cell population. However, to maintain an established cell line, 
routine passaging is essential. In the past serial passaging was not considered as playing 
a significant role in a “clonal evolution model”. In a study with Ishikawa cells a similar 
observation was made, which showed a heterogeneous copy number in the early passages 
and distinct profiles in later passages (Kasai et al., 2016). This can be directly connected 
to the current study, where the LOH could be explained to outgrowth of a novel dominant 
clone. Therefore, future studies, should consider a model to identify when the LOH has 
taken place (overgrowth of a dominant clone). Cell lines should be controlled after each 
passage via STR typing towards the original biopsy. Furthermore, sequencing analysis 
could identify genomic changes per passage, including differences of single isolated 
clones of each passage.  
 
It was demonstrated in a previous study that PCOC growth can be successfully supported 
with post-mitotic 3T3 feeder cells (Pirotte, 2017).  This support using 3T3 feeder cells 
was continued for the PCOC study from PCOC-13 to PCOC-23. Experiments were 
performed to demonstrate that culture without 3T3 feeders was possible at high cell 
densities, however cells grew better, especially at low densities with 3T3 support. 
 
Different technologies are available to derive primary tumour cell lines from original 
tumour samples to be used in research to optimize personalized cancer therapy (Kodack 
et al., 2017). These technologies include for example, chemical reprogramming, cancer 
stem cell isolation, sandwich culture, enzymatic degradation and explant (Mitra et al., 
2013). More recently, organoid culture has also been developed to support this aim (Drost 
and Clevers, 2018). In the current study the explant method was used. In this process, the 
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tissue fragment is cut into small pieces (<1mm) and placed on a FBS coated plate. The 
explant methods was described in Stanley et al., (2002) and adapted for the start of the 
PCOC study (Pirotte, 2017, Stanley, 2002). This method was also successfully used for 
cell line development of vulval cell lines in our laboratory (Bryant et al., 2014a). It was 
successfully adapted for developing OPSCC cell lines in the same laboratory (Pirotte, 
2017).  The explant method is also used for culture of keratinocytes isolated from human 
foreskin (e.g. HEKn) (Orazizadeh et al., 2015). It is a technique that facilitates the 
retention of native tissue architecture and microenvironment, with better representation 
of molecular interaction in-vivo (Mitra et al., 2013). Furthermore, it has the advantage of 
reducing the exposure of chemicals such as trypsin to a minimum, as only 1-2 
trypsinisation steps are needed. This is desirable as increased chemical exposure could 
affect cell viability. Compared to the methods using single cells suspension, the explant 
method provided intact cells within the biopsy piece, even following mechanical 
disaggregation.  
Once cell lines were established, the possibility of single cell cloning was considered, as 
opposed to retaining cell lines comprising a mixed population of cells. Advantages of the 
single clone method would have been to investigate differences in HPV integration or 
expression in various sub clones (Bryant et al., 2014a, Bryant et al., 2014b). However, 
tumours usually consist of heterogeneous cell populations, and the aim was to mimic this 
in cell culture with CU-OP-17 and CU-OP-20. This comparison provided the chance to 
investigate the response of IR on a more heterogeneous cell culture similar to the original 
tumour.  
 
Long term culture increases the risk of genetic drift (away from the original tumour) but 
also loss of heterogeneity within the cellular population (Mitra et al., 2013). To reduce 
the risk of these effects, CU-OP-17 and CU-OP-20 were used at the earliest possible 
passage numbers (i.e. at the earliest passage after a substantial number of stock aliquots 
could be generated). In the experiments described in this thesis, the use of cells at p8 to 
p11, should increase the chance of results being based on a heterologous cell culture 
population, which better reflects the original tumours. Some loss of heterogeneity did 
occur though, as evidenced by observing the cell culture microscopically, which showed 
loss of differentiated multi-layered cell growth (loss of peak shaped colonies – likely to 
contain normal cells) and establishment of a flat monolayer culture. The loss of colonies 
showing multilayer cell growth, which possibly contained normal cells, could be due to 
telomere shortening and senescence. Alternatively, this could reflect diluting out of 
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differentiated cells that produce fewer progeny over multiple passages. From a cell culture 
perspective, it would be interesting to clone and characterise the two populations more 
thoroughly, by HPV typing and/or via deep sequencing.  
 
Senescence, possibly mediated via telomere shortening, may have influenced the success 
rate of cell line development in the current study. All of the biopsies successfully 
produced explants (cell outgrowth), and this suggests that the initial biopsy handling and 
cell culture conditions were appropriate. However, the majority (9/11 – 82%) of the 
explants did not produce immortal cell lines. Instead they showed reduced growth after 
p1 to p5 and ultimately stopped proliferating; for example, for PCOC-15 and PCOC-16 
at p8 and p9. This could have happened through senescence associated with telomere 
shortening, alternatively it might reflect stress induced senescence associated with the 
culture conditions (e.g. due to non-physiological high oxygen tensions). It is interesting 
to note that many other studies report similarly low success rates in deriving tumour cell 
lines, though this does appear to vary by tumour site; e.g.(Kodack et al., 2017) report a 
success rate of 26% based on 568 tumour samples with highest success rates in lung 
cancers and lowest in breast cancers (29% versus 15%; p < 0.01). The success rate of 
18% in the current study lies within this range and is consistent with the start of the PCOC 
study of HPV driven OPSCC tumours (Pirotte, 2017).  
 
CU-OP-17 and CU-OP-20 originated from treatment naïve patients, and so they have not 
been subject to treatments that are likely to inflict additional mutations or select for 
subpopulations of possibly resistant cells. The patient from whom CU-OP-20 was derived 
showed characteristics that are typical of a HPV-positive patient i.e. he was a relatively 
young (55 years), male and a non-smoker, with an OPSSC of the tonsil. It therefore 
appears likely to be a valuable new model to investigate the biology of this increasingly 
common disease. 
Conversely CU-OP-17 represents an atypical HPV-negative case, in that it is HPV-
negative, but p16 positive (Figure 3-6 and Table 3-1). In a UK and a Dutch study, 14-
17% of HPV-negative head and neck cancer patients were identified as p16 positive 
(Evans et al., 2013, Lewis et al., 2010, Rietbergen et al., 2014). In a later Dutch study, the 
proportion of p16-positive OPSCC patients (n=388) who tested HPV-negative was 
12.4%. This subgroup showed some distinct demographic, clinical and morphologic 
characteristics. It showed a significantly worse five-year overall survival compared with 
the HPV-positive OPSCC tumours (p < 0.001) (Nauta et al., 2018). It is therefore helpful 
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to have an additional model for this clinically significant but diagnostically difficult 
group. P16 is classically regarded as a prominent tumour suppressor gene, and mediator 
of cellular senescence. It is therefore surprising that p16 expression appears to be 
upregulated in these tumours, however p16 overexpression has been reported in several 
other tumours including endometrial, colorectal and basal cell carcinoma (Romagosa et 
al., 2011), although its function in this context is unclear. 
 
Another interesting point compared to literature was the difference in the average age of 
OPSCC patients. In a large cohort study (n=1,529) the average age of OPSCC patients 
was defined as 59.3 years of age compared to this study (n=11) with an average age of 
65.45 years of age (Schache et al., 2016). The difference in the average age could be due 
to the smaller number of patients in the current study. A higher number of patients could 
better reflect the average age of OPSCC patients, as previously reported (Chu et al., 2013, 
Schache et al., 2016). 
 
All the PCOC biopsy samples except PCOC-17 tested positive for HPV-16. The high 
proportion of HPV-positive samples in the current study does not directly reflect the 
HPV-prevalence in oropharyngeal in the UK. The HPV prevalence in OPSCC in Wales 
was 55% (2001-2006); in the UK it was 51.8% (2002-2011) (Evans et al., 2013, Schache 
et al., 2016). However due to the small sample size of the current study, it is not surprising 
that it does not reflect the general population. It is also possible that patients who were 
more likely to have HPV-positive tumours may have been selected and consented by the 
clinical team. 
 
Strengths and weaknesses  
 
The methods used in this study had a high success rate in producing explants. This implied 
that cells had no problems in growing in the culture environment provided over short 
periods. The low number of established cell lines might be the greatest weakness. The 
explant increases the chance of the cell lines reflecting at early passages the 
heterogeneous population of the original tumour, which was considered as a strength in 
this study. Lower passage numbers were used for all experiments (depending on the 
number of aliquots). Another strength was the successful confirmation by STR analysis, 
that the cell lines were derived from the original biopsies. The generation of STR profiles 
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also facilitates ongoing validation of the lines identities (e.g. when they are provided to 
collaborators).  
3.9. Conclusion  
 
Two new OPSCC cell lines were successfully established from fresh biopsies of 
oropharyngeal cancer. One of the cell lines was identified as HPV-positive OPSCC cell 
line (CU-OP-20), which reflects the typical HPV-positive patients (relatively young, fit, 
non-smoker). CU-OP-17 represents one of the few HPV-negative cell lines that is p16 
positive. These cell lines are a valuable resource to support investigation of HPV and 
OPSCC biology.  
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Chapter 4 : Investigation of response to ionising radiation in    
oropharyngeal cancer cell lines                                                 
 
4.1. Introduction 
  
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is increasing and this 
increase is closely connected to greater incidence of human papillomavirus (HPV)-
positive tumours (Evans et al., 2013, Nasman et al., 2015). Most patients with OPSCC 
will receive radiotherapy as part of their treatment. In general, patients with HPV-positive 
OPSCC tend to respond better to treatment than patients with HPV-negative OPSCC 
(Dayyani et al., 2010, Evans et al., 2013). 
In the last few years, several studies have investigated the potential mechanisms for the 
observed superior patient survival associated with HPV-positive OPSCC, by testing 
responses to radiotherapy using in-vitro models. These in-vitro models consisted of 
different panels of HPV-positive and HPV-negative head and neck cancer (HNSCC) cell 
lines. The main findings were that as a group, HPV-positive cell lines showed greater 
sensitivity to radiation compared to HPV-negative cell lines, and this was associated with 
more substantial G2 cell cycle arrest in HPV-positive cell lines after treatment (Arenz et 
al., 2014, Kimple et al., 2013, Rieckmann et al., 2013). It has been suggested that the 
increased sensitivity to radiation was connected to a deficiency in double strand break 
(DSB) repair in HPV-positive cell lines, which leads to accumulation of unrepaired 
breaks and apoptosis (Arenz et al., 2014, Rieckmann et al., 2013).  
The primary aim of the work described in this chapter was to use clonogenic assays, 
which assess proliferative capacity after irradiation, to investigate the radio-sensitivity of 
a panel of OPSCC cell lines, including both HPV-positive and HPV-cell lines. Increased 
sensitivity to IR might also be partly attributable to residual p53 activity in HPV-positive 
cases. For example, it is possible that the tumour cell lines used in in-vitro studies might 
have low levels of functional p53 present due to incomplete degradation by the HPV-E6 
protein, as opposed to entirely inactive p53 protein following p53 gene mutation (Kimple 
et al., 2013). Therefore, levels of p53 were also assessed in the current study. 
In terms of the link between cell cycle arrest and p53 status, some discrepancies have 
been reported in the literature. Two studies reported similar findings, where they observed 
a direct correlation between cell cycle arrest and p53 status (Arenz et al., 2014, 
Rieckmann et al., 2013), whereas a third study did not observe this connection (Kimple 
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et al., 2013). This may be explained by different panels of cell lines being in the various 
studies, although there was some overlap in the lines used. Therefore, effects on cell cycle 
distribution (G2 arrest) were investigated in this study. Overall, this study aimed to clarify 
the relationship between HPV, p53 status and radio-sensitivity, in vitro using a cell line 
panel including established and newly generated OPSCC cell lines. However, the 
intensity of DNA damage caused by IR was not measured, as residual p53 activation was 
associated with greater sensitivity after IR. After investigation of p53 
accumulation/activation, abnormalities cell cycle arrest was investigated (e.g. G2 arrest). 
The role of DNA repair and DNA damage should be included in future studies to confirm 
the collected data of survival, p53 activation/accumulation and cell cycle arrest.   
 
It was hypothesised that:  
1. Sensitivity to ionising radiation would correlate with HPV status; specifically, 
HPV-positive OPSCC cell lines would show a greater sensitivity to radiation 
compared to HPV-negative OPSCC cell lines.  
2. Increased radiation sensitivity would be associated with accumulation of p53, due 
to incomplete degradation by HPV E6, in HPV-positive OPSCC cell lines. 
a. Accumulation of p53 will be directly correlated to accumulation of p-p53 
and p21. 
3. HPV-positive OPSCC cell lines would show greater G2 cell cycle arrest following 
IR compared to HPV-negative OPSCC cell lines. 
a. Greater G2 arrest would be expected to be greater in HPV-positive 
OPSCC cell lines due to the involvement of HPV E6 (p53) and HPV E7 
(pRb) on cell cycle regulations.  
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4.2. Defining seeding density of OPSSC cells for clonogenic assays 
 
Before clonogenic assays could be used to determine radio-sensitivity, it was necessary 
to determine the optimal number of cells to use in these assays (i.e. the seeding density). 
Too low a seeding density would result in too few colonies to achieve statistically 
significant results, while too high a seeding density would lead to errors in counting due 
to control plates becoming confluent, and also from colonies not emerging from single 
cells. The seeding density was defined for the majority of the panel of cell lines during 
an earlier study (Pirotte, 2017). For the three new cell lines (UMSCC-6, CU-OP-17, CU-
OP-20) the seeding density was optimized, as it represents a key parameter for clonogenic 
assays. The differences observed between the seeding densities per cell line in the current 
study indicate a difference in doubling time. This could be a possible confounder, which 
might result in different length of the assay or state of confluence per cell line used. As 
described above, too confluent plates would lead to counting errors. The effect or 
influence of differences in doubling time on the proliferation assay was tried to be reduced 
by defining a specific seeding density. This resulted in a similar length of the assay per 
cell line (10-15 days), 
As previously reported, none of the OPSSC cell lines could initiate and sustain growth 
from low plating densities (Rieckmann et al., 2013). In a previous study (Pirotte, 2017), 
it was concluded that post-mitotic 3T3 cells were needed to address the issue of limited 
cell growth at low seeding density. These “feeder” cells can promote growth by providing 
cell-cell contact, ECM and growth factors (Rheinwald and Green, 1975b, Rheinwald and 
Green, 1975a). Use of feeders supports plating of OPSCC cells at low density and so 
allows clonogenic assays to be assessed after 10-15 days of culture (Pirotte, 2017). 
Therefore, in this study, all clonogenic assays were set-up with the support of 3T3 feeder 
cells. Seeding density tests for UMSCC-6, CU-OP-17 and CU-OP-20 were set-up with a 
range of cell densities, on a layer of post-mitotic 3T3 feeder cells (Figure 4-1). Frequency 
of media changes, duration of tests and evaluation of the cell lines are described in detail 
in the Material and Methods chapter. Based on the results of the density tests, optimal 
seeding densities were defined as 4000 cells for UMSCC-6, 4500 cells for CU-OP-20 and 
7000 cells for CU-OP-17 per 10cm culture plate. A 10-15 days’ assay duration then 
resulted in countable colonies for all cell lines (mimicking the control plate conditions).  
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Figure 4-1: Effect of seeding density with the presence of 3T3 feeder cells on colony formation with 
UMSCC-6, CU-OP-17 and CU-OP-20 
Cells were seeded at densities between 20,000 and 1,000 cells with the support of 3T3 feeder cells. 3T3 
feeder cells were washed off with PBS before crystal violet staining. Plates were incubated at 37°C for 
10-15 days, then stained with crystal violet and photographed (images above). Colonies with >50 cells 
were counted.  
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4.3. Colony formation capacity after ionising radiation  
 
Cell lines were defined as sensitive or resistant to ionising radiation on the basis of the 
surviving fraction obtained after clonogenic assays.  Clonogenic assays were specifically 
designed for testing response to ionising radiation in cell lines, and are the standard assay 
used worldwide. They test the ability of cells to proliferate following radiation exposure, 
i.e. to retain reproductive ability to form large colonies or a clone (hence the term 
“clonogenic”) (Munshi et al., 2005). Clonogenic assays can also be used to test drug 
sensitivity on cell lines or drugs in combination with radiation (Franken et al., 2006, 
Munshi et al., 2005, Rafehi et al., 2011).  
In a study by West et al., (1993), cell lines derived from early stage cervical cancers were 
classified as radio-sensitive if they displayed a surviving fraction (SF) of less than 40% 
(SF < 0.40) and radio-resistant if they showed a SF of more than 40% (SF > 0.40), after 
2Gy treatments. This classification appeared to be clinically relevant as survival of cancer 
patients was shown to correlate with the response of their cultured cells to this dose (West 
et al., 1993). A similar approach was used in the current study: cell lines were classified 
as radiation sensitive if the SF post-treatment with 2Gy IR was above or below 40%, In 
other studies on OPSCC cell lines, lines were simply defined as “less” or “more radio-
sensitive” (Arenz et al., 2014, Kimple et al., 2013, Rieckmann et al., 2013).  
To assess response to ionising radiation (IR), cells were treated with IR and the surviving 
fractions were compared. Examples of the experimental plates are shown in Figure 4-2. 
The remaining cell lines are shown in Appendix 2. A wide range of responses was 
observed across the cell lines panel, with greater variation within the HPV-positive 
OPSCC cell lines (Figure 4-3). The surviving fraction of all cell lines combined (Figure 
4-3) showed an overlap between HPV-positive and HPV-negative OPSCC cell lines. The 
normal human keratinocytes cell lines showed an intermediate response to radiation after 
2Gy with a SF of 32.7% (classified as sensitive).  
This greater variation in sensitivity was especially observed in HPV-positive OPSCC 
compared to HPV-negative OPSCC cell lines, following treatment with 2Gy IR, (Figure 
4-3). The surviving fraction indicated radio-resistant and radio-sensitive cell lines in the 
HPV-positive group (Figure 4-3A). At 2Gy, the surviving fractions within the HPV-
positive OPSCC cell lines were UMSCC-47 (SF=14.1%), UPCI-SCC-90 (SF=28.3%) 
and CU-OP-20 (SF=20.4%), therefore classified as radio-sensitive, whereas CU-OP-2 
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(SF=44.7%) and CU-OP-3 (SF=60.4%) were classified as radio-resistant. CU-OP-2 and 
CU-OP-3 were only sensitive to IR after 4Gy to 6Gy treatment (Table 4-1).  
Significant differences in SF were measured between the HPV-positive OPSCC cell lines 
at 2Gy treatment between the most resistant and sensitive cell lines, UMSCC-47 to CU-
OP-2 (p=0.0001, two-way ANOVA), UMSCC-47 to CU-OP-3 (p<0.0001, two-way 
ANOVA), UPCI-SCC-90 to CU-OP-3 (p<0.0001, two-way ANOVA), CU-OP-3 to CU-
OP-20 (p<0.0001, two-way ANOVA) and CU-OP-2 to CU-OP-20 (as shown in Figure 
4-3.  
Table 4-1: Surviving fraction of HPV-positive OPSCC cell lines after treatment doses from 0.5Gy 
to 6Gy  
Treatment dose 
(Gy) 
Surviving fraction 
UMSCC-47 UPCI-SCC-90 CU-OP-20 CU-OP-2 CU-OP-3 
0.5  78.4 72.5 66.8 93.6 90.5 
1  44.4 48.5 46.9 64.1 83.3 
2 14.1 28.3 20.4 44.7 60.4 
4 1.3 7.5 3.8 12.2 19.1 
6 0.3 1.7 0.8 7.2 12.1 
 
HPV-negative OPSCC cell lines shared a similar pattern after IR treatment with the 
majority being radio-resistant after 2Gy treatment (Table 4-2). The only HPV-negative 
cell line with a SF below the 40% threshold defined at the beginning of the assay, was 
UMSCC-19 with a SF of 32.4%, which was therefore classified as radio-sensitive. All 
other HPV-negative OPSCC cell lines were classified as radio-resistant with an SF > 40% 
(Table 4-2; Figure 4-3).  
Within the HPV-negative OPSCC treated with 2Gy IR, the greatest significant difference 
was observed between the most sensitive cell line UMSCC-19 and the most resistant cell 
lines CU-OP-17 (p<0.0001, two-way ANOVA). Treatment at 0.5 to 1Gy did not show an 
obvious response to IR, and a limited number of colonies were detected after 4Gy and 
6Gy in the majority of cell lines. Therefore, the focus was placed on IR response after 
2Gy treatment within the panel of cell lines (Figure 4-4). The mean SF for HPV-positive 
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OPSCC cell lines was 33.6% and for HPV-negative OPSCC cell lines was 51.4%; this 
difference was not statistically significant (t-test, p = 0.1379).  
 
Table 4-2: Surviving fraction of HPV-negative OPSCC cell lines and HEKn after treatment doses 
of 0.5-6Gy 
Treatment 
dose (Gy) 
Surviving fraction 
UMSCC-19 UMSCC-6 UMSCC-74a UMSCC-4 CU-OP-17 HEKn 
0.5 81.7 87.4 85.3 92.3 94.3 79.8 
1 69.1 62.9 70.1 85.1 84.2 70.6 
2 32.4 44.9 47.7 60.1 71.8 32.7 
4 15.5 11.3 8.9 15.6 28.8 17.6 
6 3.8 2.4 0.9 2.3 10.3 1.6 
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Figure 4-2: Survival and proliferation following IR in CU-OP-20, CU-OP-3 (HPV-positive) and CU-
OP-17 (HPV-negative) cell lines  
CU-OP-20 is representative of a sensitive cell line after 2Gy treatment; CU-OP-3 is a resistant cell line after 
2Gy treatment. CU-OP-17 represents an HPV-negative cell line with a high resistance after 2Gy treatment. 
Cells were plated at low density for 24 hours before treatment with varying doses of IR. The media was 
changed and the plates were incubated for 10-15 days. Plates were then washed, stained with crystal violet, 
and photographed (image above). Colonies >50 cells were counted.  
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Figure 4-3: Radiation response of HPV positive and negative OPSCC cell lines  
Surviving fraction of cells after varying doses of IR was measured in a clonogenic assay.  
The mean results presented are representative of at least 3 experiments, including triplicates within each 
experiment. A two-way ANOVA with a Sidak post-test was used to test for statistical significance. Error 
bars indicated standard deviation (SD). ns stands for not significant.  
(A) Surviving fraction of all HPV-positive OPSCC cell lines: Greater variation in SF was observed among 
the HPV-positive OPSCC cell lines in response to IR, relative to the HPV-negative lines. The colony 
formation capacities of UMSCC-47, UPCI-SCC-90 and CU-OP-20 were reduced after 2Gy treatment. An 
example of a comparison between UMSCC-47 and CU-OP-3 is illustrated (****p-value: <0.0001 at 2Gy). 
ns stands for not significant 
(B) Surviving fraction of all HPV-negative OPSCC cell lines: HPV-negative cell lines shared a similar 
pattern of response to IR. UMSCC-19 was the most sensitive cell line within HPV-negative cell lines after 
2Gy. As an example the result of the comparison between UMSCC-19 and CU-OP-17 is illustrated (****p-
value <0.0001 at 2Gy). ns stands for not significant 
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Figure 4-4: Summary of response to 2Gy irradiation in OPSCC cell lines  
Depending on their response to treatment with 2Gy IR, the cell lines were classified as sensitive or resistant. 
Within the HPV-positive cell lines 3 cell lines were defined as sensitive to IR (UMSCC-47, UPCI-SCC-90 
and CU-OP-20). The HPV-negative cell lines shared a similar pattern after 2Gy, 4 cell lines were defined 
as resistant, and only UMSCC-19 was defined as radio sensitive cell line. Significant differences were 
observed between the most sensitive HPV-positive cell line to the most resistant with a p-value range of 
<0.0001 to 0.0216. Statistical significance was assessed using two-way ANOVA with a Sidak post-test. 
Error bars indicate standard deviation.  An example comparison between the most sensitive HPV-positive 
OPSCC cell line (UMSCC-47) and the most resistant HPV-negative cell line (CU-OP-17) is illustrated 
(**** p-value: <0.0001).  
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4.4. Molecular effect of ionising radiation  
 
Cells respond to IR, an important physiological stress factor, by activating multiple 
signalling pathways, including induction of DNA repair or apoptosis (Braunstein et al., 
2009). DNA damage, as induced by IR, usually triggers an increase in p53 protein, which 
leads to three major possible outcomes: cell cycle arrest, DNA repair and/or apoptosis 
(Blagosklonny, 2002, Haupt et al., 2003). The induced DNA damage leads to 
phosphorylation of p53 at Ser15 and Ser20 which reduces interaction with the negative 
regulator Mdm2. This promotes p53 accumulation and activation in response to DNA 
damage (Shieh et al., 1997). Phosphorylation at Ser15 of p53 has a key role in up-
regulation and activation of p53 (Tibbetts et al., 1999). This phosphorylation was reported 
to happen in conjunction with CDKs at S and G2/M cell cycle phase, which promotes 
p53 binding to Waf1/p21 binding sites. Waf1/p21/Cip1, which is induced by p53 is found 
in several kinase complexes, including those in the S and G2 phase (Wang and Prives, 
1995). Therefore, levels of p53, its activated form phospho-p53 (Ser15), and CDKN1A 
(p21) (a cyclin dependent kinase inhibitor whose transcription is regulated by p53) were 
assessed in the panel of OPSCC cell lines. This analysis was undertaken to determine if 
response to IR was mediated through p53 dependent or independent pathways.  
The time point of 24h was chosen to investigate a long term effect of p53 after IR towards 
a correlation of greater sensitivity to IR. This was correlated with literature, where 
stronger bands were seen after 24h after IR (Kimple et al., 2013). Activation of p53 was 
detected via p-p53. To investigate the 24h effect on p53 activation the same time point 
was chosen for p-p53.  
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4.4.1. p53, phosho-p53 and p21 expression in OPSCC cell lines after IR treatment 
 
Expression of p53 was detected in all 5 HPV-positive OPSCC cell lines (Figure 4-5 to 4-
8), but with substantial variation. By contrast, expression of phospho-p53 (p-p53) was not 
reliably detected by western blot in any of the HPV-positive cell lines.  
In UMSCC-47, equally strong expression of p53 was found before and after irradiation. 
However, in this cell line the strongest p21 expression was observed in the non-irradiated 
(untreated) sample. The p21 signal expression became weaker after treatment of 2Gy and 
6Gy (approximately 50% and 25% of the original signal respectively). No expression of 
phospho-p53 was detected in UMSCC-47. CU-OP-2 showed a similar expression patterns 
to UMSCC-47 for p53, p21 and phospho-p53.  
Weaker expression of p53 was seen in UPCI-SCC-90, CU-OP-3 and CU-OP-20. Each of 
these 3 cell lines demonstrated stronger expression of p21 compared to levels of p53. No 
activation of p53 was detected, as indicated by the absence of phospho-p53.   Expression 
of p53, phospho-p53 and p21 was detected in all HEKn 10Gy samples (positive control).  
Among the HPV-negative cell lines variation in the levels of p53 was observed as well 
(Figures 4-7 and 4-8). For the cell lines UMSCC-4, -6 and -19, no visible expression of 
p53 and phospho-p53 was seen whereas UMSCC-74a and CU-OP-17 showed some 
accumulation of p53 and activation of p53 (p-p53) after 2Gy and 6Gy treatment. Weak 
expression of phospho-p53 was seen in both untreated samples. p21 expression was 
observed in all HPV-negative cell lines, despite the absence of p53.  
In HEKn cells, accumulation of p53 was evident, as well as p-p53 expression after 2Gy 
and 6Gy treatment. P21 expression appeared to be stronger than p53 in every HEKn 
sample tested.  
In summary, p53 was detected in all HPV-positive cell lines (5 out of 5 cell lines), 
whereas only two HPV-negative cell lines demonstrated detectable expression of p53 (2 
out of 5 cell lines). Phospho-p53 expression was difficult to detect in the majority of cell 
lines tested, however there was accumulation of phospho-p53 in UMSCC-74 and CU-
OP-17 after 2Gy and 6Gy treatment. p53-independent transcription of p21 was seen in 3 
out of 5 HPV-negative cell lines. In the majority of cell lines tested, p21 expression 
became weaker after IR treatment, which might indicate a negative relationship between 
IR treatment and p21 expression in the majority of the HPV-negative cell lines (Stuart 
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and Wang, 2009). The majority of HPV-positive cell lines showed a positive association 
between IR treatment and levels of p21.  
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Figure 4-5: Expression of p53, p21 and phospho-p53 for UMSCC-47, UPCI-SCC-90 and CU-OP-2 
(HPV-positive) cell lines  
Western blot images. Cell line samples were arranged in order of treatment dose i.e. untreated to 2Gy and 
6Gy IR treatment (collected after 24h incubation after IR treatment). HEKn treated with 10Gy and 
harvested after 24h was added as positive control. p53, p21 and phospho-p53 were run on three individual 
gels/membranes (3 membranes used). Membrane was stripped and re-probed with ß-actin antibody. ß-actin 
(1-2min exposure) was tested for all three individual runs. p53 (45min exposure) bands are seen in all three 
cell lines, with minor differences in expression level. The second membrane was probed for p21 (25-40 
min exposure). The third membrane was probed with phospho-p53 (45min exposure).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                         Investigation of response to ionizing radiation in oropharyngeal cancer cell lines 
 
119 
 
 
 
 
 
Figure 4-6: Expression of p53, p21 and phospho-p53 for CU-OP-3 and CU-OP-20 (HPV-positive) cell 
lines 
Western blot images. Cell line samples were arranged in order of treatment dose i.e. untreated to 2Gy and 
6Gy IR treatment (collected after 24h incubation after IR treatment). HEKn treated with 10Gy and 
harvested after 24h was added as positive control. p53, p21 and phospho-p53 were run on three individual 
gels/membranes (3 membranes used). Membrane was stripped and re-probed with ß-actin antibody. ß-actin 
(1-2min exposure) was tested for all three individual runs. p53 (45min exposure) bands are seen in all three 
cell lines, with minor differences in expression level. The second membrane was probed for p21 (25-40 
min exposure). The third membrane was probed with phospho-p53 (45min exposure). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                         Investigation of response to ionizing radiation in oropharyngeal cancer cell lines 
 
120 
 
 
 
 
 
Figure 4-7: Expression of p53, p21 and phospho-p53 for UMSCC-4, UMSCC-6 and UMSCC-19 
(HPV-negative) cell lines  
Western blot images. Cell line samples were arranged in order of treatment dose i.e. untreated to 2Gy and 
6Gy IR treatment (collected after 24h incubation after IR treatment). HEKn treated with 10Gy and 
harvested after 24h was added as positive control. p53, p21 and phospho-p53 were run on three individual 
gels/membranes (3 membranes used). Membrane was stripped and re-probed with ß-actin antibody. ß-actin 
(1-2min exposure) was tested for all three individual runs. p53 (45min exposure) bands are seen in all three 
cell lines, with minor differences in expression level. The second membrane was probed for p21 (25-40 
min exposure). The third membrane was probed with phospho-p53 (45min exposure). 
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Figure 4-8: Expression of p53, p21 and phospho-p53 for UMSCC-74a, CU-OP-17 (HPV-negative) 
and HEKn (normal human keratinocytes) cell lines 
Western blot images. Cell line samples were arranged in order of treatment dose i.e. untreated to 2Gy and 
6Gy IR treatment (collected after 24h incubation after IR treatment). HEKn treated with 10Gy and 
harvested after 24h was added as positive control. p53, p21 and phospho-p53 were run on three individual 
gels/membranes (3 membranes used). Membrane was stripped and re-probed with ß-actin antibody. ß-actin 
(1-2min exposure) was tested for all three individual runs. TP53 (45min exposure) bands are seen in all 
three cell lines, with minor differences in expression level. The second membrane was probed for p21 (25-
40 min exposure). The third membrane was probed with phosho-p53 (45min exposure). 
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4.5. Cell cycle response following IR  
 
The original hypothesis, that HPV-positive cell lines would show an increased G2 cell 
cycle arrest following IR compared to HPV-negative OPSCC cell lines. It was based on 
the expected clear difference between HPV-positive and HPV-negative OPSCC cell lines 
after the radio-sensitivity assays (Chapter 4). The hypothesis was slightly revised 
according to the data obtained within the radio-sensitivity assays, where a greater 
variation within the HPV-positive cell lines and some overlap with the HPV-negative cell 
lines in response to IR was seen. Furthermore, no clear difference was observed between 
the HPV-positive and HPV-negative OPSCC cell lines in terms of levels of phospho-p53 
(sensitive and resistant cell lines), or p21. Accumulation of p53 was seen in all HPV-
positive cell lines with some variation, whereas only 2 out of 5 HPV-negative cell lines 
showed accumulation of p53. Differences in doubling time of each cell line, as indicated 
in different seeding densities, might play a role in differences in cell cycle arrest.  
Hypothesis:  
 Sensitivity to IR within the HPV-positive cell lines is associated with greater G2 
arrest after IR, due to absence of functional p53 (p-p53). 
o This predicts that the IR sensitive cell lines UMSCC-47, UPCI-SCC-90 
and CU-OP-20 will differ from the IR resistant cell lines CU-OP-2 and 
CU-OP-3.  
 HPV negative OPSCC cell lines with absence of p53 and p-p53 will have a greater 
accumulation of cells in S-phase or G2 phase after IR. 
 
4.5.1. IR leads to cell cycle arrest in OPSCC cell lines  
 
The effect of ionising radiation induced DNA damage on progression through the cell 
cycle was investigated using flow cytometry (detailed description of set-up in Chapter 2). 
The mean distribution of cells between the phases of the cell cycle was calculated based 
on three experimental runs. The experiment was designed to compare the data obtained 
for each treatment dose and time point (8, 24 and 48h) to the untreated sample of “time 
zero”, to identify changes in cell cycle distribution after IR treatment. Therefore, no 
additional untreated samples were included after 8, 24 and 48h. The collection time of the 
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untreated sample is equal to the time of treatment of the reaming plates for the cell cycle 
analysis.  
The data for HPV-positive OPSCC cell lines are presented in Figure 4-9, for HPV-
negative OPSCC cell lines in Figure 4-10 and for HEKn cell line in Figure 4-11. One 
representative flow cytometry experiment for each cell line is shown in Figure 4-12 for 
HPV-positive OPSCC cell lines, in Figure 4-13 for HPV-negative OPSCC cell lines and 
in Figure 4-14 for the HEKn cell line.  
A similar distribution between the phases of the cell cycle was observed in the untreated 
samples across the panel of OPSCC cell lines with an average percentage in G1 around 
50-60% (Figure 4-9). Interestingly, HEKn showed a slightly higher proportion of cells in 
G1 than the other cell lines (both HPV-positive and HPV-negative cell lines), which 
suggests a lower proportion of actively cycling cells (Figure 4-11). Other cell lines, such 
as UMSCC-19, UMSCC-4, CU-OP-17and CU-OP-3 showed fewer cells in G1 phase 
compared to the untreated sample, indicating a higher proportion of proliferating cells 
within these cell lines.  (Figure 4-9 and Figure 4-10). However, a significant difference 
in G1 arrest was seen between the untreated control sample and 2Gy 8h for UMSCC-47 
(two-way ANOVA, p=0.0031), UMSCC-74a (two-way ANOVA, p=0.0077) and 
UMSCC-4 (two-way ANOVA, p<0.0001). UMSCC-74a was the only cell line, which 
showed a significant increase of cells in G1 compared to the untreated control sample 
after 2Gy and 24h (two-way ANOVA, p=0.0037). CU-OP-17 showed a significant 
decrease in G1 compared between the untreated control sample and 2Gy 24h (two-way 
ANOVA, p=0.0402). After 6Gy treatment UMSCC-47 (two-way ANOVA, p=0.0056), 
UPCI-SCC-90 (two-way ANOVA, p<0.0001), UMSCC-4 (two-way ANOVA, p=0.0307) 
and UMSCC-19 (two-way ANOVA, p=0.0312), showed a significant difference after 24h 
compared to the untreated control sample.  
Eight hours after treatment with IR, the proportion of cells in S-phase increased in all cell 
lines compared to the corresponding untreated sample with significant differences after 
2Gy for UMSCC-47 (two-way ANOVA, p=0.0002) and UMSCC-4 (two-way ANOVA, 
p<0.0001). Significant differences were observed after 6Gy for UMSCC-47 (two-way 
ANOVA, p=0.0004), UPCI-SCC-90 (two-way ANOVA, p=0.0123), CU-OP-2 (two-way 
ANOVA, p=0.0144) and UMSCC-4 (two-way ANOVA, p=0.0061), but subsequently 
decreased over 24-48 hours (Figure 4-9 to 4-10) with no significant differences after 2Gy 
and 6Gy treatment in the entire cell line panel. This would be consistent with an initial 
arrest, with a subsequent return to cell cycle following DNA repair, or with apoptosis of 
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arrested cells. The highest proportion of cells in S-phase were detected in HPV-negative 
OPSCC cell lines e.g. UMSCC-4, only had a relatively limited number of cells in G1 and 
G2 after 8 hours (2 and 6Gy) (Figure 4-10). This decrease of cells in G1 was significant 
for UMSCC-4 between the untreated sample (time zero) and for 2Gy (two-way ANOVA, 
p<0.0001) and 6Gy treatment (two-way ANOVA, p=0.0077).  
An increase of cells in G2 was observed in all HPV-positive OPSCC cell lines between 
the untreated and the 2Gy 24 hours, as well as untreated and 6Gy 24 hours. A significant 
increase in cells in G2 after 2Gy was apparent only for UMSCC-47 (two-way ANOVA, 
p=0.0135) and CU-OP-3 (two-way ANOVA, p=0.0075). UPCI-SCC-90, CU-OP-20 and 
CU-OP-2 did not show a significant difference in the proportion of cells in G2 between 
the 2Gy treatment and the untreated sample.  
All HPV-positive samples showed a significant increase in cells in G2 after 24 hours, 
when comparing 6Gy treated cells and the untreated sample. This was indicated for 
UMSCC-47 (two-way ANOVA, p<0.0001), CU-OP-20 (two-way ANOVA, p=0.0004) 
UPCI-SCC-90 (two-way ANOVA, p<0.0001), CU-OP-2 (two-way ANOVA p=0.0019) 
and CU-OP-3 (two-way ANOVA, p=0.0647) (Figure 4-9).  
Within the HPV-negative cell lines, only UMSCC-4 demonstrated a significant difference 
between the untreated and 2Gy 24 hours’ sample (two-way ANOVA, p= 0.0222). After 
6Gy treatment CU-OP-17 was the only HPV-negative cell line that showed a significant 
difference compared to the untreated sample after 24 hours (two-way ANOVA, 
p=0.0052) (Figure 4-10).  
The normal human keratinocytes (HEKn) showed no significant changes in the 
proportion of cells in G1, S and G2 between the untreated samples and the 2Gy and 6Gy 
samples (8, 24 and 48h) (Figure 4-11). A decrease of cells in G1 with a corresponding 
increase in S and G2 was observed after 6Gy treatment for all time points. The cell cycle 
distribution varied for the 2Gy treated samples, with a decrease of cells in G1 after 8 
hours, a minor increase after 24 hours and a decrease after 48 hours, with an opposite 
effect of G2.  
Overall, there was no significant difference in cell cycle distributions for any of the HPV-
negative cell lines including the normal human keratinocytes after 48 hours. In a 
comparison between the samples after 24 and 48 hours, UMSCC-74a was the only cell 
line where a clear visual decrease of G2 was observed, compared to the 24 hours. 
However, this decrease did not show a significant difference. UMSCC-6 did not show an 
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effect of IR on cell cycle distribution throughout the entire panel of treatment doses and 
time points.  
All HPV-positive OPSCC cell lines showed a decrease of G2 after 48 hours compared to 
the 24 hours’ samples. Only minor decreases were observed after 2Gy treatment, which 
was confirmed after statistical analysis with no identified significant differences between 
24 hours and 48 hours. A significant difference was measured after 6Gy treatment 
between 24 hours and 48 hours for UMSCC-47, UPCI-SCC-90, CU-OP-2. CU-OP-3 did 
not show a significant difference after 6Gy treatment between 24 hours and 48 hours. The 
only significant increase of cells in G1 was shown in UMSCC-47 and CU-OP-2. 
In summary, all HPV-positive cell lines showed a G2 cell cycle arrest after 24 hours (2Gy 
and 6Gy) and a decrease of cells in G2 after 48 hours. Three out of 5 HPV-negative cell 
lines showed a similar pattern to the HPV-positive cell lines. However, these differences 
were only statistically significant in 2 HPV-positive OPSCC and 1 HPV-negative OPSCC 
cell line after 2Gy 24h and statistically significant in all HPV-positive cell lines after 6Gy 
24h.  
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Figure 4-9: Cell cycle distribution in HPV-positive OPSCC cell lines in response to IR 
All cell lines showed a similar pattern of cell cycle arrest after IR. The untreated time point was collected 
at the beginning of the assay and defines time zero of the cell cycle phases. Cells were treated with 2Gy 
and 6Gy and collected after 3 different time points (8, 24 and 48 hours); they were then fixed with 70% 
Ethanol for a minimum of 1 hour. Cell pellets were stained with PI and the cell cycle distribution assessed 
using a BD Accuri Flow Cytometer. Cell cycle was analysed using FlowJo software utilising the Watson 
pragmatic algorithm to define the proportion of cells per cell cycle phase. All experiments were performed 
in triplicated; the error bars represent the standard deviation between the three experimental runs. Statistical 
significance was assessed using a two-way ANOVA with a Sidak post-test per cell line to compare the 
proportion of cells in G2 phase between untreated and 24-hour time points, between 24 hours and 48 hours. 
The stars representing the strength of significance (e.g: 0.00332 (*), 0.0021 (*), 0.0002 (***), <0.0001 
(****). Ns stands for not significant and N/A stands for not available. For CU-OP-20 one data set of 6Gy 
48 hours is missing and a two-way ANOVA could not be assessed.  
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Figure 4-10: Cell cycle distribution in HPV-negative OPSCC cell lines following IR  
Three out of 5 cell lines showed a similar pattern as the HPV-positive OPSCC cell lines after IR (CU-OP-
17, UMSCC-19 and UMSCC-4). Less G2 arrest was observed in UMSCC-74 and UMSCC-6. The untreated 
time point was collected at the beginning of the assay and defines time zero of the cell cycle phases 
Cells were treated with 2Gy and 6Gy and collected after 3 different time points (8, 24 and 48 hours); they 
were then fixed with 70% Ethanol for a minimum of 1 hour. Cell pellets were stained with PI and the cell 
cycle distribution assessed using a BD Accuri Flow Cytometer. Cell cycle was analysed using FlowJo 
software utilising the Watson pragmatic algorithm to define the proportion of cells per cell cycle phase. All 
experiments were performed in triplicate; the error bars represent the standard deviation between the three 
experimental runs. Statistical significance was assessed using a two-way ANOVA with a Sidak post-test 
per cell line to compare the proportion of cells in G2 phase between untreated and 24-hour time points, 
between 24 hours and 48 hours. The stars representing the strength of significance (e.g: 0.00332 (*), 0.0021 
(*), 0.0002 (***), <0.0001 (****). Ns stands for not significant.  
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Figure 4-11: Cell cycle distribution in HEKn cells following IR 
The untreated time point was collected at the beginning of the assay and defines time zero of the cell cycle 
phases.  
Cells were treated with 2Gy and 6Gy and collected after 3 different time points (8, 24 and 48 hours); they 
were then fixed with 70% Ethanol for a minimum of 1 hour. Cell pellets were stained with PI and the cell 
cycle distribution assessed using a BD Accuri Flow Cytometer. Cell cycle was analysed using FlowJo 
software utilising the Watson pragmatic algorithm to define the proportion of cells per cell cycle phase. All 
experiments were performed in triplicated; the error bars represent the standard deviation between the three 
experimental runs. Statistical significance was assessed using a two-way ANOVA with a Sidak post-test 
per cell line to compare the proportion of cells in G2 phase between untreated and 24-hour time points, 
between 24 hours and 48 hours. The stars representing the strength of significance (e.g: 0.00332 (*), 0.0021 
(*), 0.0002 (***), <0.0001 (****). Ns stands for not significant. 
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Figure 4-12: Cell cycle analysis for HPV-positive and HPV-negative OPSCC cell lines after 2Gy  
Overlay expression of one representative run of the cell cycle phases after 2Gy treatment and 8, 24 and 48-
hour time points. (A) HPV-positive cell lines after 2Gy treatment; (B) HPV-negative cell lines after 2Gy 
treatment.  
Cells were treated with 2Gy and 6Gy and collected after 3 time points (8, 24 and 48 hours) and fixed with 
70% ethanol for a minimum of 1 hour. Cell pellets were stained with PI and cell cycle distribution measured 
on a Flow Cytometer (BD Accuri). Cell cycle was analysed in FlowJo using the Watson pragmatic 
algorithm. 
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Figure 4-13: Cell cycle analysis for HPV-positive and HPV-negative OPSCC cell lines after 6Gy  
Overlay expression of one representative run of the cell cycle phases after 6Gy treatment and 8, 24 and 48-
hour time points. (A) HPV-positive cell lines after 6Gy treatment; (B) HPV-negative cell lines after 6Gy 
treatment. 
Cells were treated with 2Gy and 6Gy and collected after 3 time points (8, 24 and 48 hours) and fixed with 
70% ethanol for a minimum of 1 hour. Cell pellets were stained with PI and cell cycle distribution measured 
on a Flow Cytometer (BD Accuri). Cell cycle was analysed in FlowJo using the Watson pragmatic 
algorithm. 
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Figure 4-14: Cell cycle analysis for Hekn cell line after 2Gy and 6Gy 
Overlay expression of one representative run of the cell cycle phases of HEKn after (A) 2Gy and (B) 6Gy.  
Cells were treated with 2Gy and 6Gy and collected after 3 time points (8, 24 and 48 hours) and fixed with 
70% ethanol for a minimum of 1 hour. Cell pellets were stained with PI and cell cycle distribution measured 
on a Flow Cytometer (BD Accuri). Cell cycle was analysed in FlowJo using the Watson pragmatic 
algorithm. 
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4.6.  Summary of main findings   
With reference to the original hypothesis and the revised hypotheses after the protein 
expression experiments, the investigations in this chapter established that:  
 At 2 and 4Gy doses, HPV-positive OPSCC cell lines showed a greater variation 
in sensitivity to IR than HPV-negative OPSCC cell lines  
o UMSCC-47, UPCI-SCC-90 and CU-OP-20 were the most sensitive HPV-
positive cell lines. CU-OP-2 and CU-OP-3 were the most resistant HPV-
positive cell lines  
 HPV-status correlated only partially with radiation sensitivity  
o 3 HPV-positive cell lines were sensitive to IR (2Gy) 
o Only one HPV-negative cell line was sensitive to IR (2Gy) 
o HEKn were also sensitive to IR (2Gy)  
 HPV-positive cell lines did not show a greater p53, p21 or p-p53 accumulation 
after IR relative to HPV-negative cell lines. 
 2/5 HPV-negative cell lines and HEKn showed accumulation of p-p53 after IR  
 p53 independent transcription of p21 was detected in 3 HPV-negative OPSCC cell 
lines  
 p21 demonstrated a greater variation in expression with up- or down-regulation 
after IR dependent on the cell line tested. 
 Degree of G1, S and G2 cell cycle arrest post irradiation did not correlate with 
HPV status – example listed for G2 arrest: 
o 2/5 HPV-positive cell lines showed a significant G2 arrest after 2Gy 24 
hours 
o 5/5 HPV-positive cell lines showed a significant G2 arrest after 6Gy 24 
hours 
o 1/5 HPV-negative cell lines showed a significant G2 arrest after 2Gy 24 
hours 
o 2/5 HPV-negative cell lines showed a significant G2 arrest after 6Gy 24 
hours  
 After 48h a decrease of cells in G2 phase was detected in 3/5 HPV-positive cell 
lines after 6Gy and no significant decrease of cells in G2 was detected within the 
HPV-negative cell lines after 48h 
The main findings of the clonogenic, western blot and cell cycle analyses in the OPSCC 
cell line panel are summarized in Table 4-3.  
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Table 4-3: Summary of OPSCC responses to IR 
  Cell lines 
Clonogenic 
assay A
 
Protein Expression B
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UMSCC-47 + + ++ ++ ++ - - - ++ + + + + 
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- 
UPCI-SCC-
90 + + + + + - - - ++ ++ + ns + 
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- 
CU-OP-20 + + + + + - - - ++ ++ ++ ns + 
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N/A 
CU-OP-2 - + ++ ++ ++ - - - ++ + + ns + 
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CU-OP-3 - + + + + - - - + ++ ++ + + 
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UMSCC-19 + + - - - - - - + + + ns ns ns ns 
UMSCC-6 - + - - - - - - ++ + + ns ns ns ns 
UMSCC-74a - + ++ ++ ++ + + + + + + ns ns ns ns 
UMSCC-4 - + - - - - - - + + ++ + + ns ns 
CU-OP-17 - + ++ ++ ++ + + + + + + ns + ns ns 
 HEKn + + + + + + + + ++ ++ ++ ns ns ns ns 
A Clonogenic survival assay result: Green indicates the sensitivity of the cell lines (SF<40%) and red 
indicates resistant cell lines (SF>40%) after 2Gy and 6Gy 
B Western blotting result: Green indicates indicates that the cell lines showed p53, p-p53 or p21 protein (+, 
++ or – represent the strength of the band) 
C Focus in the summary table was put on signifcant difference in G2 (based on previous findings in 
litearture). Green represents a signifcant accumulation of more cells in G2 phase after 2Gy and 6Gy 
compared to the untreated sample after 24h. Red represent a signifcant decrease of cell in G2, by comparing 
24h and 48h after 2Gy and 6Gy treatment (+ indicates an increase;  – indicates a decrease; ns stands for not 
signifcant;   N/A stands for not available)  
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4.7. Discussion 
 
4.7.1. Clonogenic assays 
 
The 10 OPSCC cell lines used in this study showed a wide range in sensitivity to single 
doses (0.5-6Gy) of IR. Three HPV-positive cell lines (UMSCC-47, UPCI-SCC-90 and 
CU-OP-20) showed a high sensitivity at the IR dose to 2Gy IR (this dose was used to 
classify sensitivity) and 1Gy, whereas CU-OP-2 and CU-OP-3 showed greater resistance 
at the same dose. However, CU-OP-2 was at the borderline of being a sensitive or resistant 
cell line. Minimal effects on survival were observed on all cell lines with doses of 0.5Gy. 
Therefore, 2Gy IR treatment was chosen as the main dose to analyse sensitivity of cell 
lines to IR, as at lower doses cells did not show a significant response and at higher doses 
most cells did not proliferate (resulting in a very limited number of colonies).  A similar 
pattern of response was observed in all HPV-negative cell lines, except for UMSCC-19 
which was the only HPV-negative cell line to have a SF below the set threshold of 40%. 
One interesting finding was that the SF of HEKn after 2Gy was below 40%. It was 
expected for the normal human keratinocytes cell line to show less sensitivity to 
intermediate IR doses (2Gy), as they are presumed (as a normal cell line) to be competent 
in DSB repair. In a previous study, human keratinocytes showed a SF of 49+/-8%, at 2Gy 
(Panteleeva et al., 2003). The difference between the two studies could be due to the 
different culture conditions used. The experiment in the study by Panteleeva et al., (2003) 
was performed in 25 cm2 flasks, incubated for several days and irradiated before reaching 
70% confluence and the culture medium did not cover the cells when using the X-ray 
beam (only the plastic walls were covered) (Panteleeva et al., 2003). Different culture 
conditions and radiation sources might have resulted in a higher survival fraction in the 
Panteleeva study. The SF at 2Gy for the HEKn cells was above the three most sensitive 
HPV-positive cell lines and below the most resistant HPV-positive cell lines. Therefore, 
the IR response of HEKn was intermediate compared to the HPV-positive cell lines, but 
were more sensitive at the 2Gy dose than the majority of HPV-negative cell lines.  
The IR dose range for this study was chosen on the basis of the available literature (Arenz 
et al., 2014, Kimple et al., 2013, Rieckmann et al., 2013). To test a potential intermediate 
effect of IR on the clonogenic assays, lower doses of 0.5Gy and 1Gy were included as 
well. The effect of IR on HEKn, used as a non-transformed epithelial cell control, was 
novel and a strength of the current study. As a normal cell line, HEKn cell line expresses 
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functioning p53 (wild-type) and other DNA repair related mechanisms (including cell 
cycle control) are presumably operating. Furthermore, it provided a comparison between 
normal keratinocytes and cancer cell lines (transformed/mutated keratinocytes), a feature 
that was lacking in previous studies of OPSCC (Arenz et al., 2014, Kimple et al., 2013, 
Rieckmann et al., 2013). The sensitive response to IR seen in the HEKn cells, could be 
an indication of a functional response to DNA damage (Willers et al., 2002), which could 
explain the minor increase in G2 cell cycle phase following a functioning DNA repair 
and a general decrease of G2 after 48 hours (return to normal cell distribution).  
According to the data obtained in this study, there was no clear difference detected 
between HPV-positive and HPV-negative OPSCC cell lines’ response to IR between a 
dose range of 4-6Gy. After 6Gy treatment, there was a limited capability for cell lines to 
form colonies, because the majority of the cells had died. This indicated that higher 
treatment doses are not ideal to investigate response to IR and an intermediate dose such 
as 2Gy is more appropriate. The cell lines classified as resistant to IR included both HPV-
positive and HPV-negative lines. An overlap in sensitivity to radiation among HPV-
positive and HPV-negative head and neck cancer cell lines (HNSCC) has been reported 
previously (Rieckmann et al., 2013). However, other studies have documented clear 
differences in sensitivity to IR between HPV-positive and –negative HNSCC cell lines 
(Arenz et al., 2014, Kimple et al., 2013). These differences might reflect the fact that 
different cell lines were used in the studies by Arenz and Kimple et al., (Arenz et al., 
2014, Kimple et al., 2013).  
A similar level of sensitivity to 2Gy IR treatment was measured for UMSCC-47, UPCI-
SCC-90 and UMSCC-6 in three other studies (Arenz et al., 2014, Kimple et al., 2013, 
Rieckmann et al., 2013). UMSCC-47 and UPCI-SCC-90, were reported as being the most 
sensitive cell lines and UMSCC-6, as reported in this study, was a less sensitive cell line. 
For clarification, the term resistant was not used in these three studies, the terms of “most 
and least sensitive” cell lines were used (Arenz et al., 2014, Kimple et al., 2013, 
Rieckmann et al., 2013).   
Some studies have investigated a combination of radiotherapy with other DNA damaging 
agents; for example, cisplatin with IR. Busch et al., (2016) investigated the effects of 
cisplatin and radiation and reported that the combined treatments resulted in only a minor 
enhancement in sensitivity compared to the expected large enhancement. Although they 
suggest that results may be dependent on the experimental set-up, which can result in 
variations of SF (Busch et al., 2016). Another study tested whether a CHK1 inhibitor 
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(roscovitine) in combination with radiation could enhance the sensitivity of HNSCC cell 
lines to IR in clonogenic assays. HPV-negative HNSCC cell lines showed enhanced 
sensitivity whereas the combined treatment had no effect on HPV-positive HNSCC cell 
lines (Ziemann et al., 2017). For breast cancer cell lines, an enhanced effect of combining 
olaparib (BRCA2 mutation effector) and radiotherapy has been seen (Jang et al., 2015). 
This indicated that some combination of DNA damaging agents or cell cycle inhibitors 
can enhance the effect of radiation in some transformed cell lines, but this has not been 
consistently shown for specific groups of HPV-positive or HPV-negative HNSCC cell 
lines.  
In general, the findings in this study are consistent with previous radio-sensitivity assays 
using the same cell lines, but differ slightly in the surviving fractions calculated.  
However, unlike the majority of previous studies, no clear differences in the response to 
IR were seen between HPV-positive and HPV-negative cell lines. This could be the result 
of differences in methodology (e.g. length of experiment, seeding density) or the 
inclusion of feeder cells in the current studies. These feeder cells gave OPSCC cells a 
better chance of survival. Another variable that needs to be considered are difference of 
doubling time of each cell line, indicated by different seeding densities defined, that could 
influence survival of cells after IR. However, the influence of doubling time was intended 
to be reduced a defined seeding density per cell lines before the start of the radio-
sensitivity assay. In this study the length of the experiments was set for the panel of cell 
lines between 10-15 days, whereas clonogenic assays were set-up in one study for 14-18 
days using a different radiation technique; cells were irradiated with 6 MeV photons using 
a linear accelerator (Elekta Supernova, Elekta, Stockholm, Sweden) (Arenz et al., 2014).   
Two of the HPV-negative HNSCC cell lines used in the current study were derived from 
patients receiving chemotherapy, UMSCC-4 (derived from tumour receiving post-
treatment of 2 chemotherapies) and UMSCC-74a (originated from a recurrent tumour – 
after receiving chemotherapy). In a study on adaption of cancer cells to chemotherapy, a 
slight increase of resistance in biopsies post-chemotherapy was observed (Di 
Nicolantonio et al., 2005). This might be seen in UMSCC-4 and UMSCC-74 in the current 
study. However, this would need to get confirmed by comparing it to an untreated tumour 
sample of these two cell lines, if available.  
Compared to cervical cancer cell lines, the OPSCC cell lines used in the current study 
are, in general, more sensitive to IR at 2Gy. In a previous study (Banath et al., 2004), the 
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HPV negative cervical line C33A was the only cell line with a similar sensitivity to the 
HPV positive OPSCC cell lines (UPCI-SCC-90 and CU-OP-20) used in the current study. 
Strengths and weaknesses of the clonogenic assays  
One of the strengths of the current study, i.e. a robust clonogenic assay, was achieved 
through careful definition of culture conditions and seeding density for each cell line. The 
most appropriate seeding density for 7 cancer cell lines and one HEKn cell line was 
defined previously (Pirotte, 2017), whereas the seeding densities for UMSCC-6, CU-OP-
17 and CU-OP-20 were defined in the current study. Furthermore, the optimal duration 
of experiment to measure IR response was defined for each individual cell line in the 
current study. Cell lines were treated with IR, 24 hours after seeding to minimize the 
effect of IR on cell adhesion. Image analysis software was used to count the colonies after 
crystal violet staining, to minimise potential errors generated by manual counting. A 
potential weakness is the error rate of the colony counter, as counts could vary, if pictures 
were taken from different angles on the same plate. This weakness was however 
minimized, by performing three experimental runs and three replicates per treatment 
dose. Photographs were taken for each plate from three different angles and the mean 
value calculated. 
Another strength of this study was the panel of cell lines used, that included 2 novel cell 
lines, and focussed specifically on OPSCC cell lines, with a total of 10 OPSCC cell lines 
and one normal cell line used. In contrast, other studies used a wide range of HNSCC cell 
lines derived from different anatomical sites with a cell line panel size of 8 cell lines in 
two studies (Arenz et al., 2014, Kimple et al., 2013) and 10 cell lines in another study 
(Rieckmann et al., 2013). A normal cell line control was not included in any of the three 
published studies (Arenz et al., 2014, Kimple et al., 2013, Rieckmann et al., 2013). 
4.7.2. Assessment of protein levels of p53, phospho-p53 and p21  
 
There was no apparent correlation between levels of p53, p-p53 or p21 expression and 
HPV-status. All HPV-positive cell lines expressed p53 and p21. However, only 2 out of 
5 HPV-negative cell lines showed detectable levels of p53. Interestingly, p21 was 
detected in all HPV-negative cell lines. Expression of phospho-p53 was only detected in 
three cell lines CU-OP-17, UMSCC-74a and HEKn, which can contribute to p53 
stabilization in those cell lines by preventing Mdm2-mediated degradation (Ashcroft et 
al., 1999, Shieh et al., 1997). One of the main sites of phosphorylation of p53 after DNA 
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damage is Ser15, which was the main reason to include it in the current study (Ashcroft 
et al., 1999, Shieh et al., 1997).  
Higher basal levels of p53 were expected and increased sensitivity to radiation was 
predicted due to the p53 mutation status in some of the HPV-negative cell lines (UMSCC-
4 with a point mutation and UMSCC-19 with a 10bp deletion). The absence of HPV in 
the remaining cell lines (CU-OP-17, UMSCC-6 and UMSCC-74a) combined with the 
expression of WT p53 might also lead to similar results. It might also be predicted that 
there will be a higher expression of p53 after irradiation based on the properties of these 
cell lines, as no p53 degradation by HPV E6 is possible in these HPV-negative cell lines.  
For the HPV-positive cell lines, p53 might be predicted to be undetectable because of the 
degradation of p53 mediated by HPV E6, and these cell lines would have been expected 
to be resistant to radiation due to loss of p53 mediated cell cycle arrest. However, p53 
was detected in all the HPV-positive lines, which is consistent with incomplete 
degradation of p53 and this might have caused increased sensitivity in the majority of the 
HPV-positive cell lines (Bradford et al., 2003, Ferris et al., 2005, Mandic et al., 2005, 
Somers et al., 1992). Interestingly, levels of p53 varied between the HPV-positive cell 
lines, but levels of p53 detected in each line did show any relationship with radiation dose. 
Presence of detectable p53 in the untreated samples for all HPV-positive lines would be 
consistent with incomplete E6-mediated degradation of p53, but may also suggest that 
the cells were inherently stressed as a result of the culture conditions (e.g. by low oxygen 
levels). Similarly, p53 levels did not always correlate with IR sensitivity as assessed in 
the clonogenic assays. For example, UMSCC-47 and UPCI-SCC-90 were classified as 
sensitive cell lines, but UMSCC-47 showed high levels of p53 protein while UPCI-SCC-
90 showed lower levels.  
Phosphorylation of p53 at Ser15 helps modulate the stability of p53 (Ashcroft et al., 
1999). Levels of p-p53 did not correlate with radio-sensitivity as assessed in the 
clonogenic assays. Neither was there a correlation between p53 levels and p-p53, which 
might have been expected, as phosphorylation at ser15 reduces Mdm-mediated 
degradation of p53. This might be due to a lack of transcription of Mdm, associated with 
non-functional p53. 
In the current study, UMSCC-47 showed strong expression of p53 but no p-p53 in all 
conditions. This cell line was also used in two previous studies that investigated p53 and 
p-p53 expression after IR treatment (Arenz et al., 2014, Kimple et al., 2013). These 
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studies found different expression levels of p53 after IR compared to the current study. 
One study reported no accumulation of p53 after IR (4Gy) although a weak p53 band was 
detected after 24 hours, and no phosphorylation of p53 was detected (Kimple et al., 2013). 
Another study detected weak bands of p53 and p-p53 1 and 4 hours following 6Gy IR 
(Arenz et al., 2014). This study (Arenz et al., 2014) is in agreement with the p53 results 
in this chapter. However, in the current study incubation time was longer than 4 hours, 
cells were collected after 24 hours, which might have an effect on stronger accumulation 
of p53. However, different results for phosphorylation of p53 were obtained when 
comparing the study of Arenz et al., (2014) with the current study (i.e. they were able to 
detect phosphorylation on Ser15). The reasons for this difference are unclear, as the p-
p53 (Ser15) antibody was the same between studies. This did not appear to be associated 
with a general failure of the antibody/conditions as the same antibody detected p-p53 in 
UMSCC-74a, CU-OP-17 and HEKn (normal cell line control), with stronger bands 
detected after 2Gy to 10Gy treatment. However, for the majority of the cell lines p-p53 
might be degraded after 24h, which might cause different results compared to previous 
studies. Strong bands of p53, p21 and weak bands of p-p53 could indicate stable and 
functioning p53 in UMSCC-74a, CU-OP-17 and HEKn (Ashcroft et al., 1999). 
The identities of the cell lines used in the western blotting were confirmed by short 
tandem repeat (STR) typing, as it was in the studies of Kimple and Arenz (Arenz et al., 
2014, Kimple et al., 2013). Findings for UMSCC-6 (Arenz et al., 2014) and UPCI-SCC-
90 (Kimple et al., 2013) were similar in this study for p53 and p-p53. However, the greater 
contradictory findings for UMSCC-47 might be a result of differences in methodology. 
For example, culture conditions, absence of positive controls in the previous studies, 
differences in lysis conditions (inhibitors used) and differences in exposure of films. 
Furthermore, cells could have been stressed by Trypsin-EDTA (TE) before cell lysis, 
which might explain the stronger p53 bands in the untreated UMSCC-47 sample in the 
current study. To compensate for the different findings, lysate samples of cell lines used 
in both studies would need to be tested in a new separate experimental run.  
p21 is generally regarded as a p53 regulated gene, the normal function of which is to 
cause cell cycle arrest in response to DNA damage. The role of p21 is directly connected 
to p53 transcription. P21 (cyclin-dependent kinase inhibitor p21WAF/CIP1) is a cell-
cycle checkpoint effector and inducer of senescence and is regulated by p53 (Weinberg, 
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2007). In normal cells, genotoxic stress activates the ATM-p53 pathway that upregulates 
the expression of p21, leading to cell cycle arrest (Galanos et al., 2016). 
p21 was detected in all cell lines in both untreated and treated samples even if there were 
no visible p53/p-p53 bands detected. In three HPV-negative OPSCC cell lines (UMSCC-
4, UMSCC-6 and UMSCC-19) where p53 was absent, p21 protein expression was 
detected, which might indicate p53-independent transcription. Independent transcription 
of p21 and no direct transcription through p53 was suggested in a recent study on a wide 
range of human tumours (Galanos et al., 2016). The strong expression of p21 in the 
majority of the HPV-positive OPSCC cell lines could be connected to better prognosis 
and IR sensitivity in UMSCC-47, UPCI-SCC-90 and CU-OP-20. This was observed in a 
study on tonsillar squamous cell carcinoma to investigate the prognostic value of key cell 
cycle proteins in the pRb and p53 pathway. Overexpression of p21 was determined as a 
favourable prognostic factor for tonsillar squamous cell carcinoma (Hafkamp et al., 
2009).   
Ionising radiation can be responsible for the degradation or decrease of p21 in the 
majority of HPV-negative cell lines, as suggested through studies on HEK293 cells 
(Stuart and Wang, 2009). This decrease in p21 expression might be caused by IR and 
could be an explanation for a decrease in band intensity of p21 in some HPV-negative 
OPSCC cell lines, for example UMSCC-19 and UMSCC-6. The mechanism behind the 
decrease of levels of p21 after IR in some cell lines in this panel is unclear at the moment.  
A study by Galanos et al., (2016) of a wide set of human tumours (HSNCC, lung cancer, 
urothelial carcinomas and colon precancerous lesions) suggested that p53 independent 
expression of p21 can indicate more aggressive tumour cells, increased genomic 
instability and chemo-resistance. (Galanos et al., 2016). Sustained accumulation of p21, 
which inhibits CRL4-CDT2 ubiquitin ligase (a substrate recognition factor that prevents 
degradation of cell cycle regulated proteins) leads to replication stress and genomic 
instability and more aggressive tumour cells (Galanos et al., 2016, Abbas and Dutta, 2011, 
Abbas et al., 2008).  This might be the case for these three HPV-negative cell lines, as 
they are less sensitive to IR than most of the HPV-positive OPSCC cell lines. The two 
most resistant HPV-positive OPSCC cell lines (CU-OP-2 and CU-OP-3) show both p53 
and p21 bands. CU-OP-3 (the most resistant cell line) showed weak accumulation of p53 
and stronger p21 expression, which might explain its radio-resistance and might indicate 
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that additional mechanisms besides p21 independent transcription lead to more radio-
resistance tumours.   
In a study in T-cell lymphoma parental lines, expression of p53 and p21 was directly 
connected to the wild-type or mutation (mut) allele of p53. Cells expressing p21 after IR 
showed bands of p53 (wild-type). On the other hand cell lines with mutations in p53 had 
weak or no expression of p21 (el-Deiry et al., 1994). Comparing this study of different 
cell types with OPSCC cell lines in the current study is not directly possible, but provides 
a framework for possible interpretations. In the current study, no connection between p53 
and p21 expression to its wild-type or mut-type of p53 can be directly drawn. For 
example, UMSCC-6 (wt-p53) and UMSCC-4 (mut) did not show bands of p53, but both 
express p21. However, the majority of the HPV-positive OPSCC cell lines (wild-type 
p53) showed p53 and p21 bands together. A greater variation in strength of bands for p53 
and p21 is observed within the HPV-negative OPSCC lines, which express either wild-
type and mutated alleles of p53. Furthermore, these cell lines showed levels of p21 even 
if expressing a p53 mutation.  
In summary, base-line p21 and p53 levels did not appear to be directly correlated with 
cell lines being more sensitive or resistant to IR. Hence the data did not support the 
original hypothesis that increased radiation sensitivity would be associated with 
accumulation of p53 in HPV-positive OPSCC cell lines. Other molecular factors in the 
cell cycle and DNA repair process, might play a more significant role in terms of 
sensitivity to IR and DNA repair response, which was not investigated further on protein 
level through Western blot assays. DNA damage and DNA repair after IR on protein 
levels should be determined in a future study.  
Strengths and weaknesses of the Western blotting experiments 
One of the strengths of this assay was the range of conditions assessed. At relatively low 
IR doses of 0.5Gy and 1Gy, minimal effects on proliferation were seen, while at higher 
doses between 4Gy and 6Gy limited colony formation was observed. The greatest 
variation in response to IR was observed at 2Gy, therefore this dose was used in the 
protein-based assays. The time point of 24 h post IR treatment was chosen to assess the 
short-term effect of IR, however a weakness of this assay is that these data cannot be 
compared directly to the clonogenic assays which reflect a response over 10-15 days.  
The strengths of this assay include use of an appropriate control, i.e. a normal human 
keratinocyte cell line with “normal” patterns of expression of p53 and p21 (Munro et al., 
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1999). Although the presence of p53, p-p53 and p21 in the untreated HEKn may suggest 
that these cells were stressed by the culture conditions. A potential weakness might be 
the absence of a positive control for induction of apoptosis and DNA damage specific to 
each cell line. The positive control of 10Gy irradiated HEKn (normal human keratinocytes) 
cell line for p53, p-p53 and p21 expression, partially compensated for this weakness. 
Another potential weakness in this study is the leak of measurement of the strength of 
DNA damage induced before the start of this assay. For example, yH2AX could have 
been used as such a marker. This would have helped to choose additional markers, beside 
p53, p-p53 and p21, to identify a responsible factor for the greater radio-sensitivity of 
HPV-positive OPSCC cell lines.  
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4.7.3. Analysis of cell cycle distribution before and after IR  
 
The original hypothesis at the start of the study, was that following exposure to IR, a 
greater G2 arrest would be seen in HPV-positive OPSCC cell lines compared to HPV-
negative OPSCC cell lines. This hypothesis was subsequently revised to take account of 
the wide range of sensitivity to IR seen in the HPV-positive cell lines, and was reframed 
as: greater G2 arrest would be seen in the OPSCC cell lines with the greatest sensitivity 
to IR. G1 and S-phase arrests were observed as well to identify an initial response to IR. 
This was done to identify a clear difference in terms of IR response on cell cycle 
distribution between G1, S or G2 arrest. A G2 arrest was previously reported in eukaryotic 
cells in response to IR (Bernhard et al., 1995, Branzei and Foiani, 2008). 
Cell cycle distribution was assessed at three different time points (8, 24 and 48 hours). 
Out of these three time points, 24 hour appeared the best possible indicator for IR induced 
cell cycle arrest.  The reason for this, was that the highest G2 arrest was observed after 
24 hours, whereas no obvious G2 arrest was observed after 8h or 48h. G1 arrest after IR 
can be regulated by p53, which causes an induction of p21, which leads to a delay in S-
phase and a further delay in G2. G2 arrest was previously demonstrated in eukaryotic 
cells after IR (Bernhard et al., 1995, Branzei and Foiani, 2008). The effect of IR (2Gy and 
6Gy) on cell cycle distribution in terms of G1 and G2 arrest were most apparent after 24 
hours. The panel of HPV-positive OPSCC cell lines showed an increase of cells in G2 
after 24 hours in 2Gy treated samples and a more substantial arrest in 6Gy treated 
samples, with a decrease in G1 phase after 24 hours. A decreased proportion of the cells 
were in G2 after 48 hours. The decrease of G1 was not significant for the HPV-positive 
OPSC cell lines after 2Gy and 24h, but was significant for 2/5 cell lines after 6Gy 24h. 
However, only 2/5 HPV-negative OPSCC cell lines significant difference to the untreated 
sample after 2Gy 24h. Out of these two cell lines UMSCC-74a showed a significant 
increase after 2/6Gy 24h, which could indicate a greater response to IR induced DNA 
damage. This induced DNA damage would be needed to get confirmed via an 
immunofluorescence assay for ɣH2AX at a later stage. A prolonged G2 phase after 24 
hours on the other side could indicate a delay in entering mitosis, to give the cells enough 
time to repair any DNA damage, which was suggest in a previous study by Rieckmann et 
al., (2013). This decrease observed after 48-hours provided a possible indicator of 
induction of DNA repair mechanisms and resumption of normal cell cycling. The shorter 
time point of 8 hours did not show any significant increase in G2 after IR, even at higher 
treatment doses of 2Gy or 6Gy. Induction of DNA repair between 24h to 48h was not 
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measured in the current study. The correlation of decrease of cells within G2 and DNA 
repair needs to get confirmed in a future study.    
Interestingly, UMSCC-4 showed a significant increase in S-phase after 8 hours, followed 
by an increase of cells in G2 after 24 hours. This is difficult to interpret but could be 
explained by a dysfunctional G1/S checkpoint, coupled with retention of cells in S-phase 
(although there is no published precedent for this). High p21 expression seen in the 
protein assay (Western blotting) could be responsible for the S-phase delay through the 
inhibition of cyclins(Bernhard et al., 1995, Branzei and Foiani, 2008).. By 24 hours 
however, cells appeared to accumulate in G2, which suggests the presence of a 
functioning G2/M checkpoint.  
Compared to the untreated sample (time zero), cells increase in S-phase after 8h (2 and 
6Gy) and decreased after 24 and 48h in the majority of cell lines. This initial increase 
after 8h, especially seen and described for UMSCC-4, could be a response to IR with a 
possible DNA damage response (not confirmed during this study), which keeps the cells 
in S-phase and hold replication. Cells could either retreat into G1 phase, continue into G2 
until the G2/M cell cycle checkpoint where cells finally arrest in response to IR. Another 
study associated a prolonged S-phase in response to stress or DNA damage by cells being 
trapped in a “S-phase stasis” due to the loss of CDKs and associated proteins, making 
cells unable to move forward or retreat into G1 (Borel et al., 2002). The observed decrease 
after 8h following 24h and 48h samples, suggest cells retreating into G1 (checkpoint), 
prolong replication or induced death due to incomplete replication.  
Greater G2 arrest in HPV-positive cell lines is consistent with previous findings for 
UMSCC-47 and UPCI-SCC90, where an increase of G2 after 4Gy treatment was reported 
(Kimple et al., 2013). However, in the current study no obvious difference between HPV-
positive and HPV-negative cell lines was detected; rather, 1/5 HPV-negative OPSCC cell 
lines showed a significant increase in G2 arrest after 2Gy and 24h, which was similar to 
the HPV-positive cell lines with 2/5 cell lines with a significant increase after 2Gy 24h. 
At a lower dose of 2Gy this was inconsistent with their findings in G2 arrest between 
HPV-positive and HPV-negative cell lines. However, this could be due to the lower 
treatment dose of 2Gy. At a dose of 6Gy, the HPV-positive cell lines showed a clear 
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difference in G2 arrest, as observed after 4Gy treatment in the Kimple study (Kimple et 
al., 2013).  
Normal human keratinocytes (HEKn) showed a consistent pattern in terms of cell cycle 
arrest throughout the experiment after 2Gy (8 – 48 hours) and 6Gy (8 – 48 hours) with no 
significant difference compared to the untreated sample. This leads to the conclusion that 
the cell cycle processes (e.g. cell cycle checkpoints and DNA repair mechanisms) are 
operating and prevents cells from further continuing in the cycle if damaged. Functioning 
cell cycle processes, involving cell cycle checkpoint and DNA repair mechanisms would 
need to get confirmed in future studies. 
The original hypothesis predicted that HPV-positive cell lines would show an increased 
G2 cell cycle arrest following IR, compared to HPV-negative OPSCC cell lines. All HPV-
positive OPSCC cell lines showed an increase of cells in G2 after 24 hours after 2Gy IR. 
This increase was statistically significant in only 2/5 cell lines (UMSCC-47 and CU-OP-
3) after 2Gy 24 hours. However, all HPV-positive OPSCC cell lines showed a significant 
G2 arrest after 6Gy 24 hours. A greater G2 arrest might indicate a functioning G2/M 
checkpoint, and this delay in DNA repair function, could be connected to the greater 
sensitivity of cells towards IR seen in UMCC-47 and CU-OP-20 observed in the 
clonogenic assays. However, a similar G2 arrest after 2Gy 24 hours was observed in CU-
OP-3, which was defined as a resistant cell line. This suggests that sensitive and resistant 
cell line cannot be distinguished by the degree of G2 arrest.  
Additionally, differences in doubling time have to be considered as a possibility in 
influencing the outcome in cell cycle arrest of this study. This differences in doubling 
time are indicated by the different seeding densities at the experimental set-up, Therefore, 
cells could have been at a different stage of the cell cycle.  
In summary, 2/5 HPV-positive OPSCC cell lines showed a significant G2 arrest after 2Gy 
and 24 hours, whereas HPV-negative cell lines only showed a G2 arrest in 1/5 cell lines, 
compared to the untreated samples at time zero. However, a clearer difference of 
significant G2 arrest between HPV-positive and HPV-negative OPSCC cell lines was 
observed after 6Gy 24 hours. A similar pattern was observed in a cervical cancer study 
with  cells arresting in G2 for the majority of the cell lines tested after 2Gy/5Gy treatment 
after 24 hours (Banath et al., 2004). In the current study, the difference between the mean 
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values at 2Gy 24 hours of all HPV-positive versus HPV-negative OPSCC cell lines was 
not significant (two-way ANOVA, p>0.05).  
 
Strength and weaknesses of the cell cycle analysis  
The strengths of this experiment include the use of a panel of 11 cell lines, compared to 
previous studies with fewer cell lines and no normal cell lines; all experiments were 
performed in triplicate, and the mean value and SD were calculated. The same number of 
cells for each cell line were analysed to minimise variation. The main weakness is the 
lack of untreated control samples for each time point, which in retrospect would have 
provided a useful comparison. Untreated control samples for each time point, would have 
provided the information of changes in cell cycle distribution in an untreated sample. 
Effects of confluence of cells in the individual untreated samples per time point could 
have been directly correlated to the treated counterpart of each time point. However, 
inclusion of time points at 8, 24 and 48 hours for each treatment dose, provides a useful 
comparison for increase or decrease of cells in G1, S and G2 after IR. 
Overall, a significant G2 arrest was observed in 2/5 HPV-positive OPSCC cell lines after 
2Gy and 5/5 HPV-positive OPSCC cell lines after 6Gy. Less G2 arrest was seen in the 
HPV-negative OPSCC cell lines with 1/5 HPV-negative OPSCC cell lines after 2Gy and 
2/5 HPV-negative OPSCC cell lines after 6Gy 24 hours. The decrease in G2 after 48 
hours in some HPV-positive cell lines (UMSCC-47, UPCI-SCC-90 and CU-OP-2) is 
suggested to be associated with DNA repair. However, a weakness of this study is that 
the involvement of DNA repair factors was not specifically analysed during the cell cycle 
analysis. Therefore, functioning DNA repair after 48 hours is considered as a theory 
which needs to be confirmed in future studies. This effect is observed mainly in UMSCC-
47, UPCI-SCC-90, CU-OP-20 and CU-OP-2. The study could have been improved by 
testing additional cell lines to strengthen the conclusions regarding the differences 
between HPV-positive and HPV-negative OPSCC cell lines. 
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4.8. Conclusion 
 
There are several conclusions that can be drawn from the experiments performed. One of 
the main conclusions is that there is a greater variation in sensitivity to IR among the 
HPV-positive cell lines than among HPV-negative lines. However, a consistent difference 
between HPV-positive and HPV-negative OPSCC was not observed, as the resistant cell 
lines of the HPV-positive group overlap with the HPV-negative OPSCC cell lines. The 
data obtained were partly consistent with the original hypothesis, as more HPV-positive 
OPSCC cell lines are more sensitive to IR compared to HPV-negative OPSCC cell lines. 
A greater number of in-vitro models in both groups (HPV-positive and HPV-negative), 
might provide a clearer picture. This does not mean that HPV does not play a role, but it 
is not the dominant factor determining survival in these in-vitro models. A novel finding 
in this study was the observed variation in sensitivity to IR within the HPV-positive cell 
lines. This has never been previously reported, and suggests that in future, larger panels 
of cell lines need to studied to make more robust conclusions about the link between HPV 
and sensitivity/resistance to therapy. The heterogeneity of cell lines might reflect the 
clinical situation where 80% of the HPV-positive patients respond better to treatment after 
3 years. Thus even within the HPV-positive patients a variation in treatment response is 
observed (Evans et al., 2013). At the time of this study it was not known whether the cell 
lines were derived from patients in the favourable response group (80%), or the 
unfavourable (20%) response group. 
There were also no clear differences between HPV-positive and negative OPSCC cell 
lines after IR, in terms of cell cycle or levels of p53, p21 and p-p53. Furthermore, HPV-
positive OPSCC cell lines showed p53 expression, hence p53 is not completely degraded 
by HPV E6. The observed diverse response between the two groups of HPV-positive 
versus HPV-negative cell lines (and within the groups themselves) appears to be a 
reflection of biological heterogeneity of OPSCC cell lines. This is similar to the diversity 
observed in terms of patient survival. This suggests that conclusions drawn from studies 
with a limited number of cell line models should be regarded with caution. Therefore, it 
is important to increase the number of cell lines models in further studies or to develop 
methods to research primary patient material directly and follow-up these observations 
by tracking the patient response to therapy.    
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Chapter 5 : Investigation of gene expression in OPSCC cell lines using 
mRNA sequencing  
 
5.1. Introduction  
 
mRNA sequencing or transcriptome sequencing (RNA-sequencing) is a high-throughput 
method that provides a quantitative and sensitive insight into the whole transcriptome of 
cells at a specific time point or treatment dose (Kukurba and Montgomery, 2015, 
Mortazavi et al., 2008). Furthermore, it has evolved into a technique for tumour 
characterization, and plays a key role in enhancing our fundamental understanding of the 
biology of certain cancers and their connection with virus integration (HPV integration). 
Cell lines with and without integrated HPV are characterized by different patterns of gene 
expression (Parfenov et al., 2014). One main approach of mRNA sequencing in the 
current study is to identify differences of gene expression, splice variant or mutations.  
In general, mRNA transcripts are controlled by post-transcriptional regulation, which is 
mediated by RNA-binding proteins (RBPs) that regulate specific subsets of mRNAs. 
Together with small interfering RNAs, microRNAs and protein effector complexes, 
degradation or translation of transcripts is controlled (Mata et al., 2005). Later transcripts 
assemble with translation factors and ribosomes for protein synthesis. Proteins can then 
be further controlled through modifications of amino acids, cleavage by site-specific 
proteases or degradation of proteasome. However, the protein level does not have to 
directly correlate with the mRNA expression level (Halbeisen et al., 2008). As mentioned 
above mRNA sequencing can be a helpful tool in identifying changes in gene expression, 
but it does not show protein level change in activity.  
In the current study, mRNA sequencing was used to investigate differences in gene 
expression between HPV-positive and HPV-negative OPSCC cell lines. The effect of IR 
on gene expression was also investigated. 
These was done based on the following aims:  
 To assess HPV integration and gene expression in HPV-positive cell lines, and to 
assess gene expression and p53 mutations in the whole panel of cell lines.  
 To investigate if there is a response to IR treatment in changes in gene expression 
between HPV-positive and HPV-negative OPSCC cell lines (e.g. DNA repair).  
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The hypotheses:  
1. By consideration of the HPV status, differences in gene expression will be 
observed between HPV-positive and HPV-negative OPSCC cell lines after IR. 
2. Variation in radio-sensitivity among the HPV-positive OPSCC cell lines will be 
identified by different up-/down-regulations of genes after treatment.  
a. These genes could be associated with DNA repair pathways.  
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5.1.1. Experimental design  
 
Ten cell lines, 5 HPV-positive and 5 HPV-negative OPSCC cell lines, were selected to 
use as a study panel. This study panel was extended by the corresponding 2Gy treated 
sample for each cell line. Samples were collected after 24 hours, to identify a long-term 
effect of changes in gene expression between untreated and 2Gy treated samples. This 
provided the opportunity to correlate it to the obtained radio-sensitivity assays (10-15 
days), by choosing a relative longer time point for the mRNA sequencing study. Later the 
data obtained from the radio-sensitivity data was used to classify some analysis in this 
chapter according to the sensitivity status to IR. 
The experiment was performed with a single sample of each cell line and treatment dose. 
Due to the direct comparison of untreated with treated samples of each cell line, one 
replicate was considered to be sufficient.  
The aim of this study was to select OPSCC cell lines of a wide diversity. The HPV-
positive cell lines consisted of CU-OP-2, CU-OP-3 (derived from heavy smokers – data 
not shown) (Pirotte, 2017). CU-OP-20 was derived from a patient who has never smoked 
(described in Chapter 3). UMSCC-47 and UPCI-SCC-90 were also included. All HPV-
positive cell lines harboured wild-type p53 and were identified with the greatest variation 
to IR (Radio-sensitivity assay Chapter 4). CU-OP-20 was later identified during mRNA 
sequencing to harbour wild-type p53. The p53 status for the HPV-negative cell lines 
varied from UMSCC-19 and UMSCC-4 (derived from tumour receiving post-treatment 
of 2 chemotherapies) described previously as showing mutations for p53 and UMSCC-6 
and UMSCC-74a (originated from a recurrent tumour – after receiving chemotherapy) 
harbouring wild-type 53 (Bradford et al., 2003, Brennan et al., 1995, Brenner et al., 2010, 
Ferris et al., 2005, Lin et al., 2007, Mandic et al., 2005, Somers et al., 1992). The novel 
cell line CU-OP-17 (described Chapter 3) was later identified during mRNA sequencing 
to harbour wild-type p53 in the coding region, but represents a likely pathogenic SNP at 
the UTR 5’ region of p53.   
The experiment was used to test the general differences in gene expression between HPV-
positive and negative cell lines. Furthermore, this experiment was designed to test 
changes in gene expression after IR treatment (e.g. DNA repair pathways) in the entire 
panel of OPSCC cell lines. Differences of gene expression were further investigated 
regarding the sensitivity to IR within the HPV-positive cell lines.  
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5.2. Data and quality control  
 
Preliminary bioinformatics quality control analyses were performed by Dr. Peter Giles 
(Wales Gene Park). Sample quality control was performed as described in section 2.8.4 
(Material and Methods). Reads were mapped against the HPV-16 reference sequence 
(NC_001526) and the human reference sequence hg19 (genome build 19) (Table 5-1 for 
untreated and 2Gy IR treated samples).  
 
Table 5-1: Mapped reads for HPV-16 and human (hg19) sequences from untreated and treated 
samples 
    Cell line Mapped reads (hg19) Mapped reads (HPV-16) 
H
P
V
-p
o
si
ti
v
e 
u
n
tr
ea
te
d
 UMSCC-47 55,704,368 1336 
UPCI-SCC-90 49,934,662 11252 
CU-OP-20 43,679,896 11040 
CU-OP-2 25,625,574 2156 
CU-OP-3 25,594,880 9409 
2
G
y
 I
R
 t
re
a
te
d
 
UMSCC-47 37,853,816 1690 
UPCI-SCC-90 34,994,300 15703 
CU-OP-20 33,492,546 8110 
CU-OP-2 48,538,120 2484 
CU-OP-3 45,589,324 8506 
H
P
V
-n
eg
a
ti
v
e
 
u
n
tr
ea
te
d
 UMSCC-19 39,432,500 1 
UMSCC-6 45,644,480 0 
UMSCC-74a 52,895,862 0 
UMSCC-4 31,573,578 0 
CU-OP-17 51,291,862 0 
2
G
y
 I
R
 t
re
a
te
d
 
UMSCC-19 47,035,588 0 
UMSCC-6 58,038,150 0 
UMSCC-74a 60,398,218 0 
UMSCC-4 49,670,746 0 
CU-OP-17 50,831,804 0 
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5.3. Characterization of novel and established cell lines  
 
5.3.1. HPV gene expression in HPV-positive OPSCC cell lines  
 
For all 5 HPV-positive OPSCC cell lines, RNA transcripts mapped to the HPV-16 
sequence (untreated and treated sample) (Figure 5-1). The total number of reads can vary, 
depending on the cell line (hg19_hpv16 combined) (Figure 5-1 & Table 5-1). HPV-16 
reads provided an additional confirmation of the HPV-status of the novel cell line of CU-
OP-20. HPV status was tested as well for the two novel cell lines CU-OP-17 and CU-OP-
20 by PCR testing. HPV status of the other HPV-positive cell lines was confirmed in the 
HPV group during a previous study. The data provided a confirmation of HPV status, 
type and integration sites of the known cell lines of UMSCC-47 and UPCI-SCC-90. 
(Pirotte, 2017).  
Figure 5-2 summarises the Reads Per Kilobase of transcripts per Million mapped reads 
(RPKM) of HPV gene expression within the panel of HPV-positive OPSCC cell lines. 
The expression pattern of individual HPV genes varied between the cell lines. The 
oncogenes E6 and E7 showed the strongest expression in three HPV-positive OPSCC cell 
lines (UMSCC-47, UPCI-SCC-90 and CU-OP-20) in the untreated and 2Gy treated 
samples. Furthermore, CU-OP-20 showed high expressions of E2 and E5 genes. No or 
low expression of the late genes of L1/L2 were present in all HPV-positive OPSCC cell 
lines indicating a non-productive HPV infection.  However, a low level of expression of 
L1/L2 genes was seen in UPCI-SCC-90 (untreated & treated 2Gy IR) with a range of 11 
(untreated) and 22 (treated) reads.  
The highest levels of E6 and E7 gene expression were observed in UPCI-SCC-90, CU-
OP-3 and CU-OP-20. The highest expression of E4 was observed in CU-OP-20 and 
comparably higher expression of E4 was observed as well in CU-OP-2 and CU-OP-3. 
Except for UMSCC-47, all other HPV-positive OPSCC cell lines showed expression of 
E4, E5 and E2. A disruption of E2, E4 and E5 gene expression suggests a fully integrated 
HPV virus in UMSCC-47.  
IR has an effect on the expression of HPV open-reading frames (ORF) in certain cell 
lines. A decrease of a fold-change between untreated and 2Gy treated sample was 
observed in CU-OP-20 for E2 (-0.9858), E4 (-0.9647) and E5 (-1.6646). A fold-change 
increase of HPV ORF’s after IR, was detected in UPCI-SCC-90 for E5 (1.02368), L2 
(1.12758) and L1 (1.05117). CU-OP-3 showed a fold-change increase in L1 (1.24533). 
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All other cell lines and HPV ORF’s showed a minimal fold-change difference after IR. 
Fold changes in E4, E5, L2 and L1 could indicate an episomal HPV expression (no total 
HPV integration). 
 
5.3.2. Splicing of HPV-16 transcripts  
 
HPV transcription is regulated from two main promoters, the early p97 and the late p670 
promoter. Activation of these promoters leads to synthesis of polycistronic mRNAs. 
These mRNAs are then further regulated by differential splicing. High differential or 
alternative splicing is found in the HPV-16 genome and other high risk HPV types e.g. 
HPV-18 and HPV-31. Different oncogenic potential has been ascribed to the resulting 
transcripts (e.g. splicing at E6) (Rosenberger et al., 2010).  
Splicing patterns were assessed in the current panel of cell lines (including the novel line 
CU-OP-20) and are presented as Sashimi plots (Katz et al., 2015) in Figure 5-3. Splice 
forms were identified using information from the Papillomavirus Episteme website 
(https://pave.niaid.nih.gov/#explore/transcript_maps/hpv16 - on the 14/07/2018 (Van 
Doorslaer et al., 2017). Different splicing results across the panel of HPV-positive cell 
lines (transcripts (isoforms) and position) are shown in Table 5-1 (untreated samples) and 
Table 5-2 (2Gy treated samples).  
All HPV-positive cell lines showed the most common transcripts of E6 in the untreated 
samples (E6*I and E6*II). CU-OP-2 only showed a transcript of one of the E6 isoforms, 
E6*I. The most common splicing site in the panel of HPV-positive cell lines is E1^E4, 
which suggest a transcription via episomal HPV. Expression of E2 genes, suggests no full 
integrated HPV into the host genome (Figure 5-2) (Dona et al., 2013). The E1^E4 site is 
shown in all cell lines except for UMSCC-47. CU-OP-20 showed the greatest variation 
of splicing sites in terms of transcripts within the panel of cell lines. All cell lines derived 
at Cardiff University also showed transcripts at E2 or E5. The lowest number of splicing 
sites was detected in UMSCC-47 (main sites are E6*I and E6*II).  
A change of alternative splicing sites was documented (mapped reads hg19_HPV16 
combined (bam files)) in most cell lines after 2Gy IR treatment, which might be a result 
of IR. An increase of splicing sites is documented in all OPSCC cell lines after IR (counts 
with 10 reads included): UMSCC-47 from 2 splicing sites to 3 (one identical), UPCI-
SCC-90 from 3 splicing sites to 4 (3 identical), CU-OP-20 from 7 splicing sites to 10 (6 
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identical), CU-OP-2 from 4 splicing sites to 5 (3 identical) and CU-OP-3 from 4 splicing 
sites to 7 (3 identical). Those identical splicing sites vary in number of counts. The counts 
decrease in number in all identical splicing sites, except for CU-OP-2 and CU-OP-3, were 
an increase of counts was detected for E1^E4 (880 (start nt) – 3356 (end nt). CU-OP cell 
lines showed additional splicing sites for E5 or E2 transcripts. UMSCC-47 showed a 
novel splicing site in the E6 region and E2 (10 counts) after 2Gy IR treatment.  
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Figure 5-1: Mapping of reads against HPV-16 
(A) Raw reads against HPV-16 in untreated samples (B) Raw reads against HPV-16 in treated 
samples (2Gy). The HPV-16 genome with Open reading frames (ORF’s) (E6, E7, E1, E2, E4, E5 
and the L1, L2) shown below the mapped reads. For each cell line, the number of reads mapped to 
the HPV-16 (NC_001526) are listed above. The coloured lines within the sequence indicate 
mismatches with the reference sequence. This graph was obtained by using the IGV software (IGV 
version 2.3.65, Broad Institute) (Robinson et al., 2011).  
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Figure 5-2: HPV gene expression in UMSCC-47, UPCI-SCC-90, CU-OP-20, CU-OP-2 and CU-OP-3 
Reads per Kilobase of transcript per million Mapped reads (RPKM) are plotted for each HPV Open Reading 
Frame (ORF) (per cell line). (A) HPV gene expression in untreated samples (B) HPV gene expression in 
2Gy treated samples. Greatest fold-change seen in E7, E4 and E5 expression in CU-OP-20.  
  
Chapter 5                            Investigation of gene expression in OPSCC cell lines using mRNA sequencing 
 
157 
 
 
Figure 5-3: Sashimi plots (Splice Junctions) in HPV-positive OPSCC cell lines 
Figures represent reads with ends mapping at different sites of the HPV genome, visualised using IGV. 
HPV transcription is regulated by two promoters. Activation of these promoters leads to synthesis of 
polycistronic mRNAs. These mRNAs are then further regulated by differential splicing. The loops in 
the graphs from one HPV site to another HPV site of the sequence (e.g. E6*I). It is representing 
different splicing sites of the HPV genome (A) shows the Sashimi plot of untreated samples (B) shows 
the Sashimi plot of treated samples (2Gy).   
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Table 5-2: Quantification of HPV-16 spliced transcripts in untreated samples 
U
n
tr
ea
te
d
 
Cell line Start (nt)A End (nt) CountB TranscriptC 
UMSCC-47 226 408 206 E6*I 
 226 525 40 E6*II 
UPCI-SCC-90 226 408 890 E6*I 
 226 525 82 E6*II 
 880 3356 102 E1^E4 
CU-OP-20 216 472 879 E6*I 
 226 3356 64 E5 
 226 525 72 E6*II 
 880 2707 81 E2 
 1300 3356 23 E5 
 880 3356 767 E1^E4 
 880 3359 32 E1^E4 
CU-OP-2 226 408 116 E6*I 
 226 3356 39 E5 
 880 3359 99 E1^E4 
 880 3356 25 E1^E4 
CU-OP-3 226 408 72 E6*I 
 226 525 727 E6*II 
 880 2707 57 E2 
 880 3356 72 E1^E4 
A Nucleotide (nt)  
B Splice sites with a minimum of 10 reads were considered to avoid confounding due to sequencing 
artefacts  
C Splice forms are named with reference to the Papillomavirus Episteme database (Van Doorslaer et al., 
2017).  
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Table 5-3: Quantification of HPV-16 spliced transcripts in 2Gy treated samples 
T
re
a
te
d
 2
G
y
 (
IR
) 
Cell line Start (nt)A End (nt) CountB TranscriptC 
UMSCC-47 226 525 25 E6*II 
 175 474 213 novel 
 880 2707 10 E2 
UPCI-SCC-90 226 408 428 E6*I 
 226 525 56 E6*II 
 880 3356 48 E1^E4 
 880 3359 12 E1^E4 
CU-OP-20 226 408 385 E6*I 
 226 525 44 E6*II 
 226 3356 36 E5 
 880 2579 11 E2 
 880 2707 54 E2 
 1300 3356 13 E5 
 226 3356 36 E5 
 880 3389 19 E1^E4 
 880 3356 616 E1^E4 
 880 3359 34 E1^E4 
CU-OP-2 193 450 225 E6*I 
 226 3356 31 E1^E4 
 880 3359 44 E1^E4 
 880 3356 263 E1^E4 
 880 3389 12 E5 
CU-OP-3 226 525 140 E6*II 
 161 462 1195 E6 
 221 408 10 E6*I 
 880 2707 31 E2 
 880 3389 24 E5 
 880 3356 206 E1^E4 
 880 3359 17 E1^E4 
A Nucleotide (nt)  
B Splice sites with a minimum of 10 reads were considered to avoid confounding due to sequencing 
artefacts  
C Splice forms are named with reference to the Papillomavirus Episteme database (Van Doorslaer et al., 
2017). 
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5.3.3. HPV-variants  
 
The genome sequence of HPV types is highly conserved, however minor differences 
within the HPV-16 sequence can be found. These minor differences are termed HPV-
variants, and different variants are connected to geographical and ethnic distribution. The 
variants are classified into four main groups of European, Asian, American and African, 
with subtypes for each group (Burk et al., 2013, Fontecha et al., 2015). Variations at 
specific loci in the highly conserved E6 and LCR region are used to identify the HPV-16 
specific variants listed in Table 5-3. The E6 nucleotide sequence of the new developed 
CU-OP-20 cell line was compared to mismatched sites of known HPV-16 variants; this 
analysis is presented in Table 5-3. CU-OP-20, showed sequence variation consistent with 
Asian-American origin. UPCI-SCC-90, CU-OP-2 and CU-OP-3 showed the main 
European HPV-16 variant, whereas UMSCC-47 showed an African 2A variant. UCPI-
SCC-90 and UMSCC-47 were derived in the United States of America (USA).  
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Table 5-4: Different HPV variants & comparison to HPV-16 sequence of the panel of HPV-positive 
cell lines 
Variant or 
cell line 
Nucleotide position (HPV-16 E6 sequence)A 
109 131 132 143 145 178 286 289 295 335 350 403 532 
HPV-16 
reference T A G C G T T A T C T A A 
EUR 
(A1/A2)B /C /G - - - /A - - - /T /G - - 
EASB - - - - - G/C - - - - - - - 
AFR1aB - - C G T - A G - T - - - 
AFR1bB - G - G T - A G G T G - - 
AFR2aB C - T G T - A G - T - G - 
AFR2bB - - - G T - A G - T - - - 
NAB - - - - T - A G - T G - - 
AA1B - - - - T - A G - T G - G 
AA2B - - - - T - A G - T G - /G 
UMSCC-47 
C A T G T T A  G  T T T G A 
UPCI-SCC-
90 
T G G C G T T A T C G A A 
CU-OP-20 
T A G C T T A G T T G A G 
CU-OP-2 
T  A G C G T T  A  T  C  T A A 
CU-OP-3 
T A G C G T T A T C G A A 
A A dash indicates no change to the HPV-16 reference sequence and a mismatch of nucleotide position is 
indicated in bold red. Nucleotides separated by a slash indicate a different nucleotide position for a given 
sub-lineage (e.g. A1/A2). The top half of the table shows the known HPV-16 variants described by Cornet 
et al. (Cornet et al., 2012).   
B Abbreviations: EUR – European; EAS – European-Asian; AFR – African; NA – North-American: AA – 
Asian-American.  
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5.3.4. HPV integration sites  
 
Integrated virus is present in the majority of HPV-positive tumours and integration of the 
HPV DNA into the host genome confers a proliferative advantage in-vitro (Jeon et al., 
1995, Parfenov et al., 2014). HPV-integration has a major impact on the human genome 
as alteration in DNA copy number or mRNA transcript abundance or splicing have been 
previously reported (Olthof et al., 2015, Parfenov et al., 2014). Viral integration can 
potentially change the expression of genes in the human genome and lead to 
carcinogenesis (Olthof et al., 2015). This effect might also be influenced by IR treatment. 
In combination, these effects can cause genetic instability and disease progression (Jeon 
et al., 1995, Parfenov et al., 2014). Integration sites for UMSCC-47, UPCI-SCC-90, CU-
OP-2 and CU-OP-3 have been previously reported and described in untreated samples 
(Olthof et al., 2015, Pirotte, 2017).  
 
5.3.5. Fusion transcripts  
 
The presence of integrated virus, and the site of integration into the human genome, can 
be detected by analysis of fusion transcripts that include both human and viral sequences 
(i.e. reads with one end mapping to human sequence, and the other mapping to viral 
sequence). Fusion transcripts were visualized by Circos plots, and insertion sites were 
then further analysed by using IGV (Figure 5-4 and Table 5-5). Circos plots were used to 
indicate HPV integration (NC_001526) into the human genome hg19 before and after 
2Gy IR treatment in all HPV-positive OPSCC cell lines. HPV-integration sites were of 
interest, as there might be an association between integration and adjacent host genomic 
structural variation in cancer cell lines and primary tumours (Akagi et al., 2014). Gene 
information for the main integration site was obtained from the GeneCards Human Gene 
Database (http://www.genecards.org/- on the 04/07/2017) and previous publications on 
mRNA sequencing data for UMSCC-47 and UPCI-SCC-90 (Akagi et al., 2014).  
One main integration site was detected in UMSCC-47, which was located at chromosome 
3, with fusion transcripts at E6, E7 and a few in E5 (less than 5 reads – not listed in table). 
The main integration site within chromosome 3 was located at Exon 11 and some 
additional reads at Exon 9 at the human gene TP63. TP63 is a key regulator of epithelial 
differentiation (Bergholz and Xiao, 2012) and it encodes a member of the p53 family of 
transcription factors. Alternative splicing of TP63 and the use of alternative promoters 
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can lead to different isoforms of the gene with variations in functional properties. 
Additionally, it may be required for initiation of p53/TP53 dependent apoptosis in 
response to genotoxic insults. TP63 also activates transcription of p21. Diseases 
connected to TP63 include Adult syndrome (ectodermal dysplasia e.g. excessive 
freckling) and Limb-Mammary Syndrome (ectodermal dysplasia e.g. severe hand and/or 
foot anomalies).  
The greatest number of fusion transcripts among the remaining cell lines, was detected in 
the UPCI-SCC-90 cell line as indicated in Figure 5-4. The main integration site was 
detected at chromosome 9 of the gene C9orf156 (Chromosome 9 Open Reading Frame 
156) also known as TRMO gene, with reads mapping at E6 and E7 for Exon 3 and Exon 
4 and E1 for Exon 1 and Intron 2. Another integration site was detected around 200 bp 
before FOXE1 from E7. This integration site has been previously reported for UPCI-
SCC-90 (Bergholz and Xiao, 2012, Pirotte, 2017). C9orf156 is a poorly characterized 
gene, but is known as a protein coding gene and associated with diseases as isolated cleft 
lip and cleft palate. FOXE1 belongs to the forkhead family and functions as a thyroid 
transcriptions factor connected to thyroid morphogenesis.  
The main integration site for CU-OP-2 mapped to chromosome 10 with reads originated 
at E2. Reads mapped with YME1L1 gene at Introns 6 and 7. YME1L1 is the human 
orthologue to Yme1p (yeast mitochondrial AAA metalloprotease). This protein is 
localized in the mitochondria and the gene might play a role in mitochondrial metabolism 
and could be involved in mitochondrial pathologies. Diseases associated with the gene 
include Optic Altrophy (loss of some or all nerve fibres) and Asphyxia Neonatorum 
(affects babies, if not enough oxygen during the birth process).  
The main integration site for CU-OP-3 was located at chromosome 20 at the gene CEBPB 
(CCAT/Enhancer Binding Protein Beta). The majority of fusion transcripts mapped to E7 
and a lower number mapped to E1 at Exon1. Interestingly, the CEBPB gene is only 
formed of one Exon with several fusion transcripts appear to be linked to E7 splice donor 
region. It is an important transcription factor regulating genes involved in immune and 
inflammatory responses. Furthermore, it is involved in adipogenesis, as well as in the 
gluconeogenic pathway, liver regeneration and hematopoiesis. Diseases associated with 
mutation of CEBPB included Acute Promyelocytic Leukemia.  
Main integration sites for UMSCC-47, UPCI-SCC-90, CU-OP-2 and CU-OP-3 did not 
change after ionising radiation with 2Gy. The number of minor HPV-integration sites 
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increased after IR (Figure 5-4 and Figure 5-5). Three HPV-OPSCC cell lines showed a 
greater increase of chromosomal integration sites UMSCC-47, CU-OP-20 and CU-OP-3. 
UMSCC-47 showed three chromosomal integration sites in the untreated samples, which 
increased to 16 different chromosomal integration sites after IR (difference of 13). 
However, the number of total integration reads decreased by 1% after IR. CU-OP-20 
showed 7 different chromosomal integration sites in the untreated sample, which 
increased to 20 sites after IR (difference of 13 with an increase of reads by 922,2%). CU-
OP-3 showed 6 different chromosomal integration sites in the untreated sample, which 
increased to 21 after IR (difference of 15 with an increase of reads by 76,19%). UPCI-
SCC-90 (difference of 3 chromosomal sites and a decrease of reads by 50%) and CU-OP-
2 (difference of 9 with an increase of 167,64%) showed an increase of chromosomal 
integration sites, with a minor difference to the untreated sample.  
The novel OPSCC cell line CU-OP-20 did not show any main integration site. Minor 
integration sites (less than 5 mapped reads) were detected in the untreated and treated 
samples, for example: from E7 into Exon 3 of ZC3H12C in chromosome 11 or from 
E2/E4 into Exon 8 of EEF1A1 in chromosome 6.  
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Figure 5-4: Circos plots showing HPV:human fusion transcripts in untreated and treated (2Gy) 
samples (sensitive to IR) 
The circle is comprised of HPV16 sequence in grey and human chromosomes as coloured bars. Fusion 
transcripts are represented as grey lines joining the loci to which they map in human and HPV sequence. 
Thicker/darker lines indicate multiple reads mapping to the same loci.  
The number of fusion transcripts appeared to increase following IR treatment of 2Gy. Multiple integration 
sites were detected in CU-OP-20 in untreated and treated samples.  An increase of minor integration sites 
(less than 5 mapped reads at different chromosome sites) was detected after IR or 2Gy in all OPSCC cell 
lines.  
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Figure 5-5: Circos plots showing HPV: human fusion transcripts in untreated and treated (2Gy) 
samples (resistant to IR) 
The circle is comprised of HPV16 sequence in grey and human chromosomes as coloured bars. Fusion 
transcripts are represented as grey lines joining the loci to which they map in human and HPV sequence. 
Thicker/darker lines indicate multiple reads mapping to the same loci. 
The number of fusion transcripts appeared to increase following IR treatment of 2Gy. An increase of minor 
integration sites (less than 5 mapped reads at different chromosome sites) was detected after IR or 2Gy in 
all OPSCC cell lines.   
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Table 5-5: HPV-16 integration sites for HPV-positive OPSCC cell lines in untreated and 2Gy (IR) 
treated samples.  
  
Cell line 
HPV 
gene 
Human 
chromosome 
Human geneA 
U
n
tr
ea
te
d
 
 UMSCC-47 E7 3 TP63: Exon 9 ; Exon 11 
UPCI-SCC-90  E7 9 C9orf156 Exon 3 
  E7 9 Non-coding +200 bp before FoxE1 
  E7 9 C9orf156 Exon 4 
  E6 9 C9orf156 Exon 3 
  E6 9 C9orf156 Exon 4 
  E1 9 C9orf156 Intron 2 
CU-OP-2  E2 10 YME1L1 (intron 6 and 7) 
CU-OP-3  E7 20 CEPBP Exon 1 
2
G
y
 (
IR
) 
tr
ea
te
d
 
UMSCC-47  E7 3 TP63: Exon 9 ; Exon 11 
UPCI-SCC-90 E7 9 C9orf156 Exon3 
  E6 9 C9orf156 Exon 4 
 E6 9 C9orf156 Exon 3 
  E1 9 C9orf156 Intron 2 
  E7 9 C9orf156 Intron 3 
  E7 9 C9orf156 Exon 4 
  E7 9 Non-coding +200 bp before FoxE1 
CU-OP-2 E2 10 YME1L1 (intron 6 and 7) 
CU-OP-3 E7 20 CEPBP Exon 1 
A Sites with at least 5 reads mapped are listed – CU-OP-20 did not show a main integration site (i.e. => 5 
mapped reads) and is therefore not listed in this table.  
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5.3.6. P53 status (SNPs and mutation) of OPSCC cell lines  
 
It has been suggested that p53 gene mutation is common in HPV-negative and rare in 
HPV-positive OPSCC cell lines (Guerrero-Preston et al., 2014). Published literature 
suggests that p53 is wild-type in the HPV-positive cell lines UMSCC-47 and UPCI-SCC-
90 as well as in two HPV-negative cell lines UMSCC-6 and UMSCC-74, while two HPV-
negative cell lines UMSCC-4 and UMSCC-19 were described as harbouring mutations 
of p53 (Bradford et al., 2003, Ferris et al., 2005, Mandic et al., 2005, Somers et al., 1992). 
The p53 status for CU-OP-2 and CU-OP-3 were confirmed as wild-type p53 (Pirotte, 
2017). P53 status for the novel cell lines of CU-OP-17 and CU-OP-20 was identified by 
using IGV. To determine if the cell lines used in this study conform to these previous 
results, and therefore are appropriate models of OPSCC, it was necessary to determine 
the p53 mutation status. 
 mRNA sequence data was examined to identify mismatches with the reference sequence, 
these were then individually investigated to see whether they were likely to be SNPs or 
mutations. To be considered genuine, at least five reads were required to show a 
difference from the reference sequence; this was based on the same process as for HPV-
integration (to avoid a confounding effect by counting isolated sequencing errors). 
Confirmed mismatches were searched against the NCBI dbSNP database to determine 
the allele frequency and clinical significance.  
Single nucleotide polymorphism (SNP) or mismatches were identified for all cell lines 
except for UMSCC-6 and UMSCC-19. However, a deletion in UMSCC-19 for p53 was 
detected, which consisted of a gap of 22 nucleotides in exon 8. This mutation has been 
previously reported (Somers et al., 1992).   
In both untreated and 2Gy treated UMSCC-4, a pathogenic mutation in the DNA binding 
domain (heterozygous G>A mutation) at chromosome 17:7578212 with the SNP 
reference number of rs397516436 was detected. The detectable read of the untreated 
sample only consisted of one read. The identification of this mutation was consistent with 
previous publications (Pirotte, 2017, Mandic et al., 2005)). This was considered as an 
acceptable exception to the threshold of 5 reads, as the mutation was confirmed with more 
reads in the treated sample. For the rest of the cell line panel the minimum number of 5 
reads was followed.  
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In the novel cell line CU-OP-17 (HPV-negative), a SNP at chromosome location 
17:7578478 with the SNP reference number of rs1057520000 was detected and was 
described as occurring in the UTR variant 5 prime domain, and as “likely pathogenic 
(missense mutation)”. More information about this SNP was not available on the NCBI 
dbSNP database. Minor Allele Frequency (MAF) was not available, which indicates that 
it is uncommon (rare).  On this basis, CU-OP-17 can be considered as wild-type for p53 
within the coding region.   
One SNP, rs1042522 (Minor Allele Frequency (MAF)/Minor Allele count: 
G=0.4571/2289 (1000 Genomes)), was detected in the whole panel of HPV-positive 
OPSCC cell lines except for UMSCC-6 (no detectable SNP above 5 reads). The 
MAF/Minor Allele count showed that this SNP is quite common. A study on lung cancer 
identified the rs1042522 genotype as being more likely resistant to chemotherapy (Han 
et al., 2008). The role of p53 polymorphism at codon 72 (rs1042522) in head and neck 
cancer is unclear, as expression of this SNP did not lead to greater resistance in all cell 
lines to IR. Furthermore, p53 polymorphism at codon 72 (rs1042522) in cervical cancer 
was associated with increased risk (Rosenthal et al., 1998, Storey et al., 1998). This was 
later disproved by other larger studies with no association between rs1042522 and cancer 
risk (Koshiol et al., 2009).  
In summary the novel cell lines of CU-OP-17 and CU-OP-20 the p53 status was 
investigated through the mRNA sequencing data. CU-OP-17 showed likely pathogenic 
missense mutation at a UTR region but no mutations (SNP) within the coding region. 
CU-OP-20 appeared to carry no mutations in p53, and no pathogenic SNP’s were 
detected. The p53 status of the remaining cell lines, presented in previous studies, was 
confirmed in the current study.  
In terms of SNPs and mutation there appeared to be no differences between untreated and 
2Gy treated samples. No detection of additional pathogenic mutations was made.  
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5.4. Analysis of differential gene expression  
  
The mRNA sequencing data was used to compare gene expression between three different 
sub-groups of cell lines. Comparisons were made between:  
 HPV-positive versus HPV-negative OPSCC cell lines  
 HPV-positive OPSCC: cell lines sensitive to IR versus cell lines resistant to IR 
(untreated comparison & 2Gy treated comparison)  
 OPSCC cell lines: untreated cell lines versus treated cell lines with IR (2Gy) 
Differentially expressed genes were identified using a DEseq2 analysis on normalized 
data (Love et al., 2014). The resultant p-values were corrected for multiple testing and 
false discovery using the FDR method (FDR p<0.05) (Benjamini and Hochberg, 1995). 
Data was then presented as heatmaps based on a hierarchical clustering (using average 
linkage and Pearson’s correlation as the similarity metric). DEseq2 analysis and 
generation of heatmaps are described in more detail in chapter 2 section 2.8.4.  
 
5.4.1. Differences in gene expression of HPV-positive versus HPV-negative OPSCC 
cell lines  
 
Differential gene expression between the 5 HPV-positive OPSCC and 5 HPV-negative 
cell lines was investigated. The prediction was that there would be differential gene 
expression between HPV-positive and HPV-negative OPSCC cell lines, due to 
differences in radio-sensitivity (Chapter 4) and differences in clinical response of HPV-
positive and HPV- negative patients (Evans et al., 2013). This comparison was done, 
before focusing on sensitivity comparison and effect of IR (paired comparison). Within 
this section HPV-positive and HPV-negative OPSCC cell lines were compared as 
untreated samples and 2Gy treated samples with each other (Figure 5-6 and Figure 5-7).  
Data was generated as described in the Introduction of section 5.4.  
The generated heatmaps in both untreated and treated (2Gy IR) comparison indicated that 
HPV-positive and HPV-negative OPSCC cell lines formed discrete groups with 
differential gene expression according to the HPV-status. The top 20 significant genes 
(FDR p<0.05) did not indicate any connection to DNA repair, DNA damage, cell death 
or apoptosis. (Table 5-6 and Table 5-7).   
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Figure 5-6: Heatmap representing differential gene expression between untreated HPV-positive 
and HPV-negative OPSCC cell lines.  
Gene expression was normalised across the tested samples and colour coded (green, black, red). Black 
represents a median value, green is below the median value and red is above the median value (i.e. red = 
higher expression). After correction for multiple testing, 209 genes showed a significant difference between 
the two groups (FDR p<0.05). The top 20 most significant genes are listed in Table. 5-6.  Untreated samples 
were collected at the same time as the treated counterpart.  
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Table 5-6: Differential gene expression between untreated HPV-positive and HPV-negative OPSCC 
cell lines (untreated) 
GeneA Description ID fdr p log2FCB 
GPR158 
G Protein-coupled 
Receptor 158 NM_020752_chr10 1.28E-12 -6.17 
SYCP2 
Synaptonemal Complex 
Protein 2 NM_014258_chr20 2.86E-12 4.06 
MMP13 
Matrix Metallopeptidase 
13 NM_002427_chr11 1.38E-09 -6.37 
LOC72968
3 
Uncharacterized 
LOC729683 NR_046273_chr17 1.38E-09 4.08 
KLHL35 
Kelch Like Family 
Member 35 NM_001039548_chr11 4.75E-09 3.68 
ITGA4 Integrin Subunit Alpha 4 NM_000885_chr2 6.62E-09 -6.19 
ZNF788 
Zinc Finger Family 
Member 788 NR_027049_chr19 1.01E-08 -5.46 
TCAM1P 
Testicular Cell Adhesion 
Molecule 1, Pseudogene NR_002947_chr17 7.78E-08 4.88 
LINC00662 
Long Intergenic Non-
protein Coding RNA 662 NR_027301_chr19 9.87E-08 -5.55 
ZNF541 Zinc finger protein 541 NM_001101419_chr19 2.98E-07 5.58 
LOC37519
6 
Uncharacterized 
LOC375196 NR_028386_chr2 7.21E-07 5.31 
MEI1 
Meiotic Double-stranded 
Break Formation Protein 1 NM_152513_chr22 1.14E-06 4.96 
RASIP1 Ras Interacting Protein 1 NM_017805_chr19 1.25E-06 4.35 
NEFH Neurofilament Heavy NM_021076_chr22 1.86E-06 5.72 
NMNAT2 
Nicotinamide Nucleotide 
Adenylyltransferase 2 NM_015039_chr1 4.73E-06 5.03 
ANXA2P1 Annexin A2 Pseudogene 1 NR_001562_chr4 4.73E-06 5.04 
SHCBP1L 
SHC Binding And Spindle 
Associated 1 Like NM_030933_chr1 5.74E-06 5.50 
XCL1 
X-C Motif Chemokine 
Ligand 1 NM_002995_chr1 7.27E-06 -5.12 
LCP1 
Lymphocyte Cytosolic 
Protein 1 NM_002298_chr13 1.45E-05 -5.06 
LDOC1 
Leucine Zipper Down-
regulated In Cancer 1 NM_012317_chrX 1.52E-05 -4.88 
A The 20 most significant genes are listed in this table - additional GO clustering was performed to group 
genes according to their function.  
B log2FC: Fold change between the comparison of two groups of this significant presented gene (increase 
or decrease of expression) 
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Figure 5-7: Heatmap representing differential gene expression between 2Gy IR treated HPV-
positive and HPV-negative OPSCC cell lines.  
Gene expression was normalised across the tested samples and colour coded (green, black, red). Black 
represents a median value, green is below the median value and red is above the median value (i.e. red = 
higher expression). After correction for multiple testing, 209 genes showed a significant difference between 
the two groups (FDR p<0.05). The top 20 most significant genes are listed in Table. 5-7.  Untreated samples 
were collected at the same time as the treated counterpart.  
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Table 5-7: Differential gene expression between 2Gy IR treated HPV-positive and HPV-negative 
OPSCC cell lines 
GeneA Description  ID fdr p log2FCB 
SYCP2 
Synaptonemal Complex 
Protein 2 NM_014258_chr20 2.7E-19 4.40 
LOC729683 
Uncharacterized 
LOC729683 NR_046273_chr17 2.0E-10 3.10 
ZNF541 Zinc finger protein 541 NM_001101419_chr19 4.8E-10 5.32 
KLHL35 
Kelch Like Family 
Member 35 NM_001039548_chr11 4.8E-10 2.86 
LCP1 
Lymphocyte Cytosolic 
Protein 1 NM_002298_chr13 2.4E-09 -6.29 
LOC375196 
Uncharacterized 
LOC375196 NR_028386_chr2 5.7E-09 5.43 
ITGA4 Integrin Subunit Alpha 4 NM_000885_chr2 9.9E-09 -5.78 
MMP13 
Matrix Metallopeptidase 
13 NM_002427_chr11 2.7E-08 -4.72 
GPR158 
G Protein-coupled 
Receptor 158 NM_020752_chr10 6.1E-07 -5.03 
ZNF788 
Zinc Finger Family 
Member 788 NR_027049_chr19 8.0E-07 -4.59 
XCL1 
X-C Motif Chemokine 
Ligand 1 NM_002995_chr1 3.0E-06 -5.09 
TCAM1P 
Testicular Cell Adhesion 
Molecule 1, Pseudogene NR_002947_chr17 4.7E-06 4.34 
RAB3IL1 
RAB3A Interacting 
Protein Like 1 NM_013401_chr11 6.3E-06 -2.20 
OSGIN2 
Oxidative Stress Induced 
Growth Inhibitor Family 
Member 2 NM_001126111_chr8 5.9E-05 -2.00 
JAKMIP3 
Janus Kinase And 
Microtubule Interacting 
Protein 3 NM_001105521_chr10 7.1E-05 -3.70 
MEI1 
Meiotic Double-stranded 
Break Formation Protein 
1 NM_152513_chr22 1.1E-04 4.29 
CCDC155 
Coiled-coil Domain 
Containing 155 NM_144688_chr19 1.4E-04 4.50 
DPYSL4 
Dihydropyrimidinase 
Like 4 NM_006426_chr10 1.7E-04 -4.70 
MMP1 
Matrix Metallopeptidase 
1 NM_002421_chr11 1.7E-04 -4.60 
NDUFA4L2 
Mitochondrial Complex 
Associated Like 2 NM_020142_chr12 1.7E-04 3.89 
A The 20 most significant genes are listed in this table - additional GO clustering was performed to group 
genes according to their function.  
B log2FC: Fold change between the comparison of two groups of this significant presented gene (increase 
or decrease of expression) 
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5.4.1.1.Identification of gene ontology groups between HPV-positive OPSCC cell 
lines versus HPV-negative OPSCC cell lines   
 
To allow analysis of large numbers of differentially regulated genes, gene ontology 
analysis was performed. Gene ontology highlighted several differences between HPV-
positive and HPV-negative OPSCC cell lines, in the comparisons of untreated or 2Gy IR 
treated samples (Table 5-8 and Table 5-9).  
The gene ontology overexpression analysis (GO ORA) was undertaken to gain insight 
into the biological consequences of differential expression of large numbers of genes. 
During this analysis genes were grouped into three categories: biological processes (BP), 
molecular functions (MF) and cellular component (CC). The data were corrected for 
multiple testing and false discovery using the FDR method (Falcon and Gentleman, 2007, 
Young et al., 2010). A detailed description of the methodology is given in the Material 
and Methods chapter section 2.8.4.8.  
The number of significant overrepresented GO groups (using the top 500 transcripts) for 
the untreated comparisons of HPV-positive versus HPV-negative OPSCC cell lines and 
the 2Gy IR treated counterpart (GO ORA) are presented in Table 5-8 and Table 5-9. The 
number of significant overrepresented GO groups are presented with the adjusted p-value 
(FDR p<0.05) as following for the untreated comparison: 377 (BP), 65 (MF) and 40 (CC). 
The number of significant overrepresented GO groups are presented with the adjusted p-
value (FDR p<0.05) as following for 2Gy treated comparison between HPV-positive and 
HPV-negative OPSCC cell lines: 132 (BP), 44 (MF) and 20 (CC). The top 10 significant 
groups for BP, MF and CC were presented in Table 5-8 and Table 5-9 as example GO 
groups.  
The BP ontologies that appeared to be differentially regulated between the untreated 
HPV-positive and HPV-negative OPSCC cell lines included several groups relating to 
regulation of cell communication, signalling and regulation of cellular protein metabolic 
processes. The MF ontologies showed differentially expressed processes, including 
enzyme, collagen and kinesin binding overrepresented GO groups. The CC ontologies 
showed differential expressed regulation, including within the Ku70:Ku80 complex, a 
dimeric protein complex binding to DNA double-strand breaks ends (Non homologous 
end joining) (Table 5-8).  
The BP ontologies within the 2Gy treated comparison between HPV-positive and HPV-
negative OPSCC cell lines, appeared to have differentially regulated processes, including 
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glutamine family amino acid metabolism or mRNA 3’-splice site recognition. The MF 
ontologies showed differentially regulated processes, including activities in 
phosphoglycerate dehydrogenase and glycine-gated chloride ion channel activity. The CC 
ontologies showed the top 10 significant overrepresented GO groups. Compared to the 
untreated comparison and differentially regulated Ku70:Ku80 complex, was not 
significant in the entire CC ontology comparison within the 2Gy IR treated samples 
(Table 5-9).  
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Table 5-8: Significant gene ontology categories between untreated HPV-positive OPSCC and HPV-
negative OPSCC cell lines 
CategoryA GO ID Term fdr p 
BP GO:0060255 regulation of macromolecule metabolic process 0.042 
BP GO:0009719 response to endogenous stimulus 0.042 
BP GO:0010646 regulation of cell communication 0.042 
BP GO:0023051 regulation of signaling 0.042 
BP GO:0009057 macromolecule catabolic process 0.042 
BP GO:0030182 neuron differentiation 0.042 
BP GO:0032268 regulation of cellular protein metabolic process 0.042 
BP GO:0051094 positive regulation of developmental process 0.042 
BP GO:0042325 regulation of phosphorylation 0.042 
BP GO:0009887 organ morphogenesis 0.042 
MF GO:0019899 enzyme binding 0.018 
MF GO:0004222 metalloendopeptidase activity 0.018 
MF GO:0005518 collagen binding 0.018 
MF GO:0019894 kinesin binding 0.018 
MF GO:0050750 low-density lipoprotein particle receptor binding 0.018 
MF GO:0005161 platelet-derived growth factor receptor binding 0.018 
MF GO:0004070 aspartate carbamoyltransferase activity 0.018 
MF GO:0004087 carbamoyl-phosphate synthase (ammonia) activity 0.018 
MF GO:0004088 
carbamoyl-phosphate synthase (glutamine-hydrolyzing) 
activity 0.018 
MF GO:0004151 dihydroorotase activity 0.018 
CC GO:0031090 organelle membrane 0.034 
CC GO:0005773 vacuole 0.034 
CC GO:0031233 
intrinsic component of external side of plasma 
membrane 0.034 
CC GO:0043564 Ku70:Ku80 complex 0.034 
CC GO:1990597 AIP1-IRE1 complex 0.034 
CC GO:0016935 glycine-gated chloride channel complex 0.034 
CC GO:0070743 interleukin-23 complex 0.034 
CC GO:1990630 IRE1-RACK1-PP2A complex 0.034 
CC GO:1990332 Ire1 complex 0.034 
CC GO:1990425 ryanodine receptor complex 0.034 
A Gene ontology categories = Biological Process (BP), Molecular Function (MF) and Cellular Component 
(CC) – Top 10 significant groups for BP, MF and CC are listed as representative figures in this table.  
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Table 5-9: Significant gene ontology categories between 2Gy IR treated HPV-positive OPSCC and 
HPV-negative OPSCC cell lines  
CategoryA  GO ID Term fdr p 
BP GO:0009064 glutamine family amino acid metabolic process 0.037 
BP GO:0036498 IRE1-mediated unfolded protein response 0.037 
BP GO:0032981 mitochondrial respiratory chain complex I assembly 0.037 
BP GO:0010171 body morphogenesis 0.037 
BP GO:0060325 face morphogenesis 0.037 
BP GO:0098810 neurotransmitter reuptake 0.037 
BP GO:0000389 mRNA 3'-splice site recognition 0.037 
BP GO:0003149 membranous septum morphogenesis 0.037 
BP GO:0003307 
regulation of Wnt signaling pathway involved in heart 
development 0.037 
BP GO:0018401 peptidyl-proline hydroxylation to 4-hydroxy-L-proline 0.037 
MF GO:0051879 Hsp90 protein binding 0.023 
MF GO:0004617 phosphoglycerate dehydrogenase activity 0.023 
MF GO:0015105 arsenite transmembrane transporter activity 0.023 
MF GO:0017096 acetylserotonin O-methyltransferase activity 0.023 
MF GO:0045517 interleukin-20 receptor binding 0.023 
MF GO:0022852 glycine-gated chloride ion channel activity 0.029 
MF GO:0045518 interleukin-22 receptor binding 0.029 
MF GO:0048257 3'-flap endonuclease activity 0.029 
MF GO:0036094 small molecule binding 0.031 
MF GO:0031406 carboxylic acid binding 0.031 
CC GO:0005739 mitochondrion 0.019 
CC GO:0016935 glycine-gated chloride channel complex 0.019 
CC GO:1990630 IRE1-RACK1-PP2A complex 0.019 
CC GO:1990332 Ire1 complex 0.019 
CC GO:1990425 ryanodine receptor complex 0.019 
CC GO:0016222 procollagen-proline 4-dioxygenase complex 0.021 
CC GO:1990597 AIP1-IRE1 complex 0.021 
CC GO:0005658 alpha DNA polymerase:primase complex 0.021 
CC GO:1990604 IRE1-TRAF2-ASK1 complex 0.021 
CC GO:0031975 envelope 0.026 
A Gene ontology categories = Biological Process (BP), Molecular Function (MF) and Cellular Component 
(CC) – Top 10 significant groups for BP, MF and CC are listed as representative figures in this table.  
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5.4.2. Differences in gene expression of HPV-positive OPCC cell lines 
sensitive/resistant to IR 
 
According to the obtained data from the radio-sensitivity assay, basic comparison of gene 
expression was performed on the defined sensitive and resistant cell line (untreated and 
treated comparison). Genes presented in the heatmaps were normalised and significant 
according to the FDR value (FDR p<0.05). 
These comparisons were done to identify possible key factors, which might explain the 
greater variation within the HPV-positive OPSCC cell lines (HPV-negative OPSCC cell 
lines have shown a similar IR response).  A heatmap of sensitive cell lines (UMSCC-47, 
UPCI-SCC-90 and CU-OP-20) versus resistant cell lines (CU-OP-2 and CU-OP-3) 
showed clear differences between the two groups (Figure 5-8 and Figure 5-9). The two 
resistant cell lines showed high expression of the majority of the differential expressed 
genes compared to a median or lower expression of these genes in the three sensitive cell 
lines. The most significantly differentially expressed transcripts map to genes involved in 
signal transduction, protein phosphorylation & de-phosphorylation, regulation of 
transcription, cell cycle arrest, or cell adhesion (Table 5-10).  
A similar analysis was then performed using the mRNA sequencing data from treated 
cells (Figure 5-9). This comparison showed only 19 significant differences in gene 
expression (genes listed in Table 5-11) (FDR p<0.05). A number of genes were detected 
in both groups: TXLNG2P, ZNF253, USP32P1, PPP1R3C, EDIL3 and FAM50B.  
  
Chapter 5                            Investigation of gene expression in OPSCC cell lines using mRNA sequencing 
 
180 
 
 
Figure 5-8: Heatmap representing differential gene expression between the most sensitive and 
resistant HPV-positive cell lines (untreated cells) 
Gene expression was normalised across the tested samples and colour coded (green, black, red). Black 
represents a median value, green is below the median value and red is above the median value (i.e. red = 
higher expression). After correction for multiple testing, 123 genes showed a significant difference between 
the two groups (FDR p<0.05). The top 20 most significant genes are listed in Table. 5-10.  Untreated 
samples were collected at the same time as the treated counterpart.  
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Table 5-10: Differential gene expression between sensitive and resistant cell lines (untreated) 
GenesA Description ID fdr p log2FCB 
PRKG2 
Protein Kinase, CGMP-
Dependent, Type II NM_006259_chr4 2.6E-12 -3.80 
TXLNG2P 
Taxilin Gamma 
Pseudogene, Y-linked NR_045128_chrY 2.6E-12 -6.57 
PPP1R3C 
Protein Phosphatase 1 
Regulatory Subunit 3C NM_005398_chr10 3.1E-10 -5.93 
ZNF253 Zinc Finger Protein 253 NM_021047_chr19 1.5E-08 -5.72 
RCN3 Reticulocalbin 3 NM_020650_chr19 2.4E-07 -3.43 
FAM50B 
Family with Sequence 
Similarity 50 Member B NM_012135_chr6 1.8E-06 4.37 
USP32P1 
Ubiquitin Specific 
Peptidase 32 Pseudogene 
1 NR_003190_chr17 1.3E-05 -3.54 
BRINP3 
BMP/Retinoic Acid 
Inducible Neural 
Specific 3 NM_199051_chr1 2.5E-05 -4.90 
DENND2A 
DENN Domain 
Containing 2A NM_015689_chr7 2.7E-05 -4.07 
CCND2 Cyclin D2 NM_001759_chr12 8.2E-05 -4.68 
TXLNG2P 
Taxilin Gamma 
Pseudogene, Y-linked NR_045129_chrY 8.2E-05 -4.71 
COL5A2 
Collagen Type V Alpha 
2 Chain NM_000393_chr2 1.1E-04 -4.09 
EDIL3 
EGF Like Repeats And 
Discoidin Domains 3 NM_005711_chr5 2.6E-04 4.28 
CRACR2A 
Calcium Release 
Activated Channel 
Regulator 2A NM_001144958_chr12 3.0E-04 -4.10 
HIST2H2BF 
Histone Cluster 2 H2B 
Family Member F NM_001024599_chr1 3.7E-04 -4.50 
H3F3C 
H3 Histone Family 
Member 3C NM_001013699_chr12 4.6E-04 -4.12 
KALRN Kalirin RhoGEF Kinase NM_001024660_chr3 4.8E-04 -4.46 
EIF5AL1 
Eukaryotic Translation 
Initiation Factor 5A-Like 
1 NM_001099692_chr10 5.0E-04 -3.67 
STAT5A 
Signal Transdurcer and 
Activator Of 
Transcription 5A NM_003152_chr17 7.4E-04 -2.29 
PCOLCE 
Procollagen C-
Endopeptidase Enhancer NM_002593_chr7 9.7E-04 -3.25 
A The 20 most significant genes are listed in this table - additional GO clustering was performed to group 
genes according to their function.  
B log2FC: Fold change between the comparison of two groups of this significant presented gene (increase 
or decrease of expression)   
Chapter 5                            Investigation of gene expression in OPSCC cell lines using mRNA sequencing 
 
182 
 
 
Figure 5-9: Heatmap representing differential gene expression within the 2Gy IR treated most 
sensitive and resistant HPV-positive cell lines (treated sample 2Gy 24h) 
Gene expression was normalised across the tested samples and colour coded (green, black, red). Black 
represents a median value, green is below the median value and red is above the median value (higher 
expression. After correction for multiple testing between sensitive and resistant groups within HPV-positive 
OPSCC, 19 transcripts (genes) showed a significant difference between the two groups (FDR p<0.05). The 
top 20 genes are listed as representative genes in Table. 5-11.  Untreated samples were collected at the same 
time as the treated counterpart.   
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Table 5-11: Differential gene expression between sensitive and resistant cell lines (2Gy treated) 
GenesA Description  ID fdr p log2FCB 
FAM50B 
Family with 
Sequence Similarity 
50 Member B NM_012135_chr6 2.1E-10 5.31 
TXLNG2P 
Taxilin Gamma 
Pseudogene, Y-
linked NR_045128_chrY 2.6E-10 -6.12 
USP32P1 
Ubiquitin Specific 
Peptidase 32 
Pseudogene 1 NR_003190_chr17 2.1E-08 -4.24 
GPR114 
Adhesion G Protein-
Coupled Receptor 
G5 NM_153837_chr16 2.9E-08 5.21 
PPP1R3C 
Protein Phosphatase 
1 Regulatory Subunit 
3C NM_005398_chr10 1.4E-07 -5.12 
ZNF253 
Zinc Finger Protein 
253 NM_021047_chr19 6.1E-06 -4.77 
EDIL3 
EGF Like Repeats 
And Discoidin 
Domains 3 NM_005711_chr5 1.6E-05 4.78 
TXLNG2P 
Taxilin Gamma 
Pseudogene, Y-
linked NR_045129_chrY 1.2E-04 -4.80 
TSPAN12 Tetraspanin 12 NM_012338_chr7 4.4E-03 3.50 
NCRNA00185 
Testis Specific 
Transcript, Y-linked 
14 (Non-protein 
coding) NR_001544_chrY 6.2E-03 -4.15 
HOXD9 Homeobox D9 NM_014213_chr2 1.2E-02 -3.38 
PCDH7 Protocadherin 7 NM_002589_chr4 1.2E-02 3.01 
INHBE 
Inhibin Beta E 
Subunit NM_031479_chr12 1.4E-02 -3.82 
ISL1 
ISL LIM Homeobox 
1 NM_002202_chr5 2.4E-02 3.55 
PLAC1 Placenta Specific 1 NM_021796_chrX 2.6E-02 -3.53 
SUSD2 
Sushi Domain 
Containing 2 NM_019601_chr22 3.0E-02 -2.83 
SULT4A1 
Sulfotransferase 
Family 4A Member 
1 NM_014351_chr22 3.6E-02 -3.41 
EYA2 
EYA Transcriptional 
Coactivator And 
Phosphatase 2 NM_005244_chr20 4.1E-02 3.60 
TTTY14 
Testis Specific 
Transcript, Y-linked 
14 (Non-protein 
coding) NR_001543_chrY 4.2E-02 -3.73 
RHOBTB2 
Rho Related BTB 
Domain Containing 2 NM_001160036_chr8 5.0E-02 -3.45 
A The 20 most significant genes are listed in this table - additional GO clustering was performed to group 
genes according to their function.  
B log2FC: Fold change between the comparison of two groups of this significant presented gene (increase 
or decrease of expression)   
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5.4.2.1.Identification of gene ontology groups within the HPV-positive OPSCC cell 
lines sensitive/resistant to IR  
 
To allow analysis of large numbers of differentially regulated genes, gene ontology 
analysis was performed. Gene ontology highlighted several differences between the 
sensitive and resistant lines, but none of these related to DNA repair or ionising radiation 
response (Table 5-12 and 5-13).  
The number of significant overrepresented GO groups (using the top 500 transcripts) for 
the untreated comparisons of sensitive versus resistant to IR and treated counterpart (GO 
ORA) are presented in Table 5-8 and Table 5-9. The numbers of significant 
overrepresented GO groups are presented with the adjusted p-value (FDR p<0.05) as 
following for the untreated comparison: 193 BP, 29 MP and 42 CC. The numbers of 
significant GO groups are presented with the adjusted p-value (FDR p<0.05) as following 
for the 2Gy comparison: 122 BP, 34 MF and 18 CC. The top 10 significant groups for 
BP, MF and CC were presented in Table 5-12 and Table 5-13 as example GO groups. 
The p-value represented how likely it is that this over representation has occurred by 
chance.  
The BP ontologies that appeared to be differentially regulated between sensitive and 
resistant HPV-positive OPSCC cell lines (untreated samples) included several groups 
relating to cell signalling and communication. The MF ontologies that showed 
differentially expressed processes between sensitive and resistant cell lines (untreated 
samples), including differences in transcription factor activity, RNA polymerase II 
transcription factor recruiting, glycogen synthase activity or laminin and fibronectin 
binding. Differences in the CC ontologies included factors as macromolecular complex 
or different expression of lateral plasma membrane. These seem consistent with a 
difference between the two groups in terms of cell communication. 
The BP ontologies within the treated (2Gy) comparison, appeared to show differentially 
regulation between sensitive and resistant HPV-positive OPSCC cell lines, and included 
several groups relating to cellular localization or lipid metabolic process. The only 
similarity shown between the untreated and 2Gy treated comparison in both 10 significant 
listed GO groups identified different regulation in the BP ontology of homeostasis. 
Different GO ontologies groups for MF (e.g. arrestin family protein binding) and CC (e.g. 
external side of plasma membrane) were identified compared to the untreated 
counterparts.  
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Table 5-12: Significant gene ontology categories between untreated sensitive and resistant HPV-
positive OPSCC cell lines  
CategoryA  GO ID Term fdr p 
BP GO:0010646 regulation of cell communication 0.044 
BP GO:0023051 regulation of signalling 0.044 
BP GO:0042592 homeostatic process 0.044 
BP GO:2000026 
regulation of multicellular organismal 
development 0.044 
BP GO:0048583 regulation of response to stimulus 0.044 
BP GO:0055082 cellular chemical homeostasis 0.044 
BP GO:0061458 reproductive system development 0.044 
BP GO:0030111 regulation of Wnt signalling pathway 0.044 
BP GO:0009746 response to hexose 0.044 
BP GO:0043588 skin development 0.044 
MF GO:0001968 fibronectin binding 0.011 
MF GO:0043236 laminin binding 0.022 
MF GO:0046966 thyroid hormone receptor binding 0.022 
MF GO:0001135 
transcription factor activity, RNA polymerase 
II transcription factor recruiting 0.022 
MF GO:0004373 glycogen (starch) synthase activity 0.022 
MF GO:0045519 interleukin-23 receptor binding 0.022 
MF GO:0061547 
glycogen synthase activity, transferring 
glucose-1-phosphate 0.022 
MF GO:0005518 collagen binding 0.025 
MF GO:0004521 endoribonuclease activity 0.025 
MF GO:0034618 arginine binding 0.025 
CC GO:0016328 lateral plasma membrane 0.011 
CC GO:1902911 protein kinase complex 0.020 
CC GO:0043265 ectoplasm 0.020 
CC GO:1990332 Ire1 complex 0.020 
CC GO:1990425 ryanodine receptor complex 0.020 
CC GO:0034667 integrin alpha3-beta1 complex 0.025 
CC GO:0070743 interleukin-23 complex 0.025 
CC GO:1990630 IRE1-RACK1-PP2A complex 0.025 
CC GO:0032991 macromolecular complex 0.028 
CC GO:0032299 ribonuclease H2 complex 0.028 
A Gene ontology categories = Biological Process (BP), Molecular Function (MF) and Cellular Component 
(CC) – Top 10 significant groups for BP, MF and CC are listed as representative figures in this table.  
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Table 5-13: Significant gene ontology process (BP, MF, CC) between 2Gy treated sensitive and 
resistant HPV-positive OPSCC cell lines  
Category  GO ID Term fdr p 
BP GO:1902578 single-organism localization 0.047 
BP GO:0051641 cellular localization 0.047 
BP GO:0070887 cellular response to chemical stimulus 0.047 
BP GO:0071702 organic substance transport 0.047 
BP GO:0006629 lipid metabolic process 0.047 
BP GO:0032870 cellular response to hormone stimulus 0.047 
BP GO:0002520 immune system development 0.047 
BP GO:0009628 response to abiotic stimulus 0.047 
BP GO:0042592 homeostatic process 0.047 
BP GO:0010243 response to organonitrogen compound 0.047 
MF GO:0008599 protein phosphatase type 1 regulator activity 0.016 
MF GO:0015485 cholesterol binding 0.026 
MF GO:0004352 glutamate dehydrogenase (NAD+) activity 0.026 
MF GO:0004353 
glutamate dehydrogenase [NAD(P)+] 
activity 0.026 
MF GO:1990825 sequence-specific mRNA binding 0.026 
MF GO:1990763 arrestin family protein binding 0.026 
MF GO:0004656 procollagen-proline 4-dioxygenase activity 0.029 
MF GO:0008381 mechanically-gated ion channel activity 0.029 
MF GO:0015137 citrate transmembrane transporter activity 0.029 
MF GO:0030628 pre-mRNA 3'-splice site binding 0.029 
CC GO:0071438 invadopodium membrane 0.040 
CC GO:0032541 cortical endoplasmic reticulum 0.040 
CC GO:0033263 CORVET complex 0.040 
CC GO:0016222 procollagen-proline 4-dioxygenase complex 0.040 
CC GO:0034667 integrin alpha3-beta1 complex 0.040 
CC GO:1990589 ATF4-CREB1 transcription factor complex 0.040 
CC GO:0043231 intracellular membrane-bounded organelle 0.045 
CC GO:0031300 intrinsic component of organelle membrane 0.045 
CC GO:0009897 external side of plasma membrane 0.045 
CC GO:0005666 DNA-directed RNA polymerase III complex 0.045 
A Gene ontology categories = Biological Process (BP), Molecular Function (MF) and Cellular Component 
(CC) – Top 10 significant groups for BP, MF and CC are listed as representative figures in this table.  
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5.4.3. Differential gene expression of all OPSCC cell lines after IR  
 
To understand the effect of IR on the whole panel of cell lines HPV-positive and HPV-
negative cell lines were grouped together and compared between untreated and 2Gy 
treated samples (Figure 5-10). After comparing all cell lines, the comparison was later 
focused on the difference in gene expression within the HPV-positive OPSCC cell lines 
(greater IR variation after the Radio-sensitivity assay).  
Differentially expressed genes were identified using DEseq2 analysis on normalized data 
(Love et al., 2014). The resultant p-values were corrected for multiple testing and false 
discovery issues using the FDR method (FDR p<0.05) (Benjamini and Hochberg, 1995). 
Data was then presented as heatmaps based on a hierarchical clustering (using average 
linkage and Pearson’s correlation as the similarity metric). Within this comparison a 
paired test approach was performed to compare untreated and treated samples. A paired 
comparison can be defined as location test to compare two sets of comparisons (untreated 
and treated). This repeated “location test” or “repeated measurements” are more robust to 
compare untreated and treated samples, because it can be paired with observations in the 
other sample. This analysis was performed to identify differences in gene expression 
between untreated and treated samples to identify possible down or up regulation of genes 
after IR.  
The heatmap indicates a significant increase in 519 genes after IR by comparing all 
OPSCC cell lines (Figure 5-10). Table 5-14 showed the top 20 significant genes out of 
the whole panel of significant genes (as representative figure). The differentially 
expressed genes contributing to the heatmap (Figure 5-10) did not include genes involved 
in DNA repair, DNA damage or stress response, which could have explained greater 
sensitivity or resistance within the panel of cell lines. This paired comparison indicated 
no clear difference between the HPV-positive and HPV negative cell lines in terms of low 
or higher expression of genes. Therefore, the investigation was focused on the paired 
comparison of HPV-positive OPSCC cell lines (untreated versus 2Gy treated samples) 
after section 5.5.1.1 (GO of all paired OPSCC cell lines), for possible significant genes 
which could explain variation in IR response (Radio-sensitivity assay) within this subset.  
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Figure 5-10: Heatmap representing differential gene expression between untreated and treated cell 
lines (paired comparison) 
Gene expression was normalised across the tested samples and colour coded (green, black, red). Black 
represents a median value, green is below the median value and red is above the median value (i.e. red = 
higher expression). After correction for multiple testing, 519 transcripts (genes) showed a significant 
difference between the two groups (FDR p<0.05). The 20 genes showing the most significant difference in 
transcript levels are listed in Table 5-14.  Untreated samples were collected at the same time as the treated 
counterpart. 
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Table 5-14: Differential gene expression of paired test of untreated versus treated cell lines 
GenesA Description ID fdr p log2FCB 
EEF1E1 
Eukaryotic Translation 
Elongation Factor 1 Epsilon 1 NM_004280_chr6 1.1E-05 0.66 
ITPRIP 
Inositol 1,4,5-Trisphosphate 
Receptor Interacting Protein NM_033397_chr10 1.7E-05 -0.59 
NDUFAF4 
NADH:Ubiquinone 
Oxidoreductase Complex 
Assembly Factor 4 NM_014165_chr6 1.7E-05 0.69 
SH3TC1 
SH3 Domain And 
Tetratricopeptide Repeats 1 NM_018986_chr4 5.0E-05 -0.72 
GNB4 G Protein Subunit Beta 4 NM_021629_chr3 6.4E-05 0.58 
PNPT1 
Polyribonucleotide 
Nucleotidyltransferase 1 NM_033109_chr2 7.1E-05 0.59 
POLR3G 
RNA Polymerase III Subunit 
G NM_006467_chr5 1.7E-05 0.83 
MTR 
5-Methyltetrahydrofolate-
Homocysteine 
Methyltransferase NM_000254_chr1 3.6E-04 0.38 
MIR3687-
1 MicroRNA 3687-1 NR_037458_chr21 3.6E-04 -0.98 
RPL22L1 Ribosomal Protein L22 Like 1 NM_001099645_chr3 3.6E-04 0.68 
GNPNAT1 
Glucosamine-Phosphate N-
Acetyltransferase 1 NM_198066_chr14 4.0E-04 0.51 
AGPAT5 
1-Acylglycerol-3-Phosphate 
O-Acyltransferase 5 NM_018361_chr8 4.0E-04 0.53 
CASD1 CAS1 Domain Containing 1 NM_022900_chr7 8.4E-04 0.52 
RPF2 
Ribosome Production Factor 2 
Homolog NM_032194_chr6 9.1E-04 0.50 
NDRG1C 
N-Myc Downstream 
Regulated 1 NM_001135242_chr8 NA -1.04 
EPHB3 EPH Receptor B3 NM_004443_chr3 9.1E-04 -0.62 
TWISTNB TWIST Neighbour NM_001002926_chr7 9.5E-04 0.51 
P3H2 Prolyl 3-Hydroxylase 2 NM_018192_chr3 9.5E-04 -0.73 
GSN Gelsolin NM_000177_chr9 1.4E-03 -0.95 
OTUD6B OTU Domain Containing 6B NM_016023_chr8 2.4E-03 0.57 
A The 20 most significant genes are listed in this table - additional GO clustering was performed to group 
genes according to their function.  
B log2FC: Fold change between the comparison of two groups of this significant presented gene (increase 
or decrease of expression) 
CNDRG1 listed in the table – chosen as gene candidate for testing mRNA sequencing data.  
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5.4.3.1.Identification of gene ontology groups of all OPSCC cell lines after IR  
 
The genes that were differentially expressed between treated and untreated samples were 
further classified according to gene ontology groups; genes involved in different BP, MF 
or CC are listed in Table 5-15 and 5-16.  
The number of significant overrepresented GO groups for the all OPSCC cell lines in 
comparison of treated (2Gy) and untreated samples (GO ORA) are presented in Table 5-
15 The numbers of significant GO groups with the adjusted p-value (FDR p<0.05) were 
as follows: 92 BP, 26 MP and 12 CC. The top 10 GO groups for BP, MF and CC are 
listed in Table 5-15  
The BP ontologies that appeared to be differentially regulated between untreated and 
treated OPSCC cell lines included a BP connected to cell cycle regulation. This BP 
specified the BP of “positive regulation of G0 to G1 transition” of the cell cycle. This 
positive regulation of the G0 to G1 transition causes the cell to return to G1 and resume 
growth and division. This significant GO might indicate, that cells even, if damaged are 
being processed through the cell cycle after initial 2Gy treatment and induction of DNA 
damage.  
MF ontologies appeared to be differentially regulated between untreated and treated 
OPSCC cell lines, included several groups connected to different phosphatase activities. 
CC ontologies showed differentially regulated processes in a total number of 12 GO 
groups (Table 5-15).  
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Table 5-15: Significant gene ontology categories between untreated/treated OPSCC cell lines  
CategoryA  GO ID Term fdr p 
BP GO:0035690 cellular response to drug 0.032 
BP GO:0035094 response to nicotine 0.032 
BP GO:0006102 isocitrate metabolic process 0.032 
BP GO:0010891 negative regulation of sequestering of triglyceride 0.032 
BP GO:0036018 cellular response to erythropoietin 0.032 
BP GO:0044268 multicellular organismal protein metabolic process 0.032 
BP GO:0070318 positive regulation of G0 to G1 transition 0.032 
BP GO:2000535 regulation of entry of bacterium into host cell 0.032 
BP GO:0021913 
regulation of transcription from RNA polymerase 
II promoter involved in ventral spinal cord 
interneuron specification 0.032 
BP GO:0034287 detection of monosaccharide stimulus 0.032 
MF GO:0004449 isocitrate dehydrogenase (NAD+) activity 0.016 
MF GO:0008240 tripeptidyl-peptidase activity 0.016 
MF GO:0008969 phosphohistidine phosphatase activity 0.016 
MF GO:0031711 bradykinin receptor binding 0.016 
MF GO:0003920 GMP reductase activity 0.016 
MF GO:0008241 peptidyl-dipeptidase activity 0.016 
MF GO:0034417 bisphosphoglycerate 3-phosphatase activity 0.016 
MF GO:0052826 inositol hexakisphosphate 2-phosphatase activity 0.016 
MF GO:0097020 COPII adaptor activity 0.016 
MF GO:0017176 
phosphatidylinositol N-
acetylglucosaminyltransferase activity 0.022 
CC GO:0043194 axon initial segment 0.040 
CC GO:0000124 SAGA complex 0.040 
CC GO:0000506 
glycosylphosphatidylinositol-N-
acetylglucosaminyltransferase (GPI-GnT) complex 0.040 
CC GO:0035253 ciliary rootlet 0.040 
CC GO:0032584 growth cone membrane 0.040 
CC GO:1902560 GMP reductase complex 0.040 
CC GO:0000145 exocyst 0.045 
CC GO:0005892 acetylcholine-gated channel complex 0.045 
CC GO:0002102 podosome 0.045 
CC GO:0034451 centriolar satellite 0.045 
A Gene ontology categories = Biological Process (BP), Molecular Function (MF) and Cellular Component 
(CC) – Top 10 significant groups for BP, MF and CC are listed as representative figures in this table.  
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5.4.4. Gene expression differences between untreated and 2Gy treated samples in 
HPV-positive cell lines  
 
After comparing the entire panel of OPSCC cell lines between untreated and treated 
samples. By grouping all OPSCC cell lines together to investigate the effect of IR, no 
obvious up- or down-regulation of gene expression was identified between the cell lines 
according to their HPV-status. Whereas comparison of HPV-positive and negative cell 
lines showed a differential gene expression, if not grouped in untreated and treated 
groups.  
Therefore, the analysis focused again on the HPV-positive cell lines where the greatest 
difference had been seen in response to IR and compared untreated and treated samples 
within this group.  
Differently expressed genes were again identified using DEseq2 analysis on normalized 
data (Love et al., 2014). The p-value was corrected the same way as described in the 
previous sub-chapters. During this comparison within the HPV-positive OPSCC cell lines 
only two significant genes were identified: JUNB and KRTN4 (Figure 5-11 and Table 5-
16).  All other genes within this comparison were not significant (FDR p>0.05).  
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Figure 5-11: Heatmap represent differential gene expression of all HPV-positive OPSCC cell lines  
Gene expression was normalised across the tested samples and colour coded (green, black, red). Black 
represents a median value, green is below the median value and red is above the median value (higher 
expression. After correction for multiple testing between sensitive and resistant groups within HPV-positive 
OPSCC, 2 genes showed a significant difference between the two groups (FDR p<0.05). These 2 genes are 
listed in Table. 5-16. All other genes within this comparison were not significant FDR p>0.05. Untreated 
samples were collected at the same time as the treated counterpart. 
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Table 5-16: Differential gene expression of paired test of HPV-positive OPSCC cell lines 
GenesA Description ID fdr p log2FC 
KRT4 Keratin 4 NM_002272_chr12 0.049 -1.02 
JUNB 
JunB Proto-Oncogene, AP-1 
Transcription Factor Subunit NM_002229_chr19 0.049 -0.83 
A only 2 genes showed a significant difference within the HPV-positive OPSCC cell lines (FDR p<0.05) 
 
 
5.4.4.1.Identification of gene ontology groups within the HPV-positive OPSCC cell 
lines after IR   
 
The number of significant overrepresented GO groups (GO ORA) for the HPV-positive 
OPSCC cell lines, comparing untreated and treated (2Gy) samples are presented in Table 
5-17. The numbers of significant GO groups are presented with the adjusted p-value (FDR 
p<0.05) as following for the untreated comparison: 121 BP, 48 MP and 33 CC. The top 
10 significant GO groups of BP, MF and CC were listed as representative groups (Table 
5-17).  
The BP ontologies that appeared to be differentially regulated between untreated and 
treated samples within the HPV-positive OPSCC cell lines, included several groups 
relating to cell death and regulation of apoptosis (GO connection between JUNB and p53 
– both involved in cell death and apoptosis).  
The MF ontologies showed a differentially regulated process, including fibronectin 
binding (connection tissue matrices) and activity of receptor signalling of protein tyrosine 
kinase inhibitor, which stops and prevents or reduces the activity of a receptor signalling 
protein tyrosine kinase.   
The CC ontologies showed significant differentially regulated processes in membrane 
enclosed lumen, intracellular organelle lumen and nucleolar ribonuclease P complex.  
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Table 5-17: Significant gene ontology categories between untreated/treated HPV-positive OPSCC 
cell lines 
CategoryA  GO ID Term fdr p 
BP GO:0010941 regulation of cell death 0.039 
BP GO:0042981 regulation of apoptotic process 0.039 
BP GO:1901615 organic hydroxy compound metabolic process 0.039 
BP GO:0051047 positive regulation of secretion 0.039 
BP GO:0042692 muscle cell differentiation 0.039 
BP GO:0010976 
positive regulation of neuron projection 
development 0.039 
BP GO:0008202 steroid metabolic process 0.039 
BP GO:0051216 cartilage development 0.039 
BP GO:0055002 striated muscle cell development 0.039 
BP GO:0009062 fatty acid catabolic process 0.039 
MF GO:0001968 fibronectin binding 0.016 
MF GO:0031432 titin binding 0.016 
MF GO:0008111 alpha-methylacyl-CoA racemase activity 0.016 
MF GO:0030294 
receptor signaling protein tyrosine kinase 
inhibitor activity 0.016 
MF GO:0033791 
3alpha,7alpha,12alpha-trihydroxy-5beta-
cholestanoyl-CoA 24-hydroxylase activity 0.016 
MF GO:0034417 bisphosphoglycerate 3-phosphatase activity 0.016 
MF GO:0052826 inositol hexakisphosphate 2-phosphatase activity 0.016 
MF GO:0097020 COPII adaptor activity 0.016 
MF GO:0001105 
RNA polymerase II transcription coactivator 
activity 0.021 
MF GO:0016402 pristanoyl-CoA oxidase activity 0.021 
CC GO:0031974 membrane-enclosed lumen 0.040 
CC GO:0070013 intracellular organelle lumen 0.040 
CC GO:0030016 myofibril 0.040 
CC GO:0044438 microbody part 0.040 
CC GO:0005782 peroxisomal matrix 0.040 
CC GO:0005655 nucleolar ribonuclease P complex 0.040 
CC GO:0030677 ribonuclease P complex 0.040 
CC GO:0030891 VCB complex 0.040 
CC GO:0046581 intercellular canaliculus 0.040 
CC GO:0070937 CRD-mediated mRNA stability complex 0.040 
A Gene ontology categories = Biological Process (BP), Molecular Function (MF) and Cellular Component 
(CC) – Top 10 significant groups for BP, MF and CC are listed as representative figures in this table.  
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5.5. Identification of gene candidates for confirming mRNA sequencing findings on 
molecular level   
 
Gene candidates for were identified by comparing the most significant genes after the 
paired comparisons of all OPSCC cell lines and within the HPV-positive cell lines. Those 
two comparisons were used to identify gene products for analysis at the protein level to 
test the effect of IR. The focus was put on the HPV-positive cell lines as these cell lines 
showed the greatest variation in response after the Radio-sensitivity assay. The cell lines 
were then grouped for Western blot experiments according to the previously identified 
groups of cell lines that were sensitive or resistant to IR.  
Reasons for choosing gene candidates:  
 Identifying differences in genes involved in cell death, apoptosis, DNA repair or 
DNA damage at molecular level within HPV-positive cell lines  
 Confirming fold-change differences of gene expression within the HPV-positive 
cell lines at molecular level after IR   
Process of identification of gene candidates: 
To start the process of identifying gene candidates, a broad identification of genes was 
done on the entire OPSCC cell lines panel (including the HPV-negative cell lines). These 
genes were listed in order of significance and limited to 20 representative genes listed in 
the individual sections above.  
The next step included, listing the significant genes of HPV-positive cell lines (untreated 
vs treated), together with their BP processes.  
The top significant genes of the HPV-positive cell line comparison and all OPSCC cell 
line comparison were then analysed according to their biological process (Gene 
Ontology), to identify genes involved in cell death, apoptosis, DNA repair or DNA 
damage to narrow down the number of genes candidates: Out of the HPV-positive cell 
line comparison and investigating the BP of all cell lines, JUNB and NDRG1 were chosen 
as candidates.  Both genes are connected to cell death, apoptosis or DNA damage 
response.  
The last step included a check of the number of reads of the gene candidates on Genview, 
to confirm an increase or decrease (fold-change) of reads after IR. This was seen as an 
exploratory mechanism (using RPKM reads).  
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At the end of this process, two genes, JUNB and NDRG1, were selected for confirmation 
of expression status (Figure 5-12).  
 
 
Figure 5-12: Process for identification of gene candidates for confirming status on molecular level  
 
5.5.1. JUNB 
 
Four out of five HPV-positive cell line showed an increase in fold-change for JUNB after 
IR (Figure 5-13). The Biological Process ontology showed that JUNB is involved in 
regulation of cell death (apoptosis), response to radiation and regulation of cell cycle.  
5.5.2. NDRG1 
 
NDRG-1 showed the greatest fold-change (2.6x) between untreated and treated (IR) for 
CU-OP-2 within the HPV-positive cell lines. The Biological Process ontology showed 
that NDRG1 is connected to DNA damage response (Signal transduction by p53 class 
mediator) and is involved in regulation of apoptotic process (Figure 5-13).  
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Figure 5-13: Gene expression of JUNB and NDRG1 in untreated and treated (2Gy) HPV-positive cell 
lines 
Histograms were generated using Genview software, and show number of reads, expressed as RPKM. The 
histograms show (A) increased expression of JunB in four of the five cell lines following IR; and (B) 
increased expression of NDRG1 in three of five cell lines following IR, with the greatest induction in CU-
OP-2. 
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5.5.3. Expression of JUNB and NDRG1  
 
Cells respond to IR, an important physiological stress factor, by activating multiple 
signalling pathways (Braunstein et al., 2009) including induction of DNA repair or 
apoptosis. Considerable variation in response to IR was seen within the panel of HPV-
positive cell lines (Radio-sensitivity assay). During the mRNA sequencing analysis, this 
variation was investigated further via sensitivity comparison and pair wise comparison 
within the HPV-positive cell lines. Different expression of numerous genes was detected 
following exposure to IR. However, only two genes fulfilled some or all of the previous 
mentioned criteria for further investigation. The protein levels of these two candidates, 
JUNB and NDRG1, were investigated (Figure 5-14 to Figure 5-17) and compared to the 
corresponding mRNA sequence data. Cell lysate was collected from untreated sample 
and treated sample after 24 hours (2Gy and additionally 6Gy). The same treatment doses 
and time point were chosen to be consistent with previous Western blots. Additionally, 
24 hours was the same time point chosen for the mRNA sequencing assay. This time to 
be more consistent with the order of the cell lines used in mRNA sequencing, cell lines 
were ordered as following: UMSCC-47, UPCI-SCC-90 and CU-OP-20 (one gel) and CU-
OP-2 and CU-OP-3 (second gel).  Cell lines were not ordered according to sensitivity as 
in previous Western blotting assays (example seen in Chapter 4, Figure 4-5). 
JUNB expression decreased after IR treatment for most of the cell lines (3 out of 5), 
whereas NDRG1 showed an increase in band intensity after 2Gy and 6Gy treatment (3 
out of 5) (Figure 5-14 to Figure 5-17). Both resistant cell lines CU-OP-2 and CU-OP-3 
showed an increase of NDRG1 after IR. The mRNA sequencing data did not directly 
correlate with the protein expression observed after western blot.  
  
Chapter 5                            Investigation of gene expression in OPSCC cell lines using mRNA sequencing 
 
200 
 
 
Figure 5-14: Western blot results for JUNB (sensitive cell lines to IR)  
(A) Protein bands of JUNB for UMSCC-47, UPCI-SCC-90 and CU-OP-20. Cell lines were ordered from 
untreated to 2Gy and 6Gy IR treated samples (collected after 24h incubation after IR treatment). HEKn 
10Gy 24h was added as positive control. Membrane was stripped and re-probed with ß-actin antibody. ß-
actin (1-2min exposure) JUNB (30-35min exposure) bands are seen in all three cell lines.  
(B) Quantification of western blot intensities of JUNB: The band intensity of the western blotting bands as 
quantified in relation to ß-actin level using Image Studio Lite. 
  
Chapter 5                            Investigation of gene expression in OPSCC cell lines using mRNA sequencing 
 
201 
 
 
Figure 5-15: Western blot results for JUNB (resistant cell lines to IR)  
(A) Protein bands of JUNB for CU-OP-2 and CU-OP-3. Cell lines were ordered from untreated to 2Gy and 
6Gy IR treated samples (collected after 24h incubation after IR treatment). HEKn 10Gy 24h was added as 
positive control. Membrane was stripped and re-probed with ß-actin antibody. ß-actin (1-2min exposure) 
JUNB (30-35min exposure) bands are seen in all three cell lines.  
(B) Quantification of western blot intensities of JUNB: The band intensity of the western blotting bands as 
quantified in relation to ß-actin level using Image Studio Lite. 
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Figure 5-16: Western blot results for NDRG1 (resistant cell lines to IR)  
(A) Protein bands of NDRG1 for UMSCC-47, UPCI-SCC-90 and CU-OP-20. Cell lines were ordered from 
untreated to 2Gy and 6Gy IR treated samples (collected after 24h incubation after IR treatment). HEKn 
10Gy 24h was added as positive control. Membrane was stripped and re-probed with ß-actin antibody. ß-
actin (1-2min exposure) NDRG1 (1-15min exposure) bands are seen in all three cell lines.  
(B) Quantification of western blot intensities of NDRG1: The band intensity of the western blotting bands 
as quantified in relation to ß-actin level using Image Studio Lite. 
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Figure 5-17: Western blot results for NDRG1 (resistant cell lines to IR)  
(A) Protein bands of NDRG1 for CU-OP-2 and CU-OP-3. Cell lines were ordered from untreated to 2Gy 
and 6Gy IR treated samples (collected after 24h incubation after IR treatment). HEKn 10Gy 24h was added 
as positive control. Membrane was stripped and re-probed with ß-actin antibody. ß-actin (1-2min exposure) 
NDRG1 (1-15min exposure) bands are seen in all three cell lines.  
(B) Quantification of western blot intensities of NDRG1: The band intensity of the western blotting bands 
as quantified in relation to ß-actin level using Image Studio Lite. 
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5.6. Genetic pathways of interest  
 
It was hypothesized that differences in DNA repair mechanism might explain the 
differences in IR sensitivity within the HPV-positive cell lines. The expression of genes 
in main DNA repair/damage pathways were investigated using GenView, a GO directed 
analysis.  
These comparisons were performed using “Subread featureCounts” Version 1.5.1 (Liao 
et al., 2014) a software package for assigning sequence reads to genomic features. Read 
summarization (counting) was generated for paired end read fragments. It was 
summarized at exon level and then grouped at transcript level. To provide stringent and 
robust data, reads overlapping more than one feature were excluded from the count 
summary, because any single fragment must originate from only one of the target genes 
but the identity of the true target gene cannot be confidently determined (as per the 
authors’ recommendations (Liao et al., 2014)). Heatmaps were then obtained using the 
Genview package. The heatmap outputs for Double-Strand Break Repair via Homologous 
Recombination (DSBR-HR), Base Excision Repair (BER) and Double-Strand Break 
Repair via Non-Homologous End Joining (DSBR-NHEJ) ontologies are shown in Figure 
5-18, Figure 5-19 and Figure 5-20. 
The heatmaps for genes involved in DSBR-HR, BER and DSBR-NHEJ showed no 
obvious differences between HPV-positive versus HPV-negative cell lines, either with 
untreated or irradiated cells (Figure 5-18, Figure 5-19 and Figure 5-20).  
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Figure 5-18: Differential expression of genes involved in the DSBR-HR pathway between HPV-
positive and HPV-negative OPSCC cell lines  
Cell lines were listed from left to right, as untreated (HPV-positive and HPV-negative) and treated 2Gy 24h 
(HPV-positive and HPV-negative). Gene expression was normalised across the tested samples and colour 
coded (green, black, red). Black represents a median value, green is below the median value and red is 
above the median value (higher expression). The heatmap presented is based on the analysis of 135 genes.  
Untreated samples were collected at the same time as the treated counterpart. 
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Figure 5-19:  Differential expression of genes involved in the BER pathway between HPV-positive 
and HPV-negative OPSCC cell lines  
Cell lines were listed from left to right, as untreated (HPV-positive and HPV-negative) and treated 2Gy 24h 
(HPV-positive and HPV-negative). Gene expression was normalised across the tested samples and colour 
coded (green, black, red). Black represents a median value, green is below the median value and red is 
above the median value (higher expression). Based on the analysis of 69 genes. Untreated samples were 
collected at the same time as the treated counterpart. 
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Figure 5-20:  Differential gene expression DSBR-NHEJ pathway between HPV-positive and HPV-
negative OPSCC cell lines 
Cell lines were listed from left to right, as untreated (HPV-positive and HPV-negative) and treated 2Gy 24h 
(HPV-positive and HPV-negative). Gene expression was normalised across the tested samples and colour 
coded (green, black, red). Black represents a median value, green is below the median value and red is 
above the median value (higher expression). Based on the analysis of 116 genes. Untreated samples were 
collected at the same time as the treated counterpart. 
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5.7. Relative expression of genes of interest in terms of IR sensitivity  
 
Based on the hypotheses predicting roles for p53, p21 and p16 in determining resistance 
to IR, an exploratory gene expression analysis was carried out using the mRNA 
sequencing data. These genes are presented (showing fold-changes after IR) in histograms 
using RPKM (multiple reads) in Genview (Figure 5-21).  
 
5.7.1. TP53 transcript levels 
 
TP53 plays a key-role in DNA repair and apoptosis. The Western blotting analysis 
performed earlier (Chapter 4) showed no obvious differences in p53 expression between 
the HPV-positive cell lines and HPV-negative cell lines after IR treatment (2Gy and 6Gy). 
Transcript levels of TP53 were investigated to shed further light on regulation of p53 
activity in OPSCC cell lines. 
After 2Gy treatment there was no obvious overall increase or decrease in p53 transcript 
level between the untreated versus treated samples. However, at the individual cell line 
level, CU-OP-2 showed an increase in fold-change after 2Gy treatment. UMSCC-47, CU-
OP-3 and CU-OP-20 also showed a minor increase in number of reads of p53 after 2Gy 
treatment whereas UPCI-SCC-90 showed a decrease of p53 transcription after 2Gy 
treatment (low fold-change) (Figure 5-21).   
Low transcription of p53 was shown in UMSCC-4, UMSCC-19 and UMSCC-6, where 
UMSCC-4 and UMSCC-19 had a mutated allele of p53 compared to the HPV-positive 
cell lines (Figure 5-21).  
 
5.7.2. CDKN1A (p21) transcript levels 
 
Between the paired comparison of untreated samples versus 2Gy treated samples no 
obvious differences in fold-changes were identified. However, all OPSCC cell lines 
showed a transcription of p21 in untreated and treated samples. A greater fold-change 
was seen in UMSCC-19 (FC: 1.6) and UMSCC-74a (FC: 1.9) after 2Gy IR treatment. 
Minor increases were detected on transcription level in all other cell lines (minor fold-
changes) (Figure 5-21).  
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5.7.3. CDKN2A (p16) transcript levels 
 
P16 a surrogate marker for HPV-16 infection (Schache et al., 2011a), was detected in all 
HPV-positive OPSCC cell lines. IR treatment had no obvious impact on fold-changes on 
p16 after IR treatment. Number of reads for p16 were measured as well in two HPV-
negative cell lines (UMSCC-19 and CU-OP-17) with a low number of transcription (no 
obvious fold-change). Detection of p16 in HPV-negative cancers is possible and therefore 
p16 expression is not a complete guarantee of HPV infection (Evans et al., 2013, Pirotte, 
2017) (Figure 5-21).    
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Figure 5-21: TP53, CDKN1A (p21) and CDKN2A (p16) transcript levels for HPV-positive and HPV-
negative OPSCC cell lines   
(A) HPV-positive (B) HPV-negative). HPV-positive paired comparison between untreated and treated groups showed 
no significant differences of TP53, p21 and p16.  Histograms generated using multiple counts (RPKM) on Genview.  
For TP53, the greatest fold change was detected with CU-OP-2, with a 2.5-fold increase compared to its untreated 
sample. The remaining HPV-positive cell lines showed a fold change between 0.79 (UPCI-SCC-90) and 1.3 (UMSCC-
47). The greatest fold change in the HPV-negative OPSCC was seen in UMSCC-4 (low read number) with 1.7 FC. For 
p21, the greatest fold change was seen in the HPV-positive OPSCC cell line CU-OP-3, with a 2-fold increase, and in 
the HPV-negative OPSCC cell line UMSCC-74a with a fold change of 3. For p16, no obvious changes were seen in in 
the HPV-positive cell lines. Two HPV-negative cell lines showed reads for p16 (UMSCC-19 and CU-OP-17). P16 
levels for UMSCC-19have been reported in a previous thesis (not published in any study by the original source).  
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5.8. Summary of main findings 
 
 The main findings of the mRNA sequencing analysis were:  
 Confirmed that all HPV-positive OPSCC cell lines had active expression of HPV 
encoded oncogenes. 
 Showed that the expression of the HPV encoded oncogenes did not change after 
IR.  
 Identified the HPV variants present in UPCI-SCC-90, UMSCC-47, CU-OP-2 and 
CU-OP-3 (consistent with previous studies). Identified the HPV-16 variant in CU-
OP-20 as Asian-American.  
 Showed that CU-OP-20 has HPV DNA integrated at multiple sites.  
 Confirmed the main HPV-integration sites, as reported in previous studies, for 
UMSCC-47, UPCI-SCC-90, CU-OP-2 and CU-OP-3.  
 Identified an increase in integration sites after IR for all HPV-positive OPSCC 
cell lines.   
 Confirmed the p53 status for the established cell lines and for CU-OP-2 and CU-
OP-3. CU-OP-20 was classified as wild-type p53. CU-OP-17 showed a likely 
pathogenic SNP at the UTR 5’ region (non-coding) but was wild-type p53 in the 
coding region.  
 Clustering of cell lines according to their IR sensitivity showed variation in 
expression levels of numerous genes. However, these genes were not obviously 
associated with DNA repair, DNA damage or apoptosis.  
 Clustering of all OPSCC cell lines showed a general difference between HPV-
positive and HPV-negative cell lines (untreated or 2Gy treated comparison). 
 Different GO processes were identified between the comparisons, these were 
generally not directly related to DNA repair or DNA damage, except for 
identification of JUNB.  
 Investigations of expression levels of individual genes showed:  
o More abundant transcripts of TP53 in HPV-positive cell lines than in 
HPV-negative lines. Consistent transcription of p21 is observed 
throughout the HPV-positive cell lines.  
o CDKN2A (p16) expression was confirmed for all HPV-positive cell lines. 
Two HPV-negative cell lines showed transcription of p16. 
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o In the majority of HPV-positive cell lines, JUNB showed increased 
expression after IR. 
o NDRG1 showed increased expression in 3/5 HPV-positive cell lines.  
  
5.9. Discussion  
 
5.9.1. Confirmation of HPV gene expression 
  
Investigations of HPV gene expression confirmed active expression of HPV genes in all 
HPV-positive OPSCC cell lines in the current study. The level of HPV gene expression 
did not change with a great fold-change in the majority of HPV-positive OPSCC cell lines 
(4 out of 5) after IR treatment (2Gy). There was a similar pattern of HPV gene expression 
before and after treatment of cell lines, with different strength of expression of HPV 
ORF’s for individual cell lines. However, CU-OP-20 was the only cell line that showed 
an obvious change in HPV gene expression, with an approximately 50% reduction in 
transcripts following IR for E6, E7, E2, E5 and E4. CU-OP-20 was also the only HPV-
positive cell line, which did not show a main integration site for HPV-16. Down-
regulation of certain HPV ORF’s after IR treatment could be a sign of an non or 
incompletely (episomal) integrated virus.  
HPV gene expression assessed by mRNA level, HPV DNA typing and p16 status are 
factors used to define an HPV-positive tumour (Schache et al., 2011b), and CU-OP-20 
fulfils this definition. Splice sites were also investigated in untreated and 2Gy treated 
samples. Patterns of splicing were previously reported (Pirotte, 2017) for several of the 
cell lines, and the current data are consistent with that report. Splice sites after 2Gy 
treatment showed a similar pattern compared to the untreated samples. There was no 
increase of E6*I or E6*II transcripts, but an increase of minor splicing sites at E2, E5 and 
E1^E4 in the CU-OP cell lines. The role of E6*I and E6*II and other E6 isoforms is 
directly connected to cancer development. The presence of E2 could be connected to 
active splicing within the CU-OP cell lines (CU-OP-3 and CU-OP-20), as E2 is an mRNA 
binding protein which regulates E6 splicing (Olmedo-Nieva et al., 2018). Expression of 
E6*I and E6*II confirmed the classification of HPV-driven tumours, including the novel 
cell lines of CU-OP-2, CU-OP-3 and CU-OP-20.  
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5.9.2. Fusion transcripts  
 
The sites of HPV-16 integration were assessed and confirmed for UMSCC-47, UPCI-
SCC-90, CU-OP-2 and CU-OP-3 (Pirotte, 2017). No main integration site was seen in 
CU-OP-20. The location of integration sites was determined, as it was previously reported 
that integration of HPV into the host genome can result in insertional mutagenesis and 
loss of function of tumour suppressor genes (Schmitz et al., 2012). The proportion of fully 
integrated HPV virus in oropharyngeal cancer is around 43% (Olthof et al., 2014), 
whereas 57% of HPV-positive samples showed extrachromosomal or mixed integration 
(Vojtechova et al., 2016). Interestingly the number of reads of mapped integration 
between the human genome and the HPV-16 genome decreased, even if the chromosomal 
sites are increasing, in UMSCC-47 and UPCI-SCC-90 (sensitive to IR). CU-OP-2 and 
CU-OP-3 showed an increase of mapped reads between untreated and treated samples. In 
CU-OP-20, HPV integration only showed a limited number of reads (mostly a single read 
per site) and showed an increase of mapped reads between HPV-16 and hg19. This is of 
interest, as CU-OP-20 is a radio-sensitive cell line. The greater variation in response to 
IR is seen as well within the integration sites (mRNA sequencing) of the HPV-positive 
cell lines, as two cell lines showed a decrease of reads compared to the remaining cell 
lines showing an increase of reads.  
The main integration sites for HPV were not affected by IR. However, the number of 
integration sites increased (number of reads) in the majority of the OPSCC cell lines. 
Initial integration is more likely to occur in cells harbouring E1 and E2 replication 
proteins (episomal) (McBride and Warburton, 2017). Expression of E1 and E2 is seen in 
the majority of the cell lines included in this study. This could lead to increase of 
integration sites after IR, as HPV DNA hijacks the host DNA damage response to 
replicate its own DNA (McBride and Warburton, 2017). The increase of integration sites 
(excluding the number of reads) can be associated with the induced double strand breaks 
in the human genome. Breaks in the host DNA and the circular viral episome must occur 
for integration. Studies on oncogenic viruses have shown that integration is increased by 
the induction of DNA double strand breaks. These DSB might be enabled in a higher 
frequency and contribute to carcinogenesis (Williams et al., 2011).  Studies in hepatitis B 
(HBV) have shown that integration frequency increases with DNA damage, and a similar 
mechanism could operate for HPV in the current study (Dandri et al., 2002). According 
to a study on integration of HPV in relation to patient prognosis, no statistically significant 
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difference was found in patient survival between those with HPV-positive integrated and 
those with extrachromosomal (episomal)/mixed forms of the virus (Vojtechova et al., 
2016).  
In general, HPV-positive patients have a better prognosis in survival compared to HPV-
negative patients in Wales,  however, the role of viral integration sites after IR was not 
investigated (Evans et al., 2013). Furthermore, during additional integration or integration 
of HPV into the human genome, epigenetic changes (DNA methylation) might occur, 
influencing whether there is active or silent integration (McBride and Warburton, 2017). 
Therefore, additional experiments have to be performed to determine the functionality of 
the new integration sites (methylation status) and confirming new integration sites e.g. 
using PCR as an additional control to mRNA sequencing results. 
 
5.9.3. Confirming p53 status  
 
The p53 status of the cell lines was also investigated using the mRNA sequence data. The 
wild-type status of the established cell lines UMSCC-47, UPCI-SCC-90, UMSCC-6 and 
UMSCC-74a was confirmed (Bradford et al., 2003, Ferris et al., 2005).  UMSCC-4 and 
UMSCC-19 were confirmed to contain mutated p53 (Mandic et al., 2005, Somers et al., 
1992). This p53 status was confirmed within this study as well. Additionally, the status 
of p53 for CU-OP-2 and CU-OP-3 was confirmed as consistent with a previous report 
(Pirotte, 2017). No mutation was found for CU-OP-20. In CU-OP-17 a SNP was 
identified in the UTR 5’prime region, but no mutations were identified. Therefore, CU-
OP-17 can be considered as wild-type p53.  
The majority of HPV-positive head and neck cancers in which there is degradation of p53 
by HPV E6,  have wild-type p53, as the selective pressure for p53 mutation is low in these 
tumours (Stransky et al., 2011). Conversely, mutations of p53 are mainly found in HPV-
negative tumours, which are associated with shorter survival times and resistance to 
chemotherapy and radiotherapy (Evans et al., 2013).  
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5.9.4. GO analysis of OPSCC cell lines and investigation of differentially expressed 
DNA repair genes (including sensitivity analysis and effect of IR)  
 
Analysis of transcription levels of significantly expressed genes, revealed a clear 
difference between HPV-positive and HPV-negative OPSCC cell lines, within the 
untreated and treated comparisons. Furthermore, GO analysis for the basic comparison of 
HPV-positive and HPV-negative OPSCC cell lines revealed various differentially 
regulated biological processes, including regulation of signalling or cell communication, 
which could play a role in how cell communicate differentially in response to DNA 
damage. Directly connected GO categories to DNA damage, DNA repair or cell cycle 
regulation (arrest) were not significantly overrepresented.  
The GO analysis (after IR – paired tests) comparing the response to IR of HPV-positive 
sensitive and resistant cell lines, revealed differences in levels of transcripts ascribed to 
several ontologies. The only BP identified was the “homeostatic process”, which is an 
important process in an organism to maintain a stable environment and plays a key role 
in cell proliferation and growth or involvement in regulatory functions of apoptosis in 
head and neck cancer (Ressnerova et al., 2016).   
While comparing the GO analysis (untreated versus IR treated) in a paired comparison 
manner for all OPSCC cell lines the BP “positive regulation of G0 to G1 transition” was 
identified, which modulates the transition from the G0 to the G1 phase of the cell cycle.  
This could be connected to cell cycle arrest after IR treatment, as observed in Chapter 4.   
 
Due to the fact that no DNA repair or DNA damage pathways were identified in the paired 
analysis including all OPSCC cell lines after IR, the focus was put on the HPV-positive 
cell lines. This was done because these lines showed the greatest variation in sensitivity 
in the radio-sensitivity assay. One of the goals of this chapter was to identify a gene, a 
pathway or a process explaining the variation in sensitivity to IR within the HPV-positive 
cell lines. By comparing the HPV-positive cell lines with each other before and after 
treatment, and including the genes identified with a greater fold-change and specific 
function, two genes were identified (JUNB and NDRG1).  
JUNB is involved in regulation of cell death, apoptotic processes and response to 
radiation. It is known as a cell proliferation inhibitor, a senescence inducer, a tumour 
suppressor and is involved in different phases of the cell cycle. It not only has cell-
division inhibiting but also cell-division promoting activities, depending on the cell cycle 
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stage (Piechaczyk and Farras, 2008). Another study reported normal expression of p53 
and p21 in hepatocytes lacking JUNB, but both proteins were significantly elevated in 
Jun deficient fibroblasts (Hess et al., 2004). However, the protein levels of p53, p21 and 
JUNB observed in the current study do not support this direct association. Alternatively, 
JUNB be might be associated with differences in sensitivity due to its characteristics as a 
cell division inhibitor and senescence inducer.  
NDRG1 has a connection to DNA damaging signalling (in connection with p53). NDRG1 
is regulated by Myc and is induced under certain stress and pathological conditions. 
Furthermore, the encoded protein is important for p53-mediated apoptosis (Zhang et al., 
2008).  
 
During the paired comparisons no processes were identified in untreated or treated 
samples with a direct connection to DNA repair or DNA damage response pathways 
within the HPV-positive cell lines (sensitive versus resistant to IR). This was confirmed 
by the automatic generated heatmaps on Genview for BER, DSBR-HR and DSBR-NHEJ 
with no substantial differences between HPV-positive and HPV-negative OPSCC cell 
lines (untreated versus treated). However, such pathways have been previously reported 
in HPV-positive tumours in a larger dataset with a wider range of head and neck cancer 
cell lines (Zhang et al., 2016). This was not confirmed by the GO analysis in the current 
study, and is consistent with another study in our research group (Pirotte, 2017). These 
findings appear to contradict the reported postulated deficiencies in DSBR association 
with HPV-positive HNSCC cell lines (Kimple et al., 2013, Rieckmann et al., 2013).  
 
5.9.5. Expression of genes of interest  
 
Relative expression of several specific genes of interest were assessed, including p53 
(TP53), p21 (CDKN1A), p16 (CDKN2A). None of these genes appeared to be 
consistently up or down regulated in response to IR. 
The p53 protein is a critical tumour suppressor, and is held in check in unstressed cells 
by Mdm2 (E3 ubiquitin ligase), which binds to p53 and targets it for proteasomal 
degradation. In response to stimuli (e.g. stress, induction of DNA damage), inhibition is 
relieved and p53 target genes are trans-activated to cause e.g. apoptosis or cell cycle arrest 
(Beckerman and Prives, 2010).   TP53 transcript levels were relatively abundant in all 
HPV-positive cell lines, and were present at equivalent levels in two of five HPV-negative 
cell lines (present in UMSCC-74a and CU-OP-17). Studies have shown that 
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overexpression of Myc and/or HPV E7 resulted in increased transcription of p53 in cell 
lines (Liu et al., 2007, Strickland and Vande Pol, 2016). Limited transcription of p53 in 
HPV-negative cell lines (except UMSCC-6) might be associated with wild-type or 
mutation status of p53, as a study has shown that mutated p53 could not trans-activate 
transcription from the p53 promotor (Deffie et al., 1993). This suggests that residual p53 
activity in HPV-positive cell lines, could stimulate p53 transcription in the co-presence 
of p21 transcription. This process, would not be present in HPV-negative cell lines 
harbouring p53 mutations.  
 
Transcription of CDKN1 (p21) is known to be directly regulated by p53 (Riley et al., 
2008). However, p53-independent transcription of p21 is also possible (Galanos et al., 
2016). Transcripts of p21 were present in all HPV-positive cell lines (untreated and 
treated). Less p21 transcription is seen in the majority of the HPV-negative cell lines. 
Functioning p53 could be present in UPCI-SCC-90 due the observed increase of 
(CDKN1) p21 transcription after IR. A similar pattern was seen for UMSCC-19 and 
UMSCC-74 after IR for p21 with fold change increase of 1.6 and 1.9, respectively.  
 
The p16 (CDKN2A) gene is a tumour suppressor gene and is involved in the p16 – cyclin 
dependent kinase (CDK) – retinoblastoma (pRB) pathway of the cell cycle (Ai et al., 
2003). It is known as a negative regulator of the cell cycle. The p16 gene encodes an 
inhibitor of CDK4 and CDK6, which regulates phosphorylation of pRB and the G1 to S 
phase transition. (Ai et al., 2003). Therefore, over-expression of p16 is directly connected 
to HPV E7 protein following down-regulation of pRB, through p16 connection in the 
pRB pathway. HPV DNA testing and p16 IHC are used as diagnostic tools to identify 
HPV driven tumours (Schache et al., 2011b). High levels of p16 were therefore expected 
in the panel of HPV-positive tumours. The p16 expression was confirmed through the 
provided patient data for the obtained biopsies and through CDKN2 (p16) expression 
after mRNA sequencing. The p16 IHC status is a known marker for the majority of HPV-
positive tumours (Schache et al., 2011b).  
However, transcription of p16 in the HPV-negative cell lines of UMSCC-19 and CU-OP-
17 was found as well. For CU-OP-17 this was consistent with the p16 IHC status of the 
original tumour. This confirms previous reports of 14-17% p16 positive cases in HPV-
negative tumours. A previous study of 187 OPSCC cases positive for p16 has identified 
that 26 cases were HPV-negative (14%) (Lewis et al., 2010). This was confirmed in 
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another study with a similar pattern where 17% of cases were identified as p16 positive 
and HPV-negative (Rietbergen et al., 2014).  
 
Another possibility for no obvious up- or down-regulation of genes after IR treatment 
could be the heterogeneous population of cells within the cell lines used in the current 
study. The included CU-OP cell lines were used at as early as possible passage numbers, 
which should mimic the heterogeneous characteristics of the original tumour. Within the 
heterogeneous population, single sub-clones could be more or less sensitive to IR, which 
might lead to the data obtained after mRNA sequencing. To identify a possible different 
response of sub-clones to IR, the heterogeneous cell culture has to be sorted into single 
cells first. A single cell RNA sequencing on the single cells/sub-clones would identify 
differences in molecular mechanism, gene expression and mutation, as suggested by 
literature (Fan et al., 2018, Wang et al., 2018). The individual profile of single cell RNA 
sequencing could then be compared to the heterogeneous mRNA sequencing profile to 
identify similarities with a specific sub-clones. Furthermore, to identify outgrowth of a 
specific sub-clone, mRNA sequencing could be performed after each passage in parallel 
to single cell isolation.   
 
Furthermore, a lack of DNA repair changes on mRNA level could be correlated to the 
lack of measurement of protein control level in activity. Indication of functioning or 
active protein could be identified through there phosphorylation status, such as p-p53 for 
p53), Identification of active protein level could lead to an active process in terms of DNA 
repair in gene expression. Parallel measurement of protein activity could have been used 
to correlate up- or downregulation of genes (e.g. DNA repair) to its functionality.   
 
In summary, these data did not show a clear induction or down-regulation of genes after 
IR, connected to DNA repair or DNA damage. Activity in up- or downregulation of this 
genes (e.g. protein level in activity) need to be confirmed for the final conclusion, if these 
two mechanisms can explain the variation in radio-sensitivity within the HPV-positive 
cell lines. However, the data do show a response to IR across a wide range of genes, 
showing a clear effect of irradiation on the cell lines.   
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Strengths and weaknesses  
 
The use of mRNA sequencing is a very robust and sensitive technique, which provided 
in depth analysis of the OPSCC cell lines panel. It was the first analysis by mRNA 
sequencing of the cell lines in the current study, including the novel cell lines CU-OP-20 
and CU-OP-17, and assisted in their characterisation. Furthermore, it provided a deeper 
assessment of genes involved in different repair pathways.  
A strength of the study is the sample size of 20 samples (10 cell lines in total), which 
included untreated samples and 2Gy IR treated samples. The main weakness, was that the 
mRNA sequencing data is based on one single sample for each cell line and condition 
(untreated and treated), which limits the statistical power. The study was limited to one 
replicate per sample by considering the size of the study cohort (number of extractions, 
cost and time factor). Additionally, the comparison between untreated to its treated 
counterpart was considered as sufficient during design of the experiment. To confirm the 
findings in this study, the experiment should be set-up and repeated a second time, within 
a larger data set, data points (treatment dose and time points) and replicates. 
Furthermore, a direct comparison of the cell line model to the original tumours is difficult 
to make, because it is unclear how close gene expression in cell lines represents gene 
expression pattern in the original tumours. Hence, the original tumours consist of the 
entire heterozygous cell composition, whereas in cell lines model, a limited number of 
clones were able to grow on a plastic cell culture plate. However, it is important to point 
out, that growth conditions were standardized (e.g. identical FBS concentration and 
culture condition) and the differences observed on transcription (mRNA), molecular 
biology, mutation profile and HPV status reflected the characteristics of the original 
tumours.  
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5.10. Conclusion  
 
The novel cell line CU-OP-20 derived in this study, showed all typical characteristics of 
a HPV driven tumour (expression of HPV genes, p53-wild-type, p16 positive and several 
integration sites). However, CU-OP-17 was defined as a HPV-negative OPSCC cell lines, 
with an unusual expression of p16 positivity (reflecting 14-17% of OPSCC).  
IR seemed to have an effect on the number of HPV integration sites (fusion transcripts).  
JUNB and NDRG1 were identified as genes, involved in cell death regulation and DNA 
damage signalling (connection to p53), which could play a part in the variation in 
sensitivity to IR within the HPV-positive cell lines.  
The main conclusion is that there is no evidence for differential induction of DNA repair 
or DNA damage pathways in association with HPV-positive compared to HPV negative 
lines, or between radiation sensitive and resistant lines, which might suggest other factors 
involved in the different survival rate of HPV-positive and HPV-negative OPSCC cell 
lines. However, DNA repair and DNA damage cannot be excluded completely, as 
activation of these genes would need to get confirmed. This could be done via a protein 
based assay in controlling protein level changes in activity. Possible alternative factors 
might be involvement of the immune system or the tumour microenvironment, which was 
not possible to test in the cell line model used in the study.   
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Chapter 6 : Final Discussion 
 
The incidence of OPSCC is increasing in the UK and across the developed world, and an 
increasing number of cases are caused by HPV (Arenz et al., 2014, Attner et al., 2010, 
Evans et al., 2013, Gillison et al., 2012a, Kimple et al., 2013, Nasman et al., 2009, 
Nasman et al., 2015, Schache et al., 2016). However, a clear understanding of how this 
disease acts at the basic molecular level is lacking, and the reason patients with HPV-
positive and HPV-negative OPSCC differ in terms of survival is still unclear. One reason 
for a lack of understanding of the disease could be the limitations of the OPSCC cell line 
models that were available when this project started (as discussed in Chapter 3), in 
particular HPV-positive OPSCC cell lines. A higher number of HPV-positive cell lines 
would provide more robust findings by providing a larger sample of a heterogeneous 
patient group. This would allow for individual patient variation and support investigation 
of the full range of responses to treatment (RT or CT).   
Furthermore, new cell lines would provide a deeper understanding of molecular 
mechanisms, possibly through assessment of transcription levels of genes involved in the 
treatment response or DNA repair. This could assist the development of tailored treatment 
options for both OPSCC groups (HPV-positive and HPV-negative).  
One of the aims of the current project was the development of new OPSCC cell lines for 
use in pre-clinical studies (described in Chapter 3).  Two cell lines (CU-OP-17 and CU-
OP-20) were successfully developed; CU-OP-20 was HPV-16 positive and p16 positive, 
and so was typical of most HPV-positive OPSCC; CU-OP-17 was HPV-negative and 16-
positive,  and this molecular profile is typical of 14-17% of all HPV-negative cases (Evans 
et al., 2013, Lewis et al., 2010, Rietbergen et al., 2014). These two cell lines were 
incorporated into the current study and their response to IR tested. Prior to this, both cell 
lines were fully characterised genetically, by comparing the STR profiles of original 
biopsy with the derived cell line, and through mRNA sequencing (Chapter 5). The 
mRNA-sequence analysis confirmed expression of HPV encoded oncogenes in CU-OP-
20. However, the generation of novel cell lines was labour intensive and time consuming, 
and the process used had a success rate of just 18%. This may appear low, but is similar 
to rates observed in other studies (Kodack et al., 2017).  This could possibly be improved 
by testing the behaviour of the biopsy growth with multiple types of media and different 
FBS concentrations. The media with the best growth characteristics, by increasing the 
total number of passages, would be considered as ideal and chosen for the individual 
biopsies. This could increase the success rate for generating cell lines and it might be 
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possible to generate multiple cell lines from each patient. The disadvantage of this 
method, is that the entire sample could be lost. The biopsy is small and may not be 
homogenous. Thus different parts of the biopsy might represent different tissue types and 
might not respond uniformly to changes in media composition.  Another option could be 
growing the human tumour in mouse models, before developing a new cell line, by 
generating patient derived xenografts. This would provide advantage of consistent tissue 
sample for establishing cell lines. However, Kimple et al., (2013) have investigated the 
treatment response and tumour growth in patient derived xenograft (PDX) models, which 
will be discussed in connection with immune targets later in the discussion (Kimple et al., 
2013).  
The initial plan is to share the newly derived cell lines through direct or indirect 
collaboration with other research groups. Availability of newly derived cell lines will be 
made public through publications and will be shared with other groups by contacting the 
principal investigator. Additionally, cell lines might be made available through a cell line 
bank at a later stage. 
A major strength of the current study was that it was based on 10 cell lines (5 HPV-
positive and 5 HPV-negative OPSCC cell lines). This was similar, or higher, than used in 
other studies of HNSCC including key publications in the same field (Arenz et al., 2014, 
Kimple et al., 2013, Rieckmann et al., 2013, Weaver et al., 2015, Ziemann et al., 2017). 
The advantage of the current panel of cell lines was that it constitutes a better model for 
studying OPSCC, because the lines were all derived from OPSCC (compared to other 
studies with a mix of HNSCC, including non-oropharyngeal) and included lines derived 
from HPV-positive non-smokers. This was not the case in previous studies (Kimple et al., 
2013, Rieckmann et al., 2013).  
One of the main findings during the radio-sensitivity assay was the variation in response 
within the HPV-positive OPSCC cell lines (Chapter 4). More cell lines were observed to 
be more sensitive to IR within the HPV-positive OPSCC cell lines, compared to the HPV-
negative OPSCC cell lines, as stated in the hypothesis. Due to the variation in radio 
sensitivity within the HPV-positive cell lines, a clear distinction between the HPV-
positive and negative cell lines could not be made. This finding was novel as in a previous 
study, a clear difference in radio sensitivity was determined between HPV-positive and 
HPV-negative HNSCC cell lines. A minor overlap between HPV-positive and HPV-
negative cell line in terms of radio sensitivity towards IR was already reported in two 
Chapter 6  Final Discussion 
 
223 
 
other HNSCC studies, with one HPV-negative HNSCC cell line lying in the middle of 
the HPV-positive cell lines (Rieckmann et al., 2013, Arenz et al., 2014). The differences 
in sensitivity to IR indicates a heterogeneous cell line panel. This may provide a model 
more accurately reflecting the heterogeneity and differential clinical response of OPSCC 
patients. 
The role of p53 pathways in determining variation in response to IR within the HPV-
positive OPSCC and in influencing differences in behaviour between HPV positive and 
negative cell lines was investigated by measuring expression of p53, p21 and p-p53. 
During the investigations no direct correlation between HPV status with different levels 
of expression of the three factors was observed. Similarly changes in transcription level 
after mRNA were not observed. This might lead to the conclusion that p53 is not directly 
involved in regulating the IR sensitivity within the HPV-positive cell lines, as p53 is still 
expressed and earlier cell cycle arrest was not seen, which might be a sign for inactive 
p53. By contrast, Kimple et al., (2013) suggested that accumulation of p53 influenced IR 
response and was associated with greater sensitivity to IR (Kimple et al., 2013). Differing 
levels of p53, could contribute to the variation in surviving fraction within the HPV-
positive OPSCC cell lines.  
The dissimilar results in IR response of cell lines obtained in this study compared to 
previously published studies could be due to the use of different experimental conditions 
e.g.  use of different cell lines for the study, inclusion and exclusion of feeder cells. No 
support of feeder cells was used for testing the effect of IR in Kimple et al., (2013) and 
Arenz et al., (2014). However, Rieckmann et al., (2013) used feeder cells for only one of 
eight cell lines. The inconsistency between experiments could have influenced the results 
obtained for IR sensitivity or growth pattern of the cell lines. This was avoided for the 
radio-sensitivity assay in the current study, where 3T3 feeder cells were added for every 
cell line in this specific assay. 3T3 feeder cells were included in the radio-sensitivity assay 
to support cell growth at low cell density.  
Clinically, radiotherapy as monotherapy could have the disadvantage of harming 
surrounding tissue during treatment. Future experiments might include more 
combinations of IR with chemotherapeutic agents. Studies for HNSCC in combination of 
IR with e.g. cisplatin or roscovitine have already been started, which might have a greater 
effect on survival or tumour treatment (Busch et al., 2016, Ziemann et al., 2017). One 
study showed a slight reduction in proliferation in HPV-positive cells, but only minor 
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effect of the combined treatment on colony formation (Busch et al., 2016). Another study 
on roscovitine did not show an increase in radio-sensitivity in HPV-positive HNSCC cell 
lines (Ziemann et al., 2017). However, a combined treatment with a chemotherapeutic 
agent or cell cycle inhibitor might lead to a reduction of the toxic effect of IR to the 
surrounding tissue and a possible increased survival of patients. In-vitro studies allow 
investigation of the different responses to varying treatment doses of IR with or without 
chemotherapeutic agents. The cell lines would provide the opportunity to test multiple 
combinations of treatments, such as combinations of several chemotherapeutic agents 
with IR, cell cycle inhibitors (e.g. Chk1/Chk2) or PARP inhibitors (e.g. Olaparib). 
Findings of these experiments could then be adapted for clinic, which could improve 
treatment of patient tumours without harming normal tissues. 
Interestingly in previous studies, it was hypothesised that down regulation of p53 by E6 
and treatment of IR would result in G2 arrest, within HPV-positive HNSCC cell lines. 
(Kimple et al., 2013, Rieckmann et al., 2013). According to the original hypothesis of the 
current study a greater G2 arrest after IR treatment, especially within the HPV-positive 
OPSCC cell lines was predicted. However, despite the differential accumulation of p53 
within the HPV-positive OPSCC cell lines and the increased sensitivity of some cell lines 
to IR, a clear association between G2 arrest and HPV-status could not be made, as some 
G2 arrest was seen in some HPV-negative cell lines as well.  Greater G2 arrest was 
observed as well in previous studies for HPV-positive HNSCC cell lines relative to HPV-
negative lines (Rieckmann et al., 2013, Kimple et al., 2013). In general, more cell lines 
in the current study showed a greater G2 arrest as well compared to the HPV-negative 
cell lines. A possible explanation of the greater G2 arrest could perhaps be residual p53 
activity due to incomplete degradation by E6. Cells arresting in G2 after IR could be 
observed independent of residual p53 activity (Bernhard et al., 1995, Branzei and Foiani, 
2008), which questions the key involvement of p53 activity in G2 arrest.  
In summary, more cells arresting in G2 could be an indication of preparing cells for repair, 
and the return to a more “normal” cell cycle distribution after 48 hours could be associated 
with DNA repair.  
p53 plays a key role in regulation of the DNA damage response pathway, with roles 
including activating apoptosis, causing cell cycle arrest or inducing DNA repair pathways 
(HR, BER, NHEJ). The two main repair pathways of DSB are HR and NHEJ. Therefore, 
the lack of increase in p53 or p21 expression after IR might explain the lack of increased 
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transcript levels in genes associated with these DNA repair pathways noted in the mRNA-
sequence analyses.   
Defective repair of DSB after IR was previously reported as being a possible explanation 
for greater sensitivity of HPV-positive HNSCC cell lines (Rieckmann et al., 2013, 
Weaver et al., 2015). This lead to the hypothesis that genes within the DNA repair 
pathways are up or down-regulated after IR, and this results in variation of radio-
sensitivity within the HPV-positive cell lines. No change in gene expression for major 
DNA repair pathways could be detected in the current study by mRNA sequencing of 
cells treated with IR. The GO analysis and general clustering of HPV-positive and HPV-
negative cell lines revealed differences in gene expression, but these were not involved 
in viral oncogenesis or IR response. These results suggest other mechanisms could be 
involved in the differences in sensitivity to IR between cell lines. However, additional to 
the mRNA sequencing protein level in activity should have been measured to confirm 
functional up- or downregulation of certain genes.  
It is possible that using a higher dose of IR or different time points might identify a 
significant change in gene expression that correlated to sensitivity to IR. This could be 
tested in the future but would require large scale experiments to properly assess the impact 
of both variables on DNA repair mechanisms.  
One of the main novel findings of the mRNA sequencing was the increase in fusion 
transcripts originating from multiple sites of HPV integration after IR. The number of 
integration sites appeared to be increased by IR, most likely due to the induction of DSB 
breaks after 2 Gy IR. Initial integrations usually takes place in regions of a lesion in a 
proliferating cell, where host and viral DNA are close. Therefore, one explanation could 
result from the known characteristics of HPV-DNA, which hijacks the host DNA damage 
response to replicate its own DNA (McBride and Warburton, 2017). So the increase in 
integration sites could be associated with the increased number of DSB (increased level 
of lesions) induced by IR. The main DNA repair pathway after inducing DSB with IR are 
NHEJ and HR, with the main difference that for HR an intact template strand is required 
compared to NHEJ, which does not need an intact DNA strand, to start the repair of DSBs 
(Jackson and Bartek, 2009, Lieber, 2010). It was notable that increased numbers of 
integration events occurred mostly in the newly established cell lines, and this may 
indicate that the presence of episomal HPV might be associated with this effect. 
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It should be noted that no experiments were performed to assess levels of DNA damage 
(e.g. assessment of ɣH2AX), before looking at different gene expression after IR. 
Determination of the level of DNA damage, could help to adjust the level of IR used to 
dose cells before further analyses. This would need to get done in future, prior to mRNA 
sequencing experiments. ɣH2AX is the best known marker of DNA damage, and 
indicates levels of DSB. Expression of ɣH2AX could be tested prior to future experiments 
via double-immunofluorescence assays. Staining with specific antibodies for ɣH2AX, 
would provide the number of foci of ɣH2AX per cell lines. The total number of foci would 
then directly correlate with the level of DNA damage induced. Testing ɣH2AX at 
different treatment doses and time points could identify when the highest damage is 
induced and show the time course of its repair. This would indicate how long it would 
take for DNA repair in the specific panel of cell lines, and help guide future mRNA 
sequencing experiments.  
Studies on cell line models (especially novel cell lines or early passages) are restricted in 
scale by the technical work necessary to culture the cell lines and by their relatively slow 
growth. These models also lack the tumour associated microenvironment and there is an 
absence of immune cells. One study has shown that HPV-positive tumours showed a 
better survival rate if there are a higher number of tumour infiltrating lymphocytes (TILs). 
There was an enrichment of CD8+ T-cells in the tumours of OPSCC patients which 
associated with improved survival (King et al., 2014, Ward et al., 2014).This was 
confirmed by another study of HPV-positive OPSCC which additionally demonstrated 
that HPV-positive OPSCC patients showed an improved survival if expressing a high 
ratio of CD8+/FoxP3+ (Nasman et al., 2017).  
Currently, immune compromised mice are widely used in HNSCC xenograft models, to 
avoid the risk of rejection by the host immune system. In a previous study, xenograft 
models (T-cell deficient) were used, by injecting HPV-positive and HPV-negative tumour 
cells and monitoring the growth of the tumours and the response to IR. In this study by 
Kimple et al., (2013), no difference was seen between irradiated and non-irradiated 
tumours within the HPV-negative xenografts. However, it showed an increased  
prolongation in time to tumour quadrupling between irradiated and non-irradiated 
tumours in HPV-positive xenografts, which was concluded with a similar response seen 
in sensitivity of the HPV-positive in-vitro models after radiation (Kimple et al., 2013). 
Future experiments could also be done in transgenic mouse models. The advantages of 
transgenic mouse models, include potential use of gene-editing technology, to upregulate 
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or downregulate certain genes. HPV-associated HNSCC transgenic mouse models have 
already been established, and used to investigate a chemical carcinogen, 4-nitroquinoline-
1-oxide (4-NQO) and to identify a synergetic effect of E6 and E7 in causing HNSCC 
(Jabbar et al., 2010). Designing a new transgenic HPV-positive mouse model with 
enriched expression of TILs, could mimic the high expression seen in human models. 
This would provide the advantage after treatment with IR or other chemotherapeutic 
agents, to include a possible influence of the immune system on the better treatment 
response.  
In the current study, there was no indication that DNA repair mechanisms could 
contribute to greater sensitivity/resistance within HPV-positive cell lines. However, it has 
to be noted that this assay only showed changes in gene expression at a fixed time point. 
Additionally, protein levels should get investigated to confirm changes in activity of 
genes involved in the DNA repair mechanisms. Limited to the obtained that, it can suggest 
involvement of other mechanisms operating in these cell lines and the situation in vivo is 
likely to be even more complex. Other factors that could influence the response to 
radiotherapy could include the host immune response or the tissue microenvironment for 
cancer cells.  
 
6.1. Final Conclusion  
 
In conclusion, two novel cell lines were successfully derived and characterised. These 
novel cell lines, together with a panel of previously established cell lines allowed 
laboratory investigation of the role of HPV in OPSCC. The study demonstrated greater 
variation in response to IR within HPV-positive cell lines compared to HPV-negative 
OPSCC cell lines, and suggested that HPV positivity was not consistently associated with 
sensitivity to IR. In the IR sensitive lines there was no evidence for greater p53 activity 
or differences in expression of genes associated with DNA repair pathways. The results 
obtained from the in-vitro models, may reflect the variation in treatment response of 
HPV-positive OPSCC patients in terms of general survival, as not all HPV-positive 
patients respond better to treatment. This study highlights the need for pre-clinical 
laboratory studies to incorporate a wide range of well-characterised cell lines to 
accurately mimic differences in response in the patient population.  
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